

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 December 2006 (21.12.2006)

PCT

(10) International Publication Number
WO 2006/135385 A2

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/00 (2006.01)
A61K 38/17 (2006.01) C12N 5/10 (2006.01)
C07K 19/00 (2006.01) C12N 15/63 (2006.01)

(21) International Application Number:

PCT/US2005/027912

(22) International Filing Date: 5 August 2005 (05.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/599,086 5 August 2004 (05.08.2004) US
60/639,176 23 December 2004 (23.12.2004) US

(71) Applicant (for all designated States except US): WYETH
[US/US]; Five Giralda Farms, Madison, NJ 07940 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YOUNG, Deborah,
A. [US/US]; 39 Nelson Road, Melrose, MA 02176 (US).
COLLINS, Mary [US/US]; 54 Rathbun Road, Natick,
MA 01760 (US). DUNUSSI-JOANNOPOULOS, Kyr-
iaki [US/US]; 64 Douglas Road, Belmont, MA 02478
(US). O'HARA, Richard, Michael, Jr. [US/US]; 65 Tyler

St., Quincy, MA 02170 (US). KASAIAN, Marion, T.
[US/US]; 18 Concord Street #1, Charlestown, MA 02129
(US). WHITTERS, Matthew, J. [US/US]; 14 Brenton
Wood Road, Hudson, MA 01749 (US).


(74) Agents: MANDRA, Raymond, R. et al.; Fitzpatrick,
Cella, Harper & Scinto, 30 Rockefeller Plaza, New York,
NY 10112-3801 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY



(57) Abstract: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression *in vivo*, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).



FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished
upon receipt of that report*

TITLE

ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY

[0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60/599,086, filed August 5, 2004, and U.S. Provisional Application Ser. No. 60/639,176, filed December 23, 2004, both of which are incorporated herein by reference in their entireties.

BACKGROUND OF THE INVENTION

Field of the Invention

[0002] The present invention relates to methods and compositions for antagonizing, reducing, and/or inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using IL-21 receptor antagonists. The methods and compositions disclosed herein are useful as immunotherapeutic agents.

Related Background Art

[0003] Human IL-21 is a cytokine that shows sequence homology to IL-2, IL-4 and IL-15 (Parrish-Novak et al. (2000) *Nature* 408:57-63). Despite low sequence homology among interleukin cytokines, cytokines share a common fold into a “four-helix-bundle” structure that is representative of the family. Most cytokines bind either class I or class II cytokine receptors. Class II cytokine receptors include the receptors for IL-10 and the interferons, whereas class I cytokine receptors include the receptors for IL-2 through IL-7, IL-9, IL-11, IL-12, IL-13,

- 2 -

and IL-15, as well as hematopoietic growth factors, leptin, and growth hormone (Cosman (1993) *Cytokine* 5:95-106).

[0004] Human IL-21 receptor (IL-21R) is a class I cytokine receptor that is expressed in lymphoid tissues, in particular by NK, B, and T cells (Parrish-Novak et al. (2000) *supra*). The nucleotide and amino acid sequences encoding human interleukin-21 (IL-21) and its receptor (IL-21R) are described in WO 00/53761; WO 01/85792; Parrish-Novak et al. (2000) *supra*; and Ozaki et al. (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97:11439-44. IL-21R has the highest sequence homology to IL-2 receptor β chain and IL-4 receptor α chain (Ozaki et al. (2000) *supra*). Upon ligand binding, IL-21R associates with the common gamma cytokine receptor chain (γc) that is shared by receptors for IL-2, IL-3, IL-4, IL-7, IL-9, IL-13 and IL-15 (Ozaki et al. (2000) *supra*; Asao et al. (2001) *J. Immunol.* 167:1-5). The widespread lymphoid distribution of IL-21R suggests that IL-21 may play a role in immune regulation. Indeed, *in vitro* studies have shown that IL-21 significantly modulates the function of B cells, CD4⁺ and CD8⁺ T cells, and NK cells (Parrish-Novak et al. (2000) *supra*; Kasaian et al. (2002) *Immunity.* 16:559-69). Nevertheless, evidence supporting a regulatory effect of IL-21 *in vivo* is limited.

SUMMARY OF THE INVENTION

[0005] Methods and compositions for interfering with the activity of and/or an interaction between interleukin-21 (IL-21) and an IL-21 receptor (also referred to herein as “IL-21R” or “MU-1”), e.g., using antagonists of IL-21 or IL-21R, are disclosed (also referred to herein as an “IL-21/IL-21R antagonist” or “antagonist” or “IL-21/IL-21R pathway antagonist”).

[0006] For example, Applicants have shown that reducing IL-21R activity by using an IL-21 antagonist, e.g., a fusion protein that includes the extracellular domain of the IL-21R fused to an Fc immunoglobulin region, ameliorates inflammatory symptoms in several different animal models reasonably predictive of inflammatory and/or autoimmune disorders, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, graft vs. host

- 3 -

disease, asthma, systemic lupus erythematosus (SLE) (including a form of glomerulonephritis), and psoriasis (Examples 7-14). Expression of IL-21R mRNA is upregulated in the paws of collagen-induced arthritis (CIA) mice (Example 8). Furthermore, a mouse deficient in IL-21R showed a reduction of symptoms in an asthma model (Example 12). Accordingly, antagonists of IL-21/IL-21R activity can be used to induce immune suppression *in vivo*, e.g., for treating or preventing inflammatory or autoimmune disorders. These antagonists can also be used to treat or prevent an immune cell-associated disorder, e.g., a disorder associated with aberrant activity of one or more of mature T cells (e.g., mature CD8+ or mature CD4+ T cells), mature NK cells, B cells, macrophages, and megakaryocytes.

[0007] Accordingly, in one aspect, the invention features a method of treating (e.g., curing, suppressing, delaying), ameliorating (e.g., lessening, alleviating, reducing, decreasing) and/or preventing (e.g., preventing the onset of, or preventing recurrence or relapse of) an inflammatory or an autoimmune disorder in a subject. The method includes: administering to the subject an IL-21/IL-21R antagonist, e.g., in an amount sufficient to treat, ameliorate, or prevent the disorder or in an amount sufficient to inhibit or reduce immune cell activity and/or cell number.

[0008] The IL-21/IL-21R antagonist can be administered to the subject alone, or in combinations of IL-21/IL-21R antagonists, or in combination with other therapeutic modalities as described herein. Preferably, the subject is a mammal, e.g., a human, suffering from or at risk for an inflammatory or an autoimmune disorder. For example, the method can be used to treat or prevent, in a subject, an inflammatory or an autoimmune disorder. Examples of such a disorder include, but are not limited to: transplant/graft rejection; diabetes mellitus (e.g., type I); multiple sclerosis; an arthritic disorder (e.g., rheumatoid arthritis (RA), juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or ankylosing spondylitis (preferably, RA)); myasthenia gravis; vasculitis; systemic lupus erythematosus (SLE); glomerulonephritis; autoimmune thyroiditis; a skin inflammatory disorder (e.g., dermatitis (including atopic dermatitis and eczematous dermatitis),

- 4 -

scleroderma, or psoriasis); lupus erythematosus; a fibrosis or fibrotic disorder (e.g., pulmonary fibrosis or liver fibrosis); a respiratory disorder (e.g., asthma or COPD); an atopic disorder (e.g., including allergy); or an intestinal inflammatory disorder (e.g., an IBD, e.g., Crohn's disease or ulcerative colitis).

[0009] Treatment of a disorder chosen from lupus erythematosus, a skin inflammatory disorder (e.g., psoriasis), an intestinal inflammatory disorder (e.g., IBD, Crohn's disease, ulcerative colitis), transplant/graft rejection, asthma, an atopic disorder, or rheumatoid arthritis, using the IL-21 or IL-21R antagonists of the present invention is preferred.

[0010] In one embodiment, the IL-21/IL-21R antagonist interacts with, e.g., binds to, IL-21 or IL-21R, preferably, mammalian, e.g., human IL-21 or IL-21R (referred to herein as an "IL-21 antagonist" and "IL-21R antagonist," respectively), and reduces or inhibits one or more IL-21 and/or IL-21R activities. Preferred antagonists bind to IL-21 or IL-21R with high affinity, e.g., with an affinity constant of at least about 10^7 M^{-1} , preferably about 10^8 M^{-1} , and more preferably, about 10^9 M^{-1} to 10^{10} M^{-1} or stronger.

[0011] For example, an IL-21/IL-21R antagonist can reduce and/or inhibit IL-21R activity by neutralizing IL-21. In one embodiment, the antagonist can be a fusion protein that includes a fragment of an IL-21R fused to a non-IL-21R fragment, e.g., an immunoglobulin Fc region. In other embodiments, the antagonist is an anti-IL-21R or anti-IL-21 antibody or an antigen-binding fragment thereof, a soluble form of the IL-21 receptor, a peptide or a small molecule inhibitor.

[0012] In one embodiment, the IL-21/IL-21R antagonist is an anti-IL-21R or anti-IL-21 antibody, or an antigen-binding fragment thereof; e.g., the antibody is a monoclonal or single specificity antibody that binds to IL-21, e.g., human IL-21, or an IL-21 receptor, e.g., human IL-21 receptor polypeptide, or an antigen-binding fragment thereof (e.g., an Fab, F(ab')₂, Fv or a single chain Fv fragment). Preferably, the antibody is a human, humanized, chimeric, or *in vitro*-generated antibody to human IL-21 or human IL-21 receptor polypeptide. Preferably, the antibody is a neutralizing antibody.

- 5 -

[0013] In other embodiments, the IL-21/IL-21R antagonist includes full length, or a fragment of an IL-21 polypeptide, e.g., an inhibitory IL-21 receptor-binding domain of an IL-21 polypeptide, e.g., a human IL-21 polypeptide (e.g., a human IL-21 polypeptide as described herein having an amino acid sequence shown as SEQ ID NO:19) or a sequence at least 85%, 90%, 95%, 98% or more identical thereto; or encoded by a corresponding nucleotide sequence shown as SEQ ID NO:18 or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Alternatively, the antagonist includes full length (e.g., from about amino acids 1-538 or 20-538 of SEQ ID NO:2; or from about amino acids 1-529 or 20-529 of SEQ ID NO:10), or a fragment of an IL-21 receptor polypeptide, e.g., an IL-21-binding domain of an IL-21 receptor polypeptide, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R; e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), or encoded by the corresponding nucleotides of SEQ ID NO:1 or 9, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto.

[0014] In one embodiment, the antagonist is a fusion protein comprising the aforesaid IL-21 or IL-21 receptor polypeptides or fragments thereof and, e.g., fused to a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, a GST, Lex-A or MBP polypeptide sequence). In a preferred embodiment, the fusion protein includes at least a fragment of an IL-21R polypeptide that is capable of binding IL-21, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R, e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), or encoded by the corresponding nucleotides of SEQ ID NO:1 or 9, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto) and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE). For example, the fusion protein can include the extracellular domain of human IL-21R, e.g., from about

- 6 -

amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2, and, e.g., fused to, a human immunoglobulin Fc chain (e.g., human IgG, e.g., human IgG1, e.g., a naturally occurring human IgG1 or a mutated form of human IgG1). In one embodiment, the human Fc sequence has been mutated at one or more amino acids, e.g., mutated at residues 254 and 257 of SEQ ID NO:28, from the naturally occurring sequence to reduce Fc receptor binding. In other embodiments, the fusion protein can include the extracellular domain of murine IL-21R, e.g., from about amino acids 1-236, 20-235 of SEQ ID NO:10 (murine), and, e.g., fused to, a murine immunoglobulin Fc chain (e.g., murine IgG, e.g., murine IgG2a or a mutated form of murine IgG2a).

[0015] The fusion proteins may additionally include a linker sequence joining the first moiety, e.g., an IL-21R fragment, to the second moiety, e.g., the immunoglobulin fragment. In other embodiments, additional amino acid sequences can be added to the N- or C-terminus of the fusion protein to facilitate expression, steric flexibility, detection, and/or isolation or purification.

[0016] Examples of antagonistic fusion proteins that can be used in the methods of the invention are shown in FIGS. 7-15. In one embodiment, the fusion protein includes an amino acid sequence chosen from, e.g., SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, or SEQ ID NO:39, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. In other embodiments, the fusion protein includes an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or SEQ ID NO:38, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Preferred fusion proteins have the amino acid sequence shown as SEQ ID NO:25 or SEQ ID NO:29 (FIGS. 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. In other embodiments, the fusion protein includes an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID NO:24 or SEQ ID NO:28 (FIGS. 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%, 95%, 98% or more

- 7 -

identical thereto. Most preferably, the fusion protein has the amino acid sequence shown as SEQ ID NO:29 or has an amino acid sequence encoded by a nucleotide sequence shown as SEQ ID NO:28 (FIG. 10A-10C).

[0017] The IL-21/IL-21R antagonists described herein, e.g., the fusion protein described herein, can be derivatized or linked to another functional molecule, e.g., another peptide or protein (e.g., an Fab' fragment). For example, the fusion protein or an antibody, or antigen-binding portion, can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as an antibody (e.g., a bispecific or a multispecific antibody), toxins, radioisotopes, cytotoxic or cytostatic agents, among others.

[0018] In one embodiment, the IL-21/IL-21R antagonists described herein, e.g., the pharmaceutical compositions thereof, are administered in combination therapy, i.e., combined with other agents, e.g., therapeutic agents, which are useful for treating inflammatory or autoimmune disorders, e.g., a disorder chosen from one or more of: an arthritic disorder (including RA, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or ankylosing spondylitis); SLE; glomerulonephritis; a skin inflammatory disorder (e.g., psoriasis); a respiratory disorder (e.g., asthma, COPD); an atopic disorder; a fibrotic disorder (e.g., pulmonary fibrosis or liver fibrosis); an intestinal inflammatory disorder (e.g., an IBD, e.g., Crohn's disease or ulcerative colitis); or transplant/graft rejection. For example, the combination therapy can include one or more IL-21/IL-21R antagonists, e.g., an anti-IL-21 or anti-IL-21R antibody or an antigen-binding fragment thereof; an IL-21R fusion protein; a soluble IL-21R receptor; a peptide inhibitor or a small molecule inhibitor) coformulated with, and/or coadministered with, one or more additional therapeutic agents, e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described herein.

[0019] Examples of preferred additional therapeutic agents that can be coadministered and/or coformulated with one or more IL-21/IL-21R antagonists,

- 8 -

include, but are not limited to, one or more of: TNF antagonists (e.g., chimeric, humanized, human or *in vitro*-generated antibodies, or antigen-binding fragments thereof, that bind to TNF; soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kDa TNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBRELTM), p55 kDa TNF receptor-IgG fusion protein; TNF enzyme antagonists, e.g., TNF α converting enzyme (TACE) inhibitors); antagonists of IL-6, IL-12, IL-15, IL-17, IL-18, IL-22; T cell and B cell depleting agents (e.g., anti-CD4 or anti-CD22 antibodies); small molecule inhibitors, e.g., methotrexate and leflunomide; sirolimus (rapamycin) and analogs thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors, TPL-2, M κ -2 and NF κ B inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin); estrogen receptor beta (ERB) agonists or ERB-NF κ B antagonists. Most preferred additional therapeutic agents that can be coadministered and/or coformulated with one or more IL-21/IL-21R antagonists include one or more of: a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kDa TNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBRELTM); methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

[0020] In another aspect, a method for decreasing immune cell activity (e.g., the activity of one or more of: a mature T cell (mature CD8⁺, CD4⁺, lymph node T cell, memory T cell), mature NK cell, B cell, antigen presenting cell (APC), e.g., a dendritic cell, macrophage or megakaryocyte, or a population of cells, e.g., a mixed or a substantially purified immune cell population, is provided. The method includes contacting the immune cell with an IL-21/IL-21R antagonist, e.g., an antagonist as described herein, in an amount sufficient to decrease immune cell activity.

[0021] In another aspect, the invention features a fusion protein that includes at least a fragment of an IL-21R polypeptide, which is capable of binding an IL-21 polypeptide, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R; e.g., from about

- 9 -

amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), or encoded by the corresponding nucleotides of SEQ ID NO:1 or SEQ ID NO:9, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto) and, e.g., fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE). For example, the fusion protein can include the extracellular domain of human IL-21R, e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2, and, e.g., fused to, a human immunoglobulin Fc chain (e.g., human IgG, e.g., human IgG1 or a mutated form of human IgG1). In one embodiment, the human Fc sequence has been mutated at one or more amino acids, e.g., mutated at residues 254 and 257 of SEQ ID NO:28, from the wild type sequence to reduce Fc receptor binding. In other embodiments, the fusion protein can include the extracellular domain of murine IL-21R, e.g., from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), and, e.g., fused to, a murine immunoglobulin Fc chain (e.g., murine IgG, e.g., murine IgG2a or a mutated form of murine IgG2a). The fusion proteins may additionally include a linker sequence joining the IL-21R fragment to the second moiety. In other embodiments, additional amino acid sequences can be added to the N- or C-terminus of the fusion protein to facilitate expression, detection and/or isolation or purification.

[0022] The invention also features nucleic acid sequences that encode the fusion proteins described herein.

[0023] In another aspect, the invention features host cells and vectors containing the nucleic acids of the invention. Preferably, the host cell is a eukaryotic cell, e.g., a mammalian cell, an insect cell, or a yeast cell, or a prokaryotic cell, e.g., *E. coli*. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell. For example, nucleic acids encoding the fusion proteins described herein can be expressed in a transgenic animal. In one

embodiment, the nucleic acids are placed under the control of a tissue-specific promoter (e.g., a mammary-specific promoter) and the antibody is produced in the transgenic animal. For example, the fusion protein is secreted into the milk of the transgenic animal, such as a transgenic cow, pig, horse, sheep, goat, or rodent.

[0024] In another aspect, the invention provides a process for producing a fusion protein, e.g., a fusion protein as described herein. The process comprises: (a) growing a culture of the host cell of the present invention in a suitable culture medium and (b) purifying the fusion protein from the culture. Proteins produced according to these methods are also provided.

[0025] In another aspect, the invention provides compositions, e.g., pharmaceutical compositions, which include a pharmaceutically acceptable carrier and at least one of IL-21/IL-21R antagonist as described herein (e.g., a fusion protein described herein). In one embodiment, the compositions, e.g., pharmaceutical compositions, comprise a combination of two or more IL-21/IL-21R antagonists. Combinations of the IL-21/IL-21R antagonists and a drug, e.g., a therapeutic agent (e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described herein) or an antigen, e.g., an antigenic peptide and/or an antigen-presenting cell, are also within the scope of the invention.

[0026] In one embodiment, the pharmaceutical composition includes an IL-21/IL-21R antagonist and at least one additional therapeutic agent, in a pharmaceutically acceptable carrier. Examples of preferred additional therapeutic agents that can be coformulated in a composition, e.g., a pharmaceutical composition, with one or more IL-21/IL-21R antagonists, include, but are not limited to, one or more of: TNF antagonists (e.g., chimeric, humanized, human or *in vitro*-generated antibodies, or antigen-binding fragments thereof, that bind to TNF; soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kDa TNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBRELTM), p55 kDa TNF receptor-IgG fusion protein; TNF enzyme antagonists, e.g., TNF α converting enzyme (TACE) inhibitors); antagonists of

- 11 -

IL-6, IL-12, IL-15, IL-17, IL-18, IL-22; T cell and B cell depleting agents (e.g., anti-CD4 or anti-CD22 antibodies); small molecule inhibitors, e.g., methotrexate and leflunomide; sirolimus (rapamycin) and analogs thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors, TPL-2, Mk-2 and NF κ B inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin); estrogen receptor beta (ERB) agonists or ERB-NF κ B antagonists. Most preferred additional therapeutic agents that can be coadministered and/or coformulated with one or more IL-21/IL-21R antagonists include one or more of: a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kDTNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBRELTM); methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

[0027] In another aspect, the invention features methods to treat, ameliorate, or prevent an atopic disorder in a subject, e.g., a mammal, e.g., a human. The method includes: administering to the subject an IL-21/IL-21R antagonist, e.g., in an amount sufficient to treat, ameliorate, or prevent the disorder or in an amount sufficient to inhibit or reduce immune cell activity and/or cell number. In one embodiment, the atopic disorder is allergic asthma. In another embodiment, the atopic disorder is atopic dermatitis, urticaria, eczema, allergic rhinitis, or allergic enterogastitis. In one embodiment, the IL-21/IL-21R antagonist can be administered in combination with another therapeutic agent, e.g., a cytokine inhibitor, an immunosuppressant, an anti-inflammatory agent, an enzyme inhibitor, a leukotriene antagonist, a bronchodilator, a beta 2-adrenoceptor agonist, an antimuscarinic, or a mast cell stabilizer. Examples of preferred therapeutic agents that can be administered in conjunction with an IL-21/IL-21R antagonist to treat, ameliorate, or prevent an atopic disorder include, e.g., TNF antagonists, IL-6 antagonists, IL-12 antagonists, IL-15 antagonists, IL-17 antagonists, IL-18 antagonists, IL-22 antagonists, T cell-depleting agents, B cell-depleting agents, methotrexate, leflunomide, sirolimus (rapamycin) or analogs thereof, Cox-2 inhibitors, cPLA2 inhibitors, NSAIDs, and p38 inhibitors.

- 12 -

[0028] In another aspect, the invention features methods to treat, ameliorate, or prevent an autoimmune disorder in a subject. The method includes: administering to the subject an IL-21/IL-21R antagonist, e.g., in an amount sufficient to treat, ameliorate, or prevent the disorder or an in amount sufficient to inhibit or reduce immune cell activity and/or cell number. In one embodiment, the autoimmune disorder is lupus, e.g., SLE. In one embodiment, the IL-21/IL-21R antagonist can be administered in combination with another therapeutic agent, e.g., a cytokine inhibitor, a growth factor inhibitor, an immunosuppressant, an anti-inflammatory agent, a metabolic inhibitor, an enzyme inhibitor, a cytotoxic agent, or a cytostatic agent. Examples of preferred therapeutic agents that can be administered in conjunction with an IL-21/IL-21R antagonist to treat, ameliorate, or prevent an autoimmune disorder include, e.g., TNF antagonists, IL-6 antagonists, IL-12 antagonists, IL-15 antagonists, IL-17 antagonists, IL-18 antagonists, IL-22 antagonists, T cell-depleting agents, B cell-depleting agents, chloroquine, hydroxychloroquine, methotrexate, leflunomide, sirolimus (rapamycin) or analogs thereof, Cox-2 inhibitors, cPLA2 inhibitors, NSAIDs, and p38 inhibitors.

[0029] In another aspect, the invention features methods to treat, ameliorate, or prevent a fibrotic disorder in a subject. The method includes: administering to the subject an IL-21/IL-21R antagonist, e.g., in an amount sufficient to treat, ameliorate, or prevent the disorder or an in amount sufficient to inhibit or reduce immune cell activity and/or cell number. For example, the subject may have or be at risk for fibrosis of an internal organ (e.g., liver fibrosis, renal fibrosis, or pulmonary fibrosis), a dermal fibrosing disorder, or a fibrotic condition of the eye.

[0030] In another aspect, the invention features methods of transplanting or grafting organs, tissues, or cells to a subject. The method includes administering to the subject an IL-21/IL-21R antagonist, e.g., before, during, or after the transplantation or grafting. The organs and tissues transplanted/grafted can include, but are not limited to, e.g., heart, kidney, liver, lung, pancreas, bone marrow, cartilage, cornea, neuronal tissue, and cells thereof. In one embodiment,

- 13 -

the IL-21/IL-21R antagonist is administered in combination with another therapeutic agent, e.g., a cytokine inhibitor, a growth factor inhibitor, an immunosuppressant, an anti-inflammatory agent, a metabolic inhibitor, an enzyme inhibitor, a cytotoxic agent, and a cytostatic agent. Examples of preferred therapeutic agents that can be administered in conjunction with IL-21/IL-21R antagonists include, e.g., rapamycin, cyclosporine, anti-CTLA-4 antibodies, anti-CD40 antibodies, anti-CD40L antibodies, and anti-CD154 antibodies.

[0031] In another aspect, the invention features a method of evaluating and treating a transplant/graft recipient for symptoms of transplant/graft rejection or a disorder associated with transplant/graft rejection, e.g., fibrosis or graft-versus-host-disease (GVHD). The method includes identifying a subject with symptoms of transplant/graft rejection and administering an IL-21/IL-21R antagonist, e.g., in an amount sufficient to treat or ameliorate the symptoms of transplant rejection. Symptoms of transplant/graft rejection include, e.g., inflammation, decreased organ function, abnormal biopsy, and fibrosis. In another embodiment, the invention provides a method of preventing (e.g., reducing the risk of) transplant/graft rejection or a disorder associated with transplant/graft rejection by administering an IL-21/IL-21R antagonist.

[0032] In another aspect, the invention features methods to treat, ameliorate, or prevent transplant/graft rejection or a disorder associated with transplant/graft rejection in a subject. The method features administering to the subject an IL-21/IL-21R antagonist in an amount sufficient to treat or ameliorate, or prevent (e.g., reduce the risk of), the rejection or in an amount sufficient to inhibit or reduce immune cell activity and/or cell number. The organs or tissues transplanted can include, e.g., heart, kidney, liver, lung, pancreas, and bone marrow. In one embodiment, the IL-21/IL-21R antagonist can be administered in combination with another therapeutic agent, e.g., a cytokine inhibitor, a growth factor inhibitor, an immunosuppressant, an anti-inflammatory agent, a metabolic inhibitor, an enzyme inhibitor, a cytotoxic agent, or a cytostatic agent. Examples of preferred therapeutic agents that can be administered in conjunction with IL-21/IL-21R antagonists to treat, ameliorate, or prevent transplant/graft rejection

- 14 -

include, e.g., rapamycin, cyclosporine, anti-CTLA-4 antibodies, anti-CD40 antibodies, anti-CD40L antibodies, and anti-CD154 antibodies.

[0033] The following sets of terms are used interchangeably herein: “MU-1” and “IL-21R,” and peptides, polypeptides, and proteins.

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0035] Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0036] FIG. 1 depicts the full-length cDNA sequence of murine IL-21R/MU-1. The nucleotide sequence corresponds to nucleotides 1-2628 of SEQ ID NO:9.

[0037] FIGS. 2A-2B depict the amino acid sequences of murine and human IL-21R/ MU-1. FIG. 2A depicts the amino acid sequence of murine IL-21R/MU-1 (corresponding to the amino acids 1-529 of SEQ ID NO:10). There is a predicted leader sequence at amino acids 1-19 (predicted by SPScan) with score of 10.1 (bold-face type). There is a predicted transmembrane domain at amino acids 237-253 of SEQ ID NO:10 (underlined). Predicted signaling motifs include the following regions: Box 1: amino acids 265-274 and Box 2: amino acids 310-324 (bold and underlined); six tyrosines are located at amino acid positions 281, 319, 361, 368, 397, and 510, of SEQ ID NO:10. The WSXWS motif (SEQ ID NO:8) is located at amino acid residue 214 to amino acid residue 218 (in large, bold-face type). Potential STAT docking sites include, amino acids 393-398 and amino acids 510-513 of SEQ ID NO:10. FIG. 2B

- 15 -

depicts the amino acid sequence of human MU-1 (corresponding to SEQ ID NO:2). The location of the predicted signal sequence (about amino acids 1-19 of SEQ ID NO:2); WSXWS motif (about amino acids 213-217 of SEQ ID NO:2); and transmembrane domain (about amino acids 236-252, 236-253, 236-254, of SEQ ID NO:2 (underlined)) are indicated. Potential JAK binding sites, signaling motifs and STAT docking sites are also indicated. The approximate location of these sites is boxed.

[0038] FIG. 3 depicts the GAP comparison of human and murine MU-1 cDNA sequences (corresponding to nucleic acids 1-2665 of SEQ ID NO:1 and nucleic acids 1-2628 of SEQ ID NO:9, respectively). HuMU-1 = human MU-1, murMU-1 = murine MU-1. Gap Parameters: Gap Weight = 50, Average Match = 10.000, Length Weight = 3, Average Mismatch = 0.000, Percent Identity = 66.116.

[0039] FIG. 4 depicts a GAP comparison of the human MU-1 protein (corresponding to amino acids of SEQ ID NO:2) and the murine MU-1 protein (corresponding to amino acids of SEQ ID NO:10). The alignment was generated by BLOSUM62 amino acid substitution matrix (Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:10915-19). Gap parameters = Gap Weight: 8, Average Match = 2.9 12, Length Weight = 2, Average Mismatch = -2.003; Percent Identity = 65.267.

[0040] FIG. 5 depicts a multiple sequence alignment of the amino acids of human MU-1 (corresponding to SEQ ID NO:2), murine MU-1 (corresponding to SEQ ID NO: 10), and human IL2 beta chain (GENBANK® Accession No. M26062). Leader and transmembrane domains are underlined. Conserved cytokine receptor module motifs are indicated by bold-face type. Potential signaling regions are indicated by underlining and bold-face type.

[0041] FIG. 6 depicts signaling through MU-1. MU-1 phosphorylates STAT 5 in Clone E7 EPO-MU-1 chimera. Under the conditions specified in Example 3, signaling through MU-1 results in the phosphorylation of STAT 5 at all time-points tested. Treatment of controls or the chimeric BAF-3 cells with IL-3 resulted in phosphorylation of STAT 3, but not STAT 1 or 5.

[0042] FIGS. 7A-7B depict an alignment of the nucleotide and amino acid sequences of human IL-21R monomer (corresponding to amino acids 20-235 of SEQ ID NO:2) fused at the amino terminal to honey bee leader sequence and His6 tags (amino acids 1-44 of SEQ ID NO:23). The nucleotide and amino acid sequences are shown as SEQ ID NO:22 and SEQ ID NO:23, respectively.

[0043] FIGS. 8A-8C depict an alignment of the nucleotide and amino acid sequences of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID NO:2) fused at the C-terminus via a linker (corresponding to amino acids 236-243 of SEQ ID NO:25) to human immunoglobulin G1 (IgG1) Fc sequence (corresponding to amino acids 244-467 of SEQ ID NO:25). The nucleotide and amino acid sequences are shown as SEQ ID NO:24 and SEQ ID NO:25, respectively.

[0044] FIGS. 9A-9C depict an alignment of the nucleotide and amino acid sequences of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID NO:2) fused at the C-terminus via a linker (corresponding to amino acids 236-243 of SEQ ID NO:27) to human immunoglobulin G1 (IgG1) Fc sequence (corresponding to amino acids 244-467 of SEQ ID NO:27), and His₆ sequence tag (corresponding to amino acids 468-492 of SEQ ID NO:27). The nucleotide and amino acid sequences are shown as SEQ ID NO:26 and SEQ ID NO:27, respectively.

[0045] FIGS. 10A-10C depict an alignment of the nucleotide and amino acid sequences of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID NO:2) fused at the C-terminus via a linker (corresponding to amino acids 236-243 of SEQ ID NO:29) to human immunoglobulin G1 (IgG1) Fc mutated sequence (corresponding to amino acids 244-467 of SEQ ID NO:29). The human Fc sequence has been mutated at residues 254 and 257 from the wild-type sequence to reduce Fc receptor binding. The nucleotide and amino acid sequences are shown as SEQ ID NO:28 and SEQ ID NO:29, respectively.

[0046] FIGS. 11A-11B depict an alignment of the nucleotide and amino acid sequences of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID NO:2) fused at the C-terminus to a rhodopsin sequence tag.

The nucleotide and amino acid sequences are shown as SEQ ID NO:30 and SEQ ID NO:31, respectively.

[0047] FIGS. 12A-12C depict an alignment of the nucleotide and amino acid sequences of human IL-21R extracellular domain (corresponding to amino acids 1-235 of SEQ ID NO:2) fused at the C-terminus to an EK cleavage site and mutated IgG1 Fc region (corresponding to amino acids 236-470 of SEQ ID NO:33). The nucleotide and amino acid sequences are shown as SEQ ID NO:32 and SEQ ID NO:33, respectively.

[0048] FIGS. 13A-13B depict an alignment of the nucleotide and amino acid sequences of murine IL-21R extracellular domain fused at the C-terminus to mouse immunoglobulin G2a (IgG2a). The nucleotide (genomic) and amino acid sequences are shown as SEQ ID NO:34 and SEQ ID NO:35, respectively.

[0049] FIGS. 14A-14B depict an alignment of the nucleotide and amino acid sequences of murine IL-21R extracellular domain fused at the C-terminus to Flag and His₆ sequence tags. The nucleotide (genomic) and amino acid sequences are shown as SEQ ID NO:36 and SEQ ID NO:37, respectively.

[0050] FIGS. 15A-15B depict an alignment of the nucleotide and amino acid sequences of (honey bee leader) murine IL-21R extracellular domain fused at the C-terminus to Flag and His₆ sequence tags. The nucleotide (genomic) and amino acid sequences are shown as SEQ ID NO:38 and SEQ ID NO:39, respectively.

[0051] FIG. 16 is a timetable summarizing the prophylactic, therapeutic and semi-therapeutic treatment schedules for the experiments using collagen-induced arthritis (CIA) mouse models.

[0052] FIG. 17 is a graph depicting the effects of MuIL-21RFc (200 µg/mouse 3x/week) on a semi-therapeutic CIA mouse as a function of days post-treatment. Mouse Ig (200 µg/mouse 3x/week) was used as a control.

[0053] FIGS. 18A-18B are photographs showing increased expression of IL-21R mRNA in arthritic paws of mice with CIA (panel A) compared to negative controls (panel B).

[0054] FIGS. 19 and 20 depict linear graphs showing a marked reduction in the clinical score of IBD-like symptoms in rats treated with muIL-21RFc and

mEnbrel, compared to the IgG control. FIG. 19, left side panel, is a photograph showing *in situ* hybridization of MU-1 mRNA in the lymphocytes and lymph nodes of the normal human intestine.

[0055] FIG. 21 is a table summarizing a reduction in histological scoring of disease severity in a rat IBD model after administration of MuIL-21RFc.

[0056] FIG. 22 is a linear graph showing the percentage of graft survival relative to days post-adoptive transfer in mice injected with retrovirally transduced T cells expressing IL-21, muIL-21RFc or control (GFP).

[0057] FIG. 23 is a linear graph showing an improvement of clinical scores in psoriatic lesions in a CD45RB^{high} adoptive transfer model after administration of MuIL-21RFc. FIG. 23, left hand side, shows photographs of mice before and after treatment with MuIL-21RFc.

[0058] FIG. 24 is a line graph depicting the levels of airway hyperresponsiveness (AHR) of ovalbumin (OVA)-sensitized mice challenged with either phosphate buffered saline (PBS) or OVA. Mice were administered sequentially increasing doses of methacholine. The Penh (enhanced pause) change is an indicator of AHR.

[0059] FIGS. 25A-25D are bar graphs depicting numbers of cells in bronchoalveolar lavage fluid (BALF) of OVA-sensitized mice challenged with either PBS or OVA. FIG. 25A depicts total BALF cell numbers. FIG. 25B depicts numbers of eosinophils in BALF. FIG. 25C depicts numbers of lymphocytes in BALF. FIG. 25D depicts numbers of neutrophils in BALF. Unfilled bars indicate PBS-challenged WT mice; filled bars indicate OVA-challenged WT mice; gray bars indicate PBS-challenged IL-21R ^{-/-} mice; hatched bars indicate OVA-challenged IL-21R ^{-/-} mice. * indicates p<0.05 as determined by Mann-Whitney U test.

[0060] FIGS. 26 and 27 are graphs depicting levels of cytokines in BALF of OVA-sensitized mice challenged with OVA. FIG. 26 depicts levels of TNF α and IL-5. FIG. 27 depicts levels of IL-13. Unfilled bars indicate PBS-challenged WT mice; filled bars indicate OVA-challenged WT mice; gray bars indicate PBS-

- 19 -

challenged IL-21R $-/-$ mice; hatched bars indicate OVA-challenged IL-21R $-/-$ mice. * indicates $p < 0.05$ as determined by Mann-Whitney U test.

[0061] FIGS. 28A-28B are bar graphs depicting levels of serum IgE in OVA-sensitized mice challenged with OVA or PBS. FIG. 28A depicts levels of total serum IgE. FIG. 28B depicts levels of anti-OVA specific IgE. Unfilled bars indicate PBS-challenged WT mice; filled bars indicate OVA-challenged WT mice; gray bars indicate PBS-challenged IL-21R $-/-$ mice; hatched bars indicate OVA-challenged IL-21R $-/-$ mice. * indicates $p < 0.05$ as determined by Mann-Whitney U test.

[0062] FIGS. 29A-29D are graphs depicting the levels of circulating dsDNA autoantibodies in MRL-*Fas^{lpr}* mice following treatment with MuIL-21RFc or control. FIG. 29A depicts levels of IgG1. FIG. 29B depicts levels of IgG2a. FIG. 29C depicts levels of IgG2b. FIG. 29D depicts levels of IgG3. * indicates $p < 0.05$ as determined by Mann-Whitney U test.

[0063] FIGS. 30A-30D are graphs depicting circulating total IgG in MRL-*Fas^{lpr}* mice following treatment with MuIL-21RFc or control. FIG. 30A depicts levels of IgG1. FIG. 30B depicts levels of IgG2a. FIG. 30C depicts levels of IgG2b. FIG. 30D depicts levels of IgG3. * indicates $p < 0.05$ as determined by Mann-Whitney U test.

[0064] FIG. 31 is a graph depicting levels of fluorescence in mouse kidney slices stained with goat anti-mouse IgG-FITC.

[0065] FIG. 32 is a schematic diagram depicting exemplary effects of IL-21 on immune responses.

[0066] FIG. 33 is a schematic diagram depicting exemplary strategies for inhibiting the IL-21/IL-21R pathway.

[0067] FIG. 34 is a schematic diagram depicting an exemplary soluble IL-21RFc receptor fusion protein.

[0068] FIG. 35 is a line graph depicting the mean psoriasis score of MuIL-21RFc-treated and control-treated groups of mice stimulated with *E. tenella* ("Etenella").

- 20 -

[0069] FIG. 36 is a table summarizing a delay in onset and reduction of symptoms of psoriasis in *E. tenella*-stimulated mice treated with MuIL-21RFc compared to control-treated mice.

[0070] FIG. 37 is a line graph depicting a reduction in weight loss in *E. tenella*-stimulated mice treated with MuIL-21RFc compared to control treated mice. Weight index is defined as the ratio of weight measured to initial weight.

[0071] FIG. 38A is a line graph depicting a reduction in mean stool score in *E. tenella*-stimulated mice treated with MuIL-21RFc compared to control-treated mice.

[0072] FIG. 38B is a graph depicting stool scores of individual *E. tenella*-stimulated mice of each treatment group at day 77 post transfer.

[0073] FIG. 39 is a table summarizing the data depicted in FIG. 38A.

[0074] FIG. 40A is a graph depicting serum IFN- γ levels in *E. tenella*-stimulated mice treated with MuIL-21RFc compared to control-treated mice.

[0075] FIG. 40B is a graph depicting stool scores for *E. tenella*-stimulated mice treated with MuIL-21RFc compared to control-treated mice.

[0076] FIG. 41 is a line graph depicting ^3H -thymidine incorporation into activated CD45RB^{hi} and CD45RB^{lo} cells following treatment with IL-21.

[0077] FIGS. 42A-B are bar graphs depicting an increase in secretion of cytokines by activated CD45RB^{hi} cells following IL-21 treatment.

[0078] FIG. 43 is a bar graph depicting a reduction in secretion of cytokines by activated CD45RB^{hi} cells following treatment with MuIL-21RFc.

[0079] FIG. 44A-B are bar (A) and scatter (B) graphs depicting that, in the GVHD model of SLE, IL-21R knockout mice engrafted with B6 bm12 spleen cells do not make anti-dsDNA autoantibodies (A) and IgG deposition is not observed in the kidneys of these mice (B).

DETAILED DESCRIPTION OF THE INVENTION

[0080] Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce

- 21 -

immune suppression *in vivo*, e.g., for treating or preventing inflammatory or autoimmune disorders. (e.g., disorders associated with aberrant activity of one or more of mature T cells (mature CD8⁺, mature CD4⁺ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant/graft rejection, psoriasis and autoimmune disorders such as rheumatoid arthritis and IBD).

[0081] In one embodiment, Applicants have shown that a reduction of IL-21R activity by using a neutralizing fusion protein that includes the extracellular domain of the IL-21R fused to an Fc immunoglobulin region ameliorates inflammatory symptoms in collagen-induced arthritis (CIA) animal models (Example 7), as well as animal models for IBD (Examples 9 and 11), graft rejection (Example 10), psoriasis (Example 11), and lupus (Example 13). Expression of IL-21R mRNA is upregulated in the paws of CIA mice (Example 8). Mice deficient in IL-21R show a reduction in antigen-induced airway inflammation (Example 12). Accordingly, IL-21R binding agents that antagonize IL-21/IL-21R activity can be used to induce immune suppression *in vivo*, e.g., for treating or preventing inflammatory or autoimmune disorders (e.g., glomerulonephritis, transplant/graft rejection, psoriasis, atopic disorders, asthma, autoimmune disorders such as rheumatoid arthritis and SLE, and IBD (e.g., Crohn's disease, ulcerative colitis)).

[0082] In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

[0083] The term "MU-1," "MU-1 protein," "interleukin-21 receptor" or "IL-21R," as used herein, refers to a class I cytokine family receptor, also known as NILR (WO 01/85792; Parrish-Novak et al. (2000) *Nature* 408:57-63; Ozaki et al. (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97:11439-444). MU-1 is homologous to the shared β chain of the IL-2 and IL-15 receptors, and IL-4 α (Ozaki et al. (2000) *supra*). Upon ligand binding, IL-21R/MU-1 is capable of interacting with a common γ cytokine receptor chain (γ c) (Asao et al. (2001) *J. Immunol.* 167:1-5), and inducing the phosphorylation of STAT1 and STAT3 (Asao et al. (2001)) or STAT5 (Ozaki et al. (2000)). MU-1 shows widespread lymphoid tissue

- 22 -

distribution. The term "MU-1" refers to a receptor (preferably of mammalian, e.g., murine or human origin) which is capable of interacting with, e.g., binding to, IL-21 (preferably of mammalian, e.g., murine or human IL-21) and having one of the following features: (i) an amino acid sequence of a naturally occurring mammalian MU-1 polypeptide IL-21R/MU-1 or a fragment thereof, e.g., an amino acid sequence shown as SEQ ID NO:2 (human) or SEQ ID NO:10 (murine) or a fragment thereof; (ii) an amino acid sequence substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, or 99% homologous to, an amino acid sequence shown as SEQ ID NO:2 (human) or SEQ ID NO:10 (murine) or a fragment thereof; (iii) an amino acid sequence that is encoded by a naturally occurring mammalian IL-21R/MU-1 nucleotide sequence or a fragment thereof (e.g., SEQ ID NO:1 (human) or SEQ ID NO:9 (murine) or a fragment thereof); (iv) an amino acid sequence encoded by a nucleotide sequence which is substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, a nucleotide sequence shown as SEQ ID NO:1 (human) or SEQ ID NO:9 (murine) or a fragment thereof; (v) an amino acid sequence encoded by a nucleotide sequence degenerate to a naturally occurring IL-21R/MU-1 nucleotide sequence or a fragment thereof, e.g., SEQ ID NO:1 (human) or SEQ ID NO:9 (murine) or a fragment thereof; or (vi) a nucleotide sequence that hybridizes to one of the foregoing nucleotide sequences under stringent conditions, e.g., highly stringent conditions.

[0084] The IL-21R/MU-1 is of mammalian, preferably, human origin. The nucleotide sequence and the predicted amino acid sequence of human IL-21R/MU-1 are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively. Analysis of the human IL-21R/MU-1 amino acid sequence (SEQ ID NO:2; FIG. 2B) revealed the following structural features: a leader sequence (about amino acids 1-19 of SEQ ID NO:2 (FIG. 2B)); WSXWS motif (about amino acids 213-217 of SEQ ID NO:2); transmembrane domain (about amino acids 236-252 of SEQ ID NO:2 (FIG. 2B)); an extracellular domain from about amino acids 1-235 of SEQ ID NO:2; and an intracellular domain from about 253-538 of SEQ

ID NO:2. The mature human IL-21R/MU-1 is believed to have the sequence of amino acids 20-538 of SEQ ID NO:2.

[0085] The IL-21R/MU-1 cDNA was deposited with the American Type Culture Collection on Mar. 10, 1998, as accession number ATCC 98687.

[0086] Any form of IL-21R/MU-1 proteins of less than full length can be used in the methods and compositions of the present invention, provided that it retains the ability to bind to an IL-21 polypeptide. IL-21R/MU-1 proteins of less than full length, e.g., soluble IL-21R, can be produced by expressing a corresponding fragment of the polynucleotide encoding the full-length MU-1 protein in a host cell. These corresponding polynucleotide fragments are also part of the present invention. Modified polynucleotides as described above may be made by standard molecular biology techniques, including construction of appropriate desired deletion mutants, site-directed mutagenesis methods or by the polymerase chain reaction using appropriate oligonucleotide primers.

[0087] As used herein, a “soluble IL-21R/MU-1 polypeptide” is an IL-21R/MU-1 polypeptide incapable of anchoring itself in a membrane. Such soluble polypeptides include, for example, MU-1 or IL-21R polypeptides that lack a sufficient portion of their membrane-spanning domain to anchor the polypeptide or are modified such that the membrane-spanning domain is nonfunctional, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R includes an amino acid sequence from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine). A soluble IL-21R/MU-1 polypeptide can additionally include, e.g., be fused to, a second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, a GST, Lex-A or MBP polypeptide sequence). For example, a fusion protein can include at least a fragment of an IL-21R polypeptide, which is capable of binding IL-21, e.g., a soluble fragment of an IL-21R (e.g., a fragment of an IL-21R comprising the extracellular domain of murine or human IL-21R; e.g., from about amino acids 1-235, 1-236, 20-235, 20-236 of SEQ ID NO:2 (human), or from about amino acids 1-236, 20-236 of SEQ ID NO:10 (murine), fused to a

- 24 -

second moiety, e.g., a polypeptide (e.g., an immunoglobulin chain, an Fc fragment, a heavy chain constant regions of the various isotypes, including: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE).

[0088] The term “interleukin-21” or “IL-21” refers to a cytokine showing sequence homology to IL-2, IL-4 and IL-15 (Parrish-Novak et al. (2000) *Nature* 408:57-63). Despite low sequence homology among interleukin cytokines, cytokines share a common fold into a “four-helix-bundle” structure that is representative of the family. It is expressed primarily in activated CD4⁺ T cells, and has been reported to have effects on NK, B and T cells (Parrish-Novak et al. (2000) *supra*; Kasaian et al. (2002) *supra*). IL-21 binds to IL-21R (also referred to herein as MU-1 and NILR). Upon IL-21 binding, activation of IL-21R leads to STAT5 or STAT3 signaling (Ozaki et al. (2000) *supra*). The term “IL-21” or “IL-21 polypeptide” refers to a protein (preferably of mammalian, e.g., murine or human origin) which is capable of interacting with, e.g., binding to, IL-21R (preferably of mammalian, e.g., murine or human IL-21) and having one of the following features: (i) an amino acid sequence of a naturally occurring mammalian IL-21 or a fragment thereof, e.g., an amino acid sequence shown as SEQ ID NO:19 (human) or a fragment thereof; (ii) an amino acid sequence substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, an amino acid sequence shown as SEQ ID NO:19 (human) or a fragment thereof; (iii) an amino acid sequence which is encoded by a naturally occurring mammalian IL-21 nucleotide sequence or a fragment thereof (e.g., SEQ ID NO:18 (human) or a fragment thereof); (iv) an amino acid sequence encoded by a nucleotide sequence which is substantially homologous to, e.g., at least 85%, 90%, 95%, 98%, 99% homologous to, a nucleotide sequence shown as SEQ ID NO:18 (human) or a fragment thereof; (v) an amino acid sequence encoded by a nucleotide sequence degenerate to a naturally occurring IL-21 nucleotide sequence or a fragment thereof, e.g., SEQ ID NO:19 (human) or a fragment thereof; or (vi) a nucleotide sequence that hybridizes to one of the foregoing nucleotide sequences under stringent conditions, e.g., highly stringent conditions.

- 25 -

[0089] The phrase “a biological activity of” a MU-1 or IL-21R polypeptide refers to one or more of the biological activities of the corresponding mature MU-1 protein, including, but not limited to, (1) interacting with, e.g., binding to, an IL-21 polypeptide (e.g., a human IL-21 polypeptide); (2) associating with signal transduction molecules, e.g., γ c, JAK1; (3) stimulating phosphorylation and/or activation of stat proteins, e.g., STAT5 and/or STAT3; and/or (4) modulating, e.g., stimulating or decreasing, proliferation, differentiation, effector cell function, cytolytic activity, cytokine secretion, and/or survival of immune cells, e.g., T cells (CD8+, CD4+ T cells), NK cells, B cells, macrophages and megakaryocytes).

[0090] As used herein, an “IL-21/IL-21R antagonist” that is useful in the method of the invention refers to an agent which reduces, inhibits or otherwise diminishes one or more biological activities of an IL-21R/MU-1 polypeptide. In one preferred embodiment, the antagonist interacts with, e.g., binds to, an IL-21R/MU-1 polypeptide. In another preferred embodiment, the antagonist interacts with, e.g., binds to, an IL-21 polypeptide. Antagonism using an IL-21/IL-21R antagonist does not necessarily indicate a total elimination of the biological activity of the IL-21R/MU-1 polypeptide and/or the IL-21 polypeptide.

[0091] As used herein, a “therapeutically effective amount” of an IL-21/IL-21R antagonist refers to an amount of an agent which is effective, upon single or multiple dose administration to a subject, e.g., a human patient, at curing, reducing the severity of, ameliorating, or preventing one or more symptoms of a disorder, or in prolonging the survival of the subject beyond that expected in the absence of such treatment.

[0092] As used herein, “a prophylactically effective amount” of an IL-21/IL-21R antagonist refers to an amount of an IL-21/IL-21R antagonist which is effective, upon single or multiple dose administration to a subject, e.g., a human patient, in preventing or delaying the occurrence of the onset or recurrence of a disorder, e.g., a disorder as described herein.

[0093] The terms “induce,” “inhibit,” “potentiate,” “elevate,” “increase,” “decrease” or the like, e.g., which denote quantitative differences between two states, refer to at least statistically significant differences between the two states.

- 26 -

[0094] The term “in combination” in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of treatment or in the subject.

[0095] As used herein, a “fusion protein” refers to a protein containing two or more operably associated, e.g., linked, moieties, e.g., protein moieties.

Preferably, the moieties are covalently associated. The moieties can be directly associated, or connected via a spacer or linker.

[0096] As used herein, the term “antibody” refers to a protein comprising at least one, and preferably two, heavy (H) chain variable regions (abbreviated herein as VH), and at least one and preferably two light (L) chain variable regions (abbreviated herein as VL). The VH and VL regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, termed “framework regions” (FR). The extent of the framework region and CDRs has been precisely defined (see, e.g., Kabat et al. (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia et al. (1987) *J. Mol. Biol.* 196:901-17, which are incorporated herein by reference). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0097] The antibody can further include a heavy and light chain constant region, to thereby form a heavy and light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are interconnected by, e.g., disulfide bonds. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. The light chain constant region is comprised of one domain, CL. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the

- 27 -

antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0098] As used herein, the term “immunoglobulin” refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin “light chains” (about 25 KDa or 214 amino acids) are encoded by a variable region gene at the NH₂-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH-terminus. Full-length immunoglobulin “heavy chains” (about 50 kDa or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids).

[0099] As used herein, “isotype” refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.

[0100] The term “antigen-binding fragment” of an antibody (or simply “antibody portion,” or “fragment”), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to an antigen (e.g., CD3). Examples of binding fragments encompassed within the term “antigen-binding fragment” of an antibody include (i) an Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) an F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a

- 28 -

single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see, e.g., Bird et al. (1988) *Science* 242:423-26; and Huston et al. (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:5879-83). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding fragment” of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0101] Sequences similar or homologous (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiments, the sequence identity can be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will hybridize under selective hybridization conditions (e.g., highly stringent hybridization conditions) to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.

[0102] Calculations of “homology” or “sequence identity” between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and nonhomologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions

shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0103] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) *J. Mol. Biol.* 48:444-53) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a BLOSUM 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used if the practitioner is uncertain about what parameters should be applied to determine if a molecule is within a sequence identity or homology limitation of the invention) are a BLOSUM 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of Meyers and Miller ((1989) *CABIOS*, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

[0104] As used herein, the term “hybridizes under stringent conditions” describes conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. A preferred, example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization

- 30 -

conditions are hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions are hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Preferably, stringent hybridization conditions are hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. Particularly preferred highly stringent conditions (and the conditions that should be used if the practitioner is uncertain about what conditions should be applied to determine if a molecule is within a hybridization limitation of the invention) are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. The isolated polynucleotides of the present invention may be used as hybridization probes and primers to identify and isolate nucleic acids having sequences identical to or similar to those encoding the disclosed polynucleotides. Hybridization methods for identifying and isolating nucleic acids include polymerase chain reaction (PCR), Southern hybridizations, *in situ* hybridization and Northern hybridization, and are well known to those skilled in the art. Further disclosure regarding hybridization conditions and reactions is provided herein.

[0105] Hybridization reactions can be performed under conditions of different stringency. The stringency of a hybridization reaction includes the difficulty with which any two nucleic acid molecules will hybridize to one another. Preferably, each hybridizing polynucleotide hybridizes to its corresponding polynucleotide under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions. Examples of stringency conditions are shown in Table 1 below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

TABLE 1

Stringency Condition	Poly-nucleotide Hybrid	Hybrid Length (bp) ¹	Hybridization Temperature and Buffer ²	Wash Temperature and Buffer ²
A	DNA:DNA	> 50	65°C; 1X SSC -or- 42°C; 1X SSC, 50% formamide	65°C; 0.3X SSC
B	DNA:DNA	<50	T _B *; 1X SSC	T _B *; 1X SSC
C	DNA:RNA	> 50	67°C; 1X SSC -or- 45°C; 1X SSC, 50% formamide	67°C; 0.3X SSC
D	DNA:RNA	<50	T _D *; 1X SSC	T _D *; 1X SSC
E	RNA:RNA	>50	70°C; 1X SSC -or- 50°C; 1X SSC, 50% formamide	70°C; 0.3X SSC
F	RNA:RNA	<50	T _F *; 1X SSC	T _F *; 1X SSC
G	DNA:DNA	>50	65°C; 4X SSC -or- 42°C; 4X SSC, 50% formamide	65°C; 1X SSC
H	DNA:DNA	<50	T _H *; 4X SSC	T _H *; 4X SSC
I	DNA:RNA	>50	67°C; 4X SSC -or- 45°C; 4X SSC, 50% formamide	67°C; 1X SSC
J	DNA:RNA	<50	T _J *; 4X SSC	T _J *; 4X SSC
K	RNA:RNA	>50	70°C; 4X SSC -or- 50°C; 4X SSC, 50% formamide	67°C; 1X SSC
L	RNA:RNA	<50	T _L *; 2X SSC	T _L *; 2X SSC
M	DNA:DNA	>50	50°C; 4X SSC -or- 40°C; 6X SSC, 50% formamide	50°C; 2X SSC
N	DNA:DNA	<50	T _N *; 6X SSC	T _N *; 6X SSC
O	DNA:RNA	>50	55°C; 4X SSC -or- 42°C; 6X SSC, 50% formamide	55°C; 2X SSC
P	DNA:RNA	<50	T _P *; 6X SSC	T _P *; 6X SSC
Q	RNA:RNA	>50	60°C; 4X SSC -or- 45°C; 6X SSC, 50% formamide	60°C; 2X SSC
R	RNA:RNA	<50	T _R *; 4X SSC	T _R *; 4X SSC

¹The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

²SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

T_B* - T_R*: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀Na⁺) + 0.41(%G + C) - (600/N), where N is the number of bases in the hybrid, and Na⁺ is the concentration of sodium ions in the hybridization buffer (Na⁺ for 1X SSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Chs. 9 & 11, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and Ausubel et al., eds., *Current Protocols in Molecular Biology*, Sects. 2.10 & 6.3-6.4, John Wiley & Sons, Inc. (1995), herein incorporated by reference.

[0106] The isolated polynucleotides of the present invention may be used as hybridization probes and primers to identify and isolate DNA having sequences encoding allelic variants of the disclosed polynucleotides. Allelic variants are naturally occurring alternative forms of the disclosed polynucleotides that encode polypeptides that are identical to or have significant similarity to the polypeptides encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 90% sequence identity (more preferably, at least 95% identity; most preferably, at least 99% identity) with the disclosed polynucleotides.

[0107] The isolated polynucleotides of the present invention may also be used as hybridization probes and primers to identify and isolate DNAs having sequences encoding polypeptides homologous to the disclosed polynucleotides. These homologs are polynucleotides and polypeptides isolated from a different species than that of the disclosed polypeptides and polynucleotides, or within the same species, but with significant sequence similarity to the disclosed polynucleotides and polypeptides. Preferably, polynucleotide homologs have at least 50% sequence identity (more preferably, at least 75% identity; most preferably, at least 90% identity) with the disclosed polynucleotides, whereas polypeptide homologs have at least 30% sequence identity (more preferably, at least 45% identity; most preferably, at least 60% identity) with the disclosed polypeptides. Preferably, homologs of the disclosed polynucleotides and polypeptides are those isolated from mammalian species.

[0108] The isolated polynucleotides of the present invention may also be used as hybridization probes and primers to identify cells and tissues that express the polypeptides of the present invention and the conditions under which they are expressed.

[0109] It is understood that the IL-21/IL-21R antagonists of the present invention may have additional conservative or nonessential amino acid substitutions, which do not have a substantial effect on their functions. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino

- 33 -

acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0110] The term “recombinant host cell” (or simply “host cell”), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but also to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein.

IL-21/IL-21R Antagonists

[0111] In one embodiment, an IL-21R/MU-1 polypeptide or active fragments thereof may be fused to a second moiety, e.g., an immunoglobulin or a fragment thereof (e.g., an Fc binding fragment thereof). For example, soluble forms of the IL-21R/MU-1 may be fused through “linker” sequences to the Fc portion of an immunoglobulin. Other fusion proteins, such as those with GST, Lex-A or MBP, may also be used.

[0112] The fusion proteins may additionally include a linker sequence joining the IL-21 or IL-21R fragment to the second moiety. For example, the fusion protein can include a peptide linker, e.g., a peptide linker of about 4 to 20, more preferably, 5 to 10, amino acids in length; in one embodiment, the peptide linker is 8 amino acids in length. Each of the amino acids in the peptide linker is selected from the group consisting of Gly, Ser, Asn, Thr and Ala; in one embodiment, the peptide linker includes a Gly-Ser element. In other embodiments, the fusion protein includes a peptide linker and the peptide linker

- 34 -

includes a sequence having the formula (Ser-Gly-Gly-Gly- Gly)_y wherein y is 1, 2, 3, 4, 5, 6, 7, or 8.

[0113] In other embodiments, additional amino acid sequences can be added to the N- or C-terminus of the fusion protein to facilitate expression, detection and/or isolation or purification. For example, IL-21/IL-21R fusion protein may be linked to one or more additional moieties, e.g., GST, His₆ tag, FLAG tag. For example, the fusion protein may additionally be linked to a GST fusion protein in which the fusion protein sequences are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of the MU-1 fusion protein.

[0114] In another embodiment, the fusion protein includes a heterologous signal sequence (i.e., a polypeptide sequence that is not present in a polypeptide encoded by a MU-1 nucleic acid) at its N-terminus. For example, the native MU-1 signal sequence can be removed and replaced with a signal sequence from another protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of MU-1 can be increased through use of a heterologous signal sequence.

[0115] A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) *Current Protocols in Molecular Biology*, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that encode a fusion moiety (e.g.,

- 35 -

an Fc region of an immunoglobulin heavy chain). A MU-1-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the immunoglobulin protein. In some embodiments, MU-1 fusion polypeptides exist as oligomers, such as dimers or trimers. The first polypeptide, and/or nucleic acids encoding the first polypeptide, can be constructed using methods known in the art.

[0116] In some embodiments, the MU-1 polypeptide moiety is provided as a variant MU-1 polypeptide having a mutation in the naturally occurring MU-1 sequence (wild type) that results in higher affinity (relative to the nonmutated sequence) binding of the MU-1 polypeptide to an IL-21.

[0117] In some embodiments, the MU-1 polypeptide moiety is provided as a variant MU-1 polypeptide having mutations in the naturally occurring MU-1 sequence (wild type) that results in a MU-1 sequence more resistant to proteolysis (relative to the nonmutated sequence). In some embodiments, the first polypeptide includes full-length MU-1 polypeptide. Alternatively, the first polypeptide comprises less than full-length MU-1 polypeptide.

[0118] A signal peptide that can be included in the fusion protein is MPLLLLLLLLLPSPLHP (SEQ ID NO:21). If desired, one or more amino acids can additionally be inserted between the first polypeptide moiety comprising the MU-1 moiety and the second polypeptide moiety.

[0119] The second polypeptide is preferably soluble. In some embodiments, the second polypeptide enhances the half-life, (e.g., the serum half-life) of the linked polypeptide. In some embodiments, the second polypeptide includes a sequence that facilitates association of the fusion polypeptide with a second MU-1 polypeptide. In preferred embodiments, the second polypeptide includes at least a region of an immunoglobulin polypeptide. Immunoglobulin fusions polypeptides are known in the art and are described in, e.g., U.S. Patent Nos. 5,516,964; 5,225,538; 5,428,130; 5,514,582; 5,714,147; and 5,455,165.

[0120] In some embodiments, the second polypeptide comprises a full-length immunoglobulin polypeptide. Alternatively, the second polypeptide comprises less than full-length immunoglobulin polypeptide, e.g., a heavy chain, light chain,

- 36 -

Fab, Fab₂, Fv, or Fc. Preferably, the second polypeptide includes the heavy chain of an immunoglobulin polypeptide. More preferably, the second polypeptide includes the Fc region of an immunoglobulin polypeptide.

[0121] In another aspect of the invention, the second polypeptide has less effector function than the effector function of a Fc region of a wild-type immunoglobulin heavy chain. Fc effector function includes for example, Fc receptor binding, complement fixation and T cell depleting activity (see, e.g., U.S. Patent No. 6,136,310). Methods for assaying T cell-depleting activity, Fc effector function, and antibody stability are known in the art. In one embodiment, the second polypeptide has low or no affinity for the Fc receptor. In an alternative embodiment, the second polypeptide has low or no affinity for complement protein C1q.

[0122] A preferred second polypeptide sequence includes the amino acid sequence of SEQ ID NO: 17. This sequence includes an Fc region. Underlined amino acids are those that differ from the amino acid found in the corresponding position of the wild-type immunoglobulin sequence:

HTCPPCPAPEALGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPVPPIEKTISKAKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMEALHNHYTQKSLSLSPGK (SEQ ID NO:17)

[0123] Examples of antagonistic fusion proteins that can be used in the methods of the invention are shown in FIGS. 7-15. In one embodiment, the fusion protein includes an amino acid sequence chosen from, e.g., SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, or SEQ ID NO:39, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. In other embodiments, the fusion protein includes an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or SEQ ID NO:38, or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Preferred fusion proteins have the amino acid sequence shown as SEQ ID NO:25 or SEQ ID NO:29 (FIGS. 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. In other embodiments, the fusion

- 37 -

protein includes an amino acid sequence encoded by a nucleotide sequence chosen from, e.g., SEQ ID NO:24 or SEQ ID NO:28 (FIGS. 8A-8C and 10A-10C, respectively), or a sequence at least 85%, 90%, 95%, 98% or more identical thereto. Most preferably, the fusion protein has the amino acid sequence shown as SEQ ID NO:29, or has an amino acid sequence encoded by a nucleotide sequence shown as SEQ ID NO:28 (FIG. 10A-10C).

[0124] In other embodiments, the IL-21/IL-21R antagonists are antibodies, or antigen-binding fragments thereof, that bind to IL-21 or IL-21R, preferably, mammalian (e.g., human or murine) IL-21 or IL-21R.

[0125] MU-1 proteins of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the MU-1 protein and which may inhibit binding of ligands to the receptor. Such antibodies may be obtained using the entire MU-1 as an immunogen, or by using fragments of MU-1. Smaller fragments of the MU-1 may also be used to immunize animals. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues. Methods for synthesizing such peptides are well known in the art.

[0126] Neutralizing or nonneutralizing antibodies (preferably monoclonal antibodies) binding to MU-1 protein may also be useful in the treatment of conditions described above. These neutralizing monoclonal antibodies may be capable of blocking ligand binding to the MU-1 receptor chain.

[0127] The present invention further provides for compositions comprising an antibody that specifically reacts with an IL-21 or an IL-21R.

[0128] Human monoclonal antibodies (mAbs) directed against IL-21 or IL-21R can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al., International Publication WO 91/00906, Kucherlapati et

al., International Publication WO 91/10741; Lonberg et al., International Publication WO 92/03918; Kay et al., International Publication WO 92/03917; Lonberg et al. (1994) *Nature* 368:856-59; Green et al. (1994) *Nat. Genet.* 7:13-21; Morrison et al. (1994) *Proc. Natl. Acad. Sci. U.S.A.* 81:6851-55; Bruggeman et al. (1993) *Year Immunol.* 7:33-40; Tuaillon et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:3720-24; Bruggeman et al. (1991) *Eur. J. Immunol.* 21:1323-1326).

[0129] Monoclonal antibodies can also be generated by other methods known to those skilled in the art of recombinant DNA technology. An alternative method, referred to as the “combinatorial antibody display” method, has been developed to identify and isolate antibody fragments having a particular antigen specificity, and can be utilized to produce monoclonal antibodies; this method is well known in the art. After immunizing an animal with an immunogen, the antibody repertoire of the resulting B cell pool is cloned. Methods are generally known for obtaining the DNA sequence of the variable regions of a diverse population of immunoglobulin molecules by using a mixture of oligomer primers and PCR. For instance, mixed oligonucleotide primers corresponding to the 5' leader (signal peptide) sequences and/or framework 1 (FR1) sequences, as well as primer to a conserved 3' constant region primer can be used for PCR amplification of the heavy and light chain variable regions from a number of murine antibodies (Larrick et al. (1991) *Biotechniques* 11:152-56). A similar strategy can also be used to amplify human heavy and light chain variable regions from human antibodies (Larrick et al. (1991) *Methods: Companion to Methods in Enzymology* 2:106-10).

[0130] Chimeric antibodies, including chimeric immunoglobulin chains, can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted (see, e.g., Robinson et al., International Patent Publication PCT/US86/02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European

Patent Application 173,494; Neuberger et al., International Publication WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-43; Liu et al. (1987) *Proc. Natl. Acad. Sci. U.S.A.* 84:3439-43; Liu et al. (1987) *J. Immunol.* 139:3521-26; Sun et al. (1987) *Proc. Natl. Acad. Sci. U.S.A.* 84:214-18; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-49; Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-59).

[0131] An antibody or an immunoglobulin chain can be humanized by methods known in the art. Humanized antibodies, including humanized immunoglobulin chains, can be generated by replacing sequences of the Fv variable region that are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison (1985) *Science* 229:1202-07; Oi et al. (1986) *BioTechniques* 4:214; and Queen et al. U.S. Patent Nos. 5,585,089, 5,693,761 and 5,693,762, the contents of all of which are hereby incorporated by reference. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Sources of such nucleic acids are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an antibody against a predetermined target. The recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.

[0132] Humanized or CDR-grafted antibody molecules or immunoglobulins can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced (see, e.g., U.S. Patent No. 5,225,539; Jones et al. (1986) *Nature* 321:552-25; Verhoeyan et al. (1988) *Science* 239:1534; Beidler et al. (1988) *J. Immunol.* 141:4053-60; Winter, U.S. Patent No. 5,225,539, the contents of all of which are hereby incorporated by reference. Winter describes a CDR-grafting method that may be used to prepare the humanized antibodies of the present invention (U.K. Patent Application GB 2188638A, filed on March 26, 1987; Winter U.S. Patent No. 5,225,539, the

contents of which are hereby incorporated by reference). All of the CDRs of a particular human antibody may be replaced with at least a portion of a nonhuman CDR or only some of the CDRs may be replaced with nonhuman CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to a predetermined antigen.

[0133] Monoclonal, chimeric and humanized antibodies, which have been modified by, e.g., deleting, adding, or substituting other portions of the antibody, e.g., the constant region, are also within the scope of the invention. For example, an antibody can be modified by: (i) deleting the constant region; (ii) replacing the constant region with another constant region, e.g., a constant region meant to increase half-life, stability or affinity of the antibody, or a constant region from another species or antibody class; or (iii) modifying one or more amino acids in the constant region to alter, for example, the number of glycosylation sites, effector cell function, Fc receptor (FcR) binding, complement fixation, among others.

[0134] Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C1 component of complement, can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see, e.g., E.P. 388,151 A1, U.S. 5,624,821 and U.S. 5,648,260, the contents of all of which are hereby incorporated by reference). Similar types of alterations could be described that, if applied to the murine or other species immunoglobulin, would reduce or eliminate these functions.

[0135] For example, it is possible to alter the affinity of an Fc region of an antibody (e.g., an IgG, such as a human IgG) for an FcR (e.g., Fc gamma R1), or for C1q binding by replacing the specified residue(s) with a residue(s) having an appropriate functionality on its side chain, or by introducing a charged functional group, such as glutamate or aspartate, or perhaps an aromatic nonpolar residue such as phenylalanine, tyrosine, tryptophan or alanine (see, e.g., U.S. 5,624,821).

[0136] Amino acid sequences of IL-21 polypeptides are publicly known. For example, the nucleotide sequence and amino acid sequence of a human IL-21 is

- 41 -

available at GENBANK[®] Acc. No. X_011082. The disclosed human IL-21 nucleotide sequence is presented below:

```

1   gctgaagtga aaacgagacc aaggtctagc tctactgttg gtacttatga gatccagtc
61  tggcaacatg gagaggattg tcatctgtct gatggtcac ttcttgggga cactggtcca
121 caaatcaagc tccaagggtc aagatcgcca catgattaga atgcgtcaac ttatagatat
181 tgttgatcag ctgaaaaatt atgtgaatga cttggtcctt gaatttctgc cagctccaga
241 agatgtagag acaaaactgtg agtggtcagc tttttcctgc ttccagaagg cccaactaaa
301 gtcagcaaat acaggaaaca atgaaaggat aatcaatgta tcaattaaaa agctgaagag
361 gaaaccacct tccacaaatg cagggagaag acagaaacac agactaacat gcccttcatg
421 tgattcttat gagaaaaaac caccctaaaga attcctagaa agattcaaat cacttctcca
481 aaagatgatt catcagcatc tgtcctctag aacacacgga agtgaagatt cctgaggatc
541 taacttgtag ttggacacta tgttacatac tctaataatag tagtgaaagt catttctttg
601 tattccaagt ggaggag (SEQ ID NO:18)

```

[0137] The amino acid sequence of the disclosed human IL-21 polypeptide is presented below:

```

MRSSPGNMERIVICLMVIFLGLTVHKSSSQGQDRHMIRMRLIDIVDQLKNYVNDLVPEFLPAPED
VETNCEWSAFSCFQKAQLKSANTGNNERI INVS IKKLKRKPPSTNAGRRQKHRLTCPSCDSEYKPK
PKEFLERFKSLLQKMIHQHLSSRTHGSEDS (SEQ ID NO:19)

```

[0138] The invention also encompasses nucleic acids that hybridize to the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or SEQ ID NO:38, under highly stringent conditions (for example, 0.1X SSC at 65° C.). Isolated polynucleotides which encode MU-1 proteins or fusion proteins, but which differ from the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or SEQ ID NO:38, by virtue of the degeneracy of the genetic code are also encompassed by the present invention. Variations in the nucleotide sequence as set forth in SEQ ID NO:1, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, or SEQ ID NO:38, which are caused by point mutations or by induced modifications are also included in the invention.

[0139] The isolated polynucleotides of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al. (1991) *Nucleic Acids Res.* 19:4485-90, in order to produce the MU-1 protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in Kaufman (1990) *Methods in*

- 42 -

Enzymology 185:537-66. As defined herein “operably linked” means enzymatically or chemically ligated to form a covalent bond between the isolated polynucleotide of the invention and the expression control sequence, in such a way that the MU-1 protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

[0140] The term “vector”, as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.

One type of vector is a “plasmid”, which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., nonepisomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector.

However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0141] The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel (1990) *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA. It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on

- 43 -

such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Preferred regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from FF-1a promoter and BGH poly A, cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and sequences thereof, see, e.g., U.S. Patent Nos. 5,168,062; 4,510,245; 4,968,615.

[0142] The recombinant expression vectors of the invention may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see, e.g., U.S. Patents Nos. 4,399,216; 4,634,665; 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in *dhfr*⁻ host cells with methotrexate selection/amplification) and the *neo* gene (for G418 selection).

[0143] A number of types of cells may act as suitable host cells for expression of the MU-1 protein or fusion protein thereof. Any cell type capable of expressing functional MU-1 protein may be used. Suitable mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12, M1x or C2C12 cells.

[0144] The MU-1 protein or fusion protein thereof may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect

- 44 -

expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, CA (e.g., the MAXBAC[®] kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. Soluble forms of the MU-1 protein may also be produced in insect cells using appropriate isolated polynucleotides as described above.

[0145] Alternatively, the MU-1 protein or fusion protein thereof may be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces strains*, *Candida*, or any yeast strain capable of expressing heterologous proteins. Suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins.

[0146] Expression in bacteria may result in formation of inclusion bodies incorporating the recombinant protein. Thus, refolding of the recombinant protein may be required in order to produce active or more active material. Several methods for obtaining correctly folded heterologous proteins from bacterial inclusion bodies are known in the art. These methods generally involve solubilizing the protein from the inclusion bodies, then denaturing the protein completely using a chaotropic agent. When cysteine residues are present in the primary amino acid sequence of the protein, it is often necessary to accomplish the refolding in an environment that allows correct formation of disulfide bonds (a redox system). General methods of refolding are disclosed in Kohno (1990) *Meth. Enzym.* 185:187-95; E.P. 0433225 and U.S. Patent No. 5,399,677 describe other appropriate methods.

[0147] The MU-1 protein or fusion protein thereof may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the MU-1 protein or fusion protein thereof.

[0148] The MU-1 protein or fusion protein thereof may be prepared by growing culture transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. Soluble forms of the MU-1 protein or fusion protein thereof can be purified from conditioned media. Membrane-bound forms of MU-1 protein of the invention can be purified by preparing a total membrane fraction from the expressing cell and extracting the membranes with a nonionic detergent such as TRITON[®] X-100.

[0149] The MU-1 protein or fusion protein can be purified using methods known to those skilled in the art. For example, the MU-1 protein of the invention can be concentrated using a commercially available protein concentration filter, for example, an AMICON[®] or PELLICON[®] ultrafiltration unit (Millipore, Billerica, MA). Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) or polyethyleimine (PEI) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred (e.g., S-SEPHAROSE[®] columns). The purification of the MU-1 protein or fusion protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-TOYOPEARL[®] or Cibacron blue 3GA SEPHAROSE[®]; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography. Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the MU-1 protein. Affinity columns including antibodies to the MU-1 protein can also be used in purification in accordance with known methods. Some or all of the foregoing

- 46 -

purification steps, in various combinations or with other known methods, can also be employed to provide a substantially purified isolated recombinant protein. Preferably, the isolated MU-1 protein is purified so that it is substantially free of other mammalian proteins.

[0150] MU-1 proteins or fusion proteins of the invention may also be used to screen for agents that are capable of binding to MU-1. Binding assays using a desired binding protein, immobilized or not, are well known in the art and may be used for this purpose using the MU-1 protein of the invention. Purified cell-based or protein-based (cell free) screening assays may be used to identify such agents. For example, MU-1 protein may be immobilized in purified form on a carrier and binding of potential ligands to purified MU-1 protein may be measured.

Pharmaceutical Compositions

[0151] IL-21/IL-21R-antagonists may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to the IL-21/IL-21R-antagonists and carrier, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a nontoxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.

[0152] The pharmaceutical composition of the invention may be in the form of a liposome in which an IL-21/IL-21R-antagonist(s) is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids that exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which are in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, e.g., in

U.S. Patent Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference.

[0153] As used herein, the term “therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, e.g., amelioration of symptoms of, healing of, or increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

[0154] In practicing the method of treatment or use of the present invention, a therapeutically effective amount of an IL-21/IL-21R-antagonist is administered to a subject, e.g., mammal (e.g., a human). An IL-21/IL-21R-antagonist(s) may be administered in accordance with the method of the invention either alone or in combination with other therapies as described in more detail herein. When coadministered with one or more agents, an IL-21- and/or IL-21R-antagonist may be administered either simultaneously with the second agent, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering the IL-21/IL-21R-antagonist(s) in combination with other agents.

[0155] Administration of an IL-21/IL-21R-antagonist used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.

[0156] When a therapeutically effective amount of an IL-21/IL-21R-agonist or antagonist is administered orally, the binding agent will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% binding agent, and preferably from about 25 to 90% binding

agent. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of the binding agent, and preferably from about 1 to 50% the binding agent.

[0157] When a therapeutically effective amount of an IL-21/IL-21R-antagonist is administered by intravenous, cutaneous or subcutaneous injection, binding agent will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to binding agent an isotonic vehicle such as sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, lactated Ringer's injection, or other vehicles as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.

[0158] The amount of an IL-21/IL-21R-antagonist in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments that the patient has undergone. Ultimately, the attending physician will decide the amount of binding agent with which to treat each individual patient. Initially, the attending physician will administer low doses of binding agent and observe the patient's response. Larger doses of binding agent may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not generally increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 μ g to about 100 mg IL-21/IL-21R-antagonist per kg body weight.

[0159] The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the IL-21/IL-21R-antagonist will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

[0160] The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Uses of IL-21/IL-21R Antagonists to Decrease Immune Cell Activity

[0161] In yet another aspect, the invention features a method for inhibiting the activity of an immune cell, e.g., mature T cells (mature CD8⁺ T cells, mature CD4⁺ T cells), mature NK cells, B cells, macrophages and megakaryocytes, or a population thereof, by contacting a population of T cells with an IL-21/IL-21R antagonist in an amount sufficient to inhibit the activity of the immune cell or population. Antagonists of IL-21 and/or IL-21R (e.g., a fusion protein or a neutralizing antibody, as described herein) can also be administered to subjects for which inhibition of an immune response is desired. These conditions or disorders include, e.g., autoimmune disorders (e.g., arthritic disorders, RA, IBD), SLE, asthma, glomerulonephritis, psoriasis, or graft/organ transplantation (and rejection related thereto).

[0162] Applicants have shown that a reduction of IL-21R activity by using a neutralizing fusion protein that includes the extracellular domain of the IL-21R fused to an Fc immunoglobulin region ameliorates inflammatory symptoms in

collagen-induced arthritis (CIA) animal models (Example 7), as well as animal models for Crohn's disease, ulcerative colitis, and IBD (Examples 9 and 11), graft rejection (Example 10), psoriasis (Example 11), and lupus (Example 13). Expression of IL-21R mRNA is upregulated in the paws of CIA mice (Example 8). Mice deficient in IL-21R show a reduction in antigen-induced airway inflammation (Example 12). Accordingly, IL-21R binding agents that antagonize IL-21/IL-21R activity can be used to induce immune suppression *in vivo*, e.g., for treating or preventing immune cell-associated pathologies, including autoimmune disorders (e.g., arthritic disorders, RA, IBD), SLE, glomerulonephritis, asthma, psoriasis, or graft/organ transplantation.

[0163] The IL-21R DNA also maps to the chromosomal locus for Crohn's disease, thus providing additional support for the use of IL-21/IL-21R antagonists to treat Crohn's disease and other inflammatory bowel diseases.

[0164] The subject method can also be used to modulate (e.g., inhibit) the activity, e.g., proliferation, differentiation, survival, of an immune cell, and, thus, can be used to treat or prevent a variety of immune disorders. Nonlimiting examples of the disorders that can be treated or prevented include, but are not limited to, transplant rejection, autoimmune diseases (including, for example, diabetes mellitus, arthritis (including RA, juvenile RA, osteoarthritis (OA), psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, SLE, glomerulonephritis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis and related skin conditions (e.g., conditions associated with UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, vitiligo, ocular cicatricial pemphigoid, and urticaria), Sjögren's syndrome, Crohn's disease, aphthous ulcer, iritis, ulcerative colitis, spondyloarthropathy, ankylosing spondylitis, intrinsic asthma, allergic asthma, chronic obstructive pulmonary disease (COPD), interstitial lung fibrosis, cutaneous lupus erythematosus, scleroderma, drug eruptions, autoimmune uveitis, allergic encephalomyelitis, Wegener's granulomatosis, hepatitis, Stevens-Johnson syndrome, idiopathic sprue, Graves'

disease, sarcoidosis, liver fibrosis, primary biliary cirrhosis, uveitis posterior, graft-versus-host disease, and allergy, such as atopic allergy. Preferred disorders that can be treated using the IL-21/IL-21R antagonists include arthritic disorders (e.g., RA, juvenile RA, OA, psoriatic arthritis, and ankylosing spondylitis (preferably, rheumatoid arthritis)), multiple sclerosis, type I diabetes, lupus (SLE), IBD (Crohn's disease, ulcerative colitis), asthma, vasculitis, allergy, scleroderma, glomerulonephritis and psoriasis.

[0165] In another embodiment, IL-21/IL-21R antagonists, alone or in combination with other therapeutic agents as described herein (e.g., TNF antagonists), can be used to treat multiple myeloma and related B lymphocytic malignancies (Brenne et al. (2002) *Blood* 99(10):3756-62).

[0166] Using the IL-21/IL-21R antagonists, it is possible to modulate immune responses in a number of ways. Downregulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, nonantigen-specific, process that requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing nonresponsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

[0167] Downregulating or preventing immune functions, e.g., using IL-21/IL-21R antagonists, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, inhibiting T cell function may reduce tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of an IL-21/IL-21R antagonist, alone or in combination with

a molecule which inhibits or blocks interaction of other immune effectors prior to, during, or following transplantation, can serve to reduce immune responses.

[0168] The efficacy of IL-21/IL-21R antagonists in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy and dosing in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4 Ig fusion proteins *in vivo*, as described in Lenschow et al. (1992) *Science* 257:789-92 and Turka et al. (1992) *Proc. Natl. Acad. Sci U.S.A.*, 89:11102-05. IL-21/IL-21R antagonists can also be evaluated in other animal models, e.g., in murine models for vascularized cardiac allografts, and full thickness skin allografts. The model can test rejection of tissues that have full MHC mismatches, and can combine IL-21 blockade with donor specific lymphocyte transfusion. In addition, murine models of GVHD (see, e.g., Paul ed., *Fundamental Immunology*, Raven Press, New York (1989) pp. 846-47) can be used to determine the effect of IL-21/IL-21R antagonists *in vivo* on the development of GVHD or SLE. The efficacy of IL-21/IL-21R antagonists in preventing organ transplant rejection or GVHD can also be assessed in combination with other therapeutic agents, e.g., an immunosuppressant, such as rapamycin, cyclosporine, or CTLA4Ig.

[0169] IL-21/IL-21R antagonists may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and that promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of IL-21/IL-21R antagonists, alone or in combination with other agents (e.g., as described herein) can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines that may be involved in the disease process. Additionally, IL-21/IL-21R antagonists, alone or in combination with other agents (e.g., as described herein) increase antigen-specific tolerance of autoreactive T cells and

lead to long-term relief from the disease. The efficacy of these agents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see, e.g., Paul ed., *Fundamental Immunology*, Raven Press, New York (1989) pp. 840-56).

[0170] In one embodiment, the IL-21/IL-21R antagonists, e.g., pharmaceutical compositions thereof, are administered in combination therapy, i.e., combined with other agents, e.g., therapeutic agents, which are useful for treating pathological conditions or disorders, such as immune and inflammatory disorders.

The term "in combination" in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of treatment or in the subject.

[0171] For example, the combination therapy can include one or more IL-21/IL-21R antagonists, e.g., an antibody or an antigen-binding fragment thereof (e.g., a chimeric, humanized, human, or *in vitro*-generated antibody or antigen-binding fragment thereof) against IL-21 or IL-21 receptor, an IL-21 fusion protein, a soluble IL-21 receptor, peptide inhibitor or a small molecule inhibitor) coformulated with, and/or coadministered with, one or more additional therapeutic agents, e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more detail herein. Furthermore, one or more IL-21/IL-21R antagonists described herein may be used in combination with two or more of the therapeutic agents described herein. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies. Moreover, the

- 54 -

therapeutic agents disclosed herein act on pathways that differ from the IL-21/IL-21R receptor pathway, and thus are expected to enhance and/or synergize with the effects of the IL-21/IL-21R antagonists.

[0172] Preferred therapeutic agents used in combination with an IL-21/IL-21R antagonist are those agents that interfere at different stages in the autoimmune and subsequent inflammatory response. In one embodiment, one or more IL-21/IL-21R antagonists described herein may be coformulated with, and/or coadministered with, one or more additional agents such as other cytokine or growth factor antagonists (e.g., soluble receptors, peptide inhibitors, small molecules, ligand fusions); or antibodies or antigen-binding fragments thereof that bind to other targets (e.g., antibodies that bind to other cytokines or growth factors, their receptors, or other cell surface molecules); and anti-inflammatory cytokines or agonists thereof. Nonlimiting examples of the agents that can be used in combination with the IL-21/IL-21R antagonists described herein, include, but are not limited to, antagonists of one or more interleukins (ILs) or their receptors, e.g., antagonists of IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, and IL-22; antagonists of cytokines or growth factors or their receptors, such as tumor necrosis factor (TNF), LT, EMAP-II, GM-CSF, FGF and PDGF. IL-21/IL-21R antagonists can also be combined with inhibitors of, e.g., antibodies to, cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, or their ligands, including CD154 (gp39 or CD40L), or LFA-1/ ICAM-1 and VLA-4/VCAM-1 (Yusuf-Makagiansar et al. (2002) *Med. Res. Rev.* 22(2):146-67). Preferred antagonists that can be used in combination with IL-21/IL-21R antagonists described herein include antagonists of IL-1, IL-6, IL-12, TNF α , IL-15, IL-17, IL-18, and IL-22.

[0173] Examples of those agents include IL-12 antagonists, such as chimeric, humanized, human or *in vitro*-generated antibodies (or antigen-binding fragments thereof) that bind to IL-12 (preferably human IL-12), e.g., the antibody disclosed in WO 00/56772, Genetics Institute/BASF); IL-12 receptor inhibitors, e.g., antibodies to human IL-12 receptor; and soluble fragments of the IL-12 receptor,

- 55 -

e.g., human IL-12 receptor. Examples of IL-6 antagonists include antibodies (or antigen-binding fragments thereof) against IL-6 or its receptor, e.g., chimeric, humanized, human or *in vitro*-generated antibodies to human IL-6 or its receptor, soluble fragments of the IL-6 receptor, and IL-6-binding proteins. Examples of IL-15 antagonists include antibodies (or antigen-binding fragments thereof) against IL-15 or its receptor, e.g., chimeric, humanized, human or *in vitro*-generated antibodies to human IL-15 or its receptor, soluble fragments of the IL-15 receptor, and IL-15-binding proteins. Examples of IL-18 antagonists include antibodies, e.g., chimeric, humanized, human or *in vitro*-generated antibodies (or antigen-binding fragments thereof), to human IL-18, soluble fragments of the IL-18 receptor, and IL-18 binding proteins (IL-18BP, Mallat et al. (2001) *Circ. Res.* 89:e41-45). Examples of IL-1 antagonists include interleukin-1-converting enzyme (ICE) inhibitors, such as Vx740, IL-1 antagonists, e.g., IL-1RA (ANIKINRA™, Amgen), sIL1RII (Immunex), and anti-IL-1 receptor antibodies (or antigen-binding fragments thereof).

[0174] Examples of TNF antagonists include chimeric, humanized, human or *in vitro*-generated antibodies (or antigen-binding fragments thereof) to TNF (e.g., human TNF α), such as D2E7, (human TNF α antibody, U.S. 6,258,562; BASF), CDP-571/CDP-870/BAY-10-3356 (humanized anti-TNF α antibody; Celltech/Pharmacia), cA2 (chimeric anti-TNF α antibody; REMICADE™, Centocor); anti-TNF antibody fragments (e.g., CPD870); soluble fragments of the TNF receptors, e.g., p55 or p75 human TNF receptors or derivatives thereof, e.g., 75 kDa TNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBREL™; Immunex; see, e.g., *Arthritis & Rheumatism* (1994) Vol. 37, S295; *J. Invest. Med.* (1996) Vol. 44, 235A), p55 kDa TNFR-IgG (55 kDa TNF receptor-IgG fusion protein (Lenercept)); enzyme antagonists, e.g., TNF α converting enzyme (TACE) inhibitors (e.g., an alpha-sulfonyl hydroxamic acid derivative, WO 01/55112, and N-hydroxyformamide TACE inhibitor GW 3333, -005, or -022); and TNF-bp/s-TNFR (soluble TNF binding protein; see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S284; *Amer. J. Physiol. - Heart and Circulatory Physiology* (1995) Vol. 268, pp. 37-42). Preferred TNF antagonists are soluble

fragments of the TNF receptors, e.g., p55 or p75 human TNF receptors or derivatives thereof, e.g., 75 kDTNFR-IgG, and TNF- α converting enzyme (TACE) inhibitors.

[0175] In other embodiments, the IL-21-/IL-21R antagonists described herein can be administered in combination with one or more of the following: IL-13 antagonists, e.g., soluble IL-13 receptors (sIL-13) and/or antibodies against IL-13; IL-2 antagonists, e.g., DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen; see, e.g., *Arthritis & Rheumatism* (1993) Vol. 36, 1223), and/or antibodies to IL-2R, e.g., anti-Tac (humanized anti-IL-2R; Protein Design Labs, *Cancer Res.* (1990) Mar 1; 50(5):1495-502). Yet another combination includes IL-21 antagonists in combination with nondepleting anti-CD4 inhibitors (IDEC-CE9.1/SB 210396 (nondepleting primatized anti-CD4 antibody; IDEC/SmithKline)). Yet other preferred combinations include antagonists of the costimulatory pathway CD80 (B7.1) or CD86 (B7.2) including antibodies, soluble receptors or antagonistic ligands; as well as p-selectin glycoprotein ligand (PSGL), anti-inflammatory cytokines, e.g., IL-4 (DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10 DNAX/Schering); IL-13 and TGF, and agonists thereof (e.g., agonist antibodies).

[0176] In other embodiments, one or more IL-21/IL-21R antagonists can be coformulated with, and/or coadministered with, one or more anti-inflammatory drugs, immunosuppressants, or metabolic or enzymatic inhibitors. Nonlimiting examples of the drugs or inhibitors that can be used in combination with the IL-21 antagonists described herein, include, but are not limited to, one or more of: nonsteroidal anti-inflammatory drug(s) (NSAIDs), e.g., ibuprofen, tenidap (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S280)), naproxen (see, e.g., *Neuro Report* (1996) Vol. 7, pp. 1209-1213), meloxicam, piroxicam, diclofenac, and indomethacin; sulfasalazine (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S281); corticosteroids such as prednisolone; cytokine suppressive anti-inflammatory drug(s) (CSAIDs); inhibitors of nucleotide biosynthesis, e.g., inhibitors of purine biosynthesis, folate antagonists (e.g., methotrexate (N-[4-[(2,4-diamino-6-

pteridiny]methyl]methylamino]benzoyl]-L-glutamic acid); and inhibitors of pyrimidine biosynthesis, e.g., dihydroorotate dehydrogenase (DHODH) inhibitors (e.g., leflunomide (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S131; *Inflammation Research* (1996) Vol. 45, pp. 103-107).

Preferred therapeutic agents for use in combination with IL-21/IL-21R antagonists include NSAIDs, CSAIDs, (DHODH) inhibitors (e.g., leflunomide), and folate antagonists (e.g., methotrexate).

[0177] Examples of additional inhibitors include one or more of: corticosteroids (oral, inhaled and local injection); immunosuppressants, e.g., cyclosporin, tacrolimus (FK-506); and mTOR inhibitors, e.g., sirolimus (rapamycin) or rapamycin derivatives, e.g., soluble rapamycin derivatives (e.g., ester rapamycin derivatives, e.g., CCI-779 (Elit (2002) *Current Opinion Investig. Drugs* 3(8):1249-53; Huang et al.. (2002) *Current Opinion Investig. Drugs* 3(2):295-304); agents which interfere with signaling by proinflammatory cytokines such as TNF α or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors); COX2 inhibitors, e.g., celecoxib and variants thereof, MK-966, see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S81); phosphodiesterase inhibitors, e.g., R973401 (phosphodiesterase Type IV inhibitor; see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282)); phospholipase inhibitors, e.g., inhibitors of cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs (U.S. 6,350,892)); inhibitors of vascular endothelial cell growth factor or growth factor receptor, e.g., VEGF inhibitor and/or VEGF-R inhibitor; and inhibitors of angiogenesis. Preferred therapeutic agents for use in combination with IL-21/IL-21R antagonists include immunosuppressants, e.g., cyclosporin, tacrolimus (FK-506); and mTOR inhibitors, e.g., sirolimus (rapamycin) or rapamycin derivatives, e.g., soluble rapamycin derivatives (e.g., ester rapamycin derivatives, e.g., CCI-779; COX2 inhibitors, e.g., celecoxib and variants thereof; and phospholipase inhibitors, e.g., inhibitors of cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs).

[0178] Additional examples of therapeutic agents that can be combined with an IL-21/IL-21R antagonist include one or more of: 6-mercaptopurines (6-MP); azathioprine sulphasalazine; mesalazine; olsalazine chloroquine/hydroxychloroquine; pencillamine; aurothiornalate (intramuscular and oral); azathioprine; colchicine; beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeterol); xanthines (theophylline, aminophylline); cromoglycate; nedocromil; ketotifen; ipratropium and oxitropium; mycophenolate mofetil; adenosine agonists; antithrombotic agents; complement inhibitors; and adrenergic agents.

[0179] The use of the IL-21/IL-21R antagonists disclosed herein in combination with other therapeutic agents to treat or prevent specific immune disorders is discussed in further detail herein.

[0180] Nonlimiting examples of agents for treating or preventing arthritic disorders (e.g., RA, inflammatory arthritis, juvenile RA, OA and psoriatic arthritis), with which an IL-21/IL-21R antagonist can be combined include one or more of the following: IL-12 antagonists as described herein, NSAIDs; CSAIDs; TNFs, e.g., TNF α , antagonists as described herein; nondepleting anti-CD4 antibodies as described herein; IL-2 antagonists as described herein; anti-inflammatory cytokines, e.g., IL-4, IL-10, IL-13 and TGF α , or agonists thereof; IL-1 or IL-1 receptor antagonists as described herein; phosphodiesterase inhibitors as described herein; COX-2 inhibitors as described herein; Iloprost (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S82); methotrexate; thalidomide (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282) and thalidomide-related drugs (e.g., Celgen); leflunomide; inhibitor of plasminogen activation, e.g., tranexamic acid (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S284); cytokine inhibitor, e.g., T-614; see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282); prostaglandin E1 (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282); azathioprine (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S281); an inhibitor of interleukin-1 converting enzyme (ICE); zap-70 and/or lck inhibitor (inhibitor of the tyrosine kinase zap-70 or lck); an inhibitor of vascular endothelial cell growth factor or vascular endothelial cell

- 59 -

growth factor receptor as described herein; an inhibitor of angiogenesis as described herein; corticosteroid anti-inflammatory drugs (e.g., SB203580); TNF-convertase inhibitors; interleukin-11 (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S296); IL-13 (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S308); IL-17 inhibitors (see, e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S120); gold; penicillamine; chloroquine; hydroxychloroquine; chlorambucil; cyclophosphamide; cyclosporine; total lymphoid irradiation; anti-thymocyte globulin; CD5-toxins; orally-administered peptides and collagen; lobenzarit disodium; Cytokine Regulating Agents (CRAs) HP228 and HP466 (Houghten Pharmaceuticals, Inc.); ICAM-1 antisense phosphorothioate oligodeoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL-2R antibodies; marine and botanical lipids (fish and plant seed fatty acids; see, e.g., DeLuca et al. (1995) *Rheum. Dis. Clin. North Am.* 21:759-777); auranofin; phenylbutazone; meclofenamic acid; flufenamic acid; intravenous immune globulin; zileuton; mycophenolic acid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose (therafectin); cladribine (2-chlorodeoxyadenosine); and azaribine. Preferred combinations include one or more IL-21 antagonists in combination with methotrexate or leflunomide, and in moderate or severe rheumatoid arthritis cases, cyclosporine.

[0181] Preferred examples of inhibitors to use in combination with IL-21/IL-21R antagonists to treat arthritic disorders include TNF antagonists (e.g., chimeric, humanized, human or *in vitro*-generated antibodies, or antigen-binding fragments thereof, that bind to TNF; soluble fragments of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kDa TNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBREL™), p55 kDa TNF receptor-IgG fusion protein; TNF enzyme antagonists, e.g., TNF α converting enzyme (TACE) inhibitors); antagonists of IL-6, IL-12, IL-15, IL-17, IL-18, IL-22; T cell and B cell depleting agents (e.g., anti-CD4 or anti-CD22 antibodies); small molecule inhibitors, e.g., methotrexate and leflunomide; sirolimus (rapamycin) and analogs

thereof, e.g., CCI-779; Cox-2 and cPLA2 inhibitors; NSAIDs; p38 inhibitors, TPL-2, Mki-2 and NF κ B inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (e.g., small molecule inhibitors, antibodies thereto, e.g., antibodies to P-selectin); estrogen receptor beta (ERB) agonists or ERB-NF κ B antagonists. Most preferred additional therapeutic agents that can be coadministered and/or coformulated with one or more IL-21/IL-21R antagonists include one or more of: a soluble fragment of a TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kDa TNFR-IgG (75 kDa TNF receptor-IgG fusion protein, ENBRELTM); methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof, e.g., CCI-779.

[0182] Nonlimiting examples of agents for treating or preventing multiple sclerosis with which an IL-21-/IL-21R antagonist can be combined include the following: interferons, e.g., interferon-alpha 1a (e.g., AVONEXTM; Biogen) and interferon-1b (BETASERONTM; Chiron/Berlex); Copolymer 1 (Cop-1; COPAXONETM; Teva Pharmaceutical Industries, Inc.); hyperbaric oxygen; intravenous immunoglobulin; cladribine; TNF antagonists as described herein; corticosteroids; prednisolone; methylprednisolone; azathioprine; cyclophosphamide; cyclosporine; methotrexate; 4-aminopyridine; and tizanidine.

Additional antagonists that can be used in combination with IL-21 include antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16, IL-18, EMAP-11, GM-CSF, FGF, and PDGF. IL-21 antagonists as described herein can be combined with antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. The IL-21 antagonists may also be combined with agents, such as methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents that interfere with signaling by proinflammatory cytokines as described herein, IL-1b converting enzyme inhibitors (e.g., Vx740), anti-P7s, PSGL, TACE inhibitors, T cell

- 61 -

signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof, as described herein, and anti-inflammatory cytokines (e.g. IL-4, IL-10, IL-13 and TGF).

[0183] Preferred examples of therapeutic agents for multiple sclerosis with which the IL-21 antagonists can be combined include interferon- β , for example, IFN β -1a and IFN β -1b; copaxone, corticosteroids, IL-1 inhibitors, TNF inhibitors, antibodies to CD40 ligand and CD80, IL-12 antagonists.

[0184] Nonlimiting examples of agents for treating or preventing inflammatory bowel disease (Crohn's disease; ulcerative colitis) with which an IL-21/IL-21R antagonist can be combined include the following: budenoside; epidermal growth factor; corticosteroids; cyclosporin, sulfasalazine; aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide; antioxidants; thromboxane inhibitors; IL-1 receptor antagonists; anti-IL-1 monoclonal antibodies; anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors; pyridinyl-imidazole compounds; TNF antagonists as described herein; IL-4, IL-10, IL-13 and/or TGF β cytokines or agonists thereof (e.g., agonist antibodies); IL-11; glucuronide- or dextran-conjugated prodrugs of prednisolone, dexamethasone or budesonide; ICAM-1 antisense phosphorothioate oligodeoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); slow-release mesalazine; methotrexate; antagonists of platelet activating factor (PAF); ciprofloxacin; and lignocaine.

[0185] In one embodiment, an IL-21/IL-21R antagonist can be used in combination with one or more antibodies directed at other targets involved in regulating immune responses, e.g., transplant rejection, graft-vs-host disease, or other immune response-related disorders. Nonlimiting examples of agents for treating or preventing immune responses with which an IL-21/IL-21R antagonist of the invention can be combined include the following: antibodies against cell surface molecules or their ligands, including but not limited to CD25 (IL-2 receptor- α), CD11a (LFA-1), CD54 (ICAM-1), CD4, CD40, CD40L, CD45,

CD28/CTLA4, CD80 (B7-1) and/or CD86 (B7-2). In yet another embodiment, an IL-21/IL-21R antagonist can be used in combination with corticosteroids; sirolimus (rapamycin) and analogs thereof, e.g., CCI-779; cyclosporin A; FK506; FTY720; azathioprine; cyclophosphamide; methotrexate; anti-IL-2R antibodies, e.g., basiliximab, daclizumab; cA2 (chimeric anti-TNF α antibody; REMICADETM, Centocor); anti-CD3 antibodies (e.g., muromonab-CD3); Copolymer 1 (Cop-1; COPAXONETM; Teva Pharmaceutical Industries, Inc.); deoxyspergualin; and mycophenolate mofetil.

[0186] Nonlimiting examples of agents for treating or preventing psoriasis and other skin conditions with which an IL-21/IL-21R antagonist can be combined include one or more of the following: inhibitors of CD2 or LFA-3 interactions (e.g., soluble CD2- or LFA-polypeptides, such as Fc fusions, or antibodies against CD2 or LFA-3), cyclosporin A, prednisone, FK506, methotrexate, PUVA, UV light, steroids, retinoids, interferon, or nitrogen mustard. Examples of preferred agents that can be used in combination with an IL-21/IL-21R antagonist include cyclosporine A and methotrexate.

[0187] Nonlimiting examples of agents for treating or preventing asthma with which an IL-21/IL-21R antagonist can be combined include one or more of the following: inhaled bronchodilators, e.g., pirbuterol, bitolterol, metaproterenol; beta 2-adrenoceptor agonists, e.g., albuterol, terbutaline, salmeterol, formoterol; antimuscarinics, e.g., ipratropium, oxitropium; systemic corticosteroids, e.g., prednisone, prednisolone, dexamethasone; inhaled corticosteroids, e.g., fluticasone, budesonide, beclomethasone, mometasone; leukotriene antagonists, e.g., montelukast sodium, zafirlukast; mast cell stabilizers, e.g., cromolyn sodium, nedocromil; omalizumab (XOLAIRTM; Genentech/Novartis); or COX-2 inhibitors, as described herein.

[0188] Nonlimiting examples of agents for treating or preventing lupus (e.g., SLE) with which an IL-21/IL-21R antagonist can be combined include one or more of the following: IL-6/IL-6R antagonists, e.g. anti-IL-6 or anti-IL-6R antibodies; NSAIDs; corticosteroids, e.g., dexamethasone, hydrocortisone,

methyprednisolone, prednisolone, prednisone; azathioprine, cyclophosphamide, hydroxychloroquine, or chloroquine.

[0189] Another aspect of the present invention accordingly relates to kits for carrying out the combined administration of the IL-21/IL-21R antagonists with other therapeutic compounds. In one embodiment, the kit comprises one or more binding agents formulated in a pharmaceutical carrier, and at least one agent, e.g., therapeutic agent, formulated as appropriate, in one or more separate pharmaceutical preparations.

Exemplary Disorders

[0190] Rheumatoid arthritis is an autoimmune inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. Rheumatoid arthritis often presents in a symmetrical pattern. The disease can affect the wrist joints and the finger joints closest to the hand. It can also affect other parts of the body besides the joints. In addition, people with rheumatoid arthritis may have fatigue, occasional fevers, and a general malaise. Positive factors for diagnosis of rheumatoid arthritis include the “rheumatoid factor” blood antibody and citrulline antibody. IL-21/IL-21R antagonists can be useful in treating, preventing, or alleviating rheumatoid arthritis or one or more symptoms of rheumatoid arthritis.

[0191] Systemic lupus erythematosus (SLE) is an autoimmune disorder that leads to inflammation and damage to various body tissues. SLE can be mediated by self-antibodies directed against one’s own DNA. Lupus can affect many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. Although various symptoms may present, some of the most common include extreme fatigue, painful or swollen joints (arthritis), unexplained fever, skin rashes, and kidney problems (e.g., glomerulonephritis). Exemplary symptoms of lupus include painful or swollen joints, unexplained fever, and extreme fatigue. A characteristic red skin rash may appear across the nose and cheeks. Rashes may also occur on the face and ears, upper arms, shoulders, chest, and hands. Other symptoms of lupus include chest pain, hair loss, anemia, mouth ulcers, and pale or purple fingers and toes from cold and stress. Some people also

experience headaches, dizziness, depression, confusion, or seizures. Positive factors for SLE diagnosis include circulating anti-nuclear antibodies, anti-DNA antibodies, and anti-Sm antibodies. IL-21/IL-21R antagonists can be useful in treating, ameliorating (alleviating), or preventing SLE or one or more symptoms of SLE.

[0192] Ankylosing spondylitis is an autoimmune disorder that not only affects the spine, but may also affect the hips, shoulders, and knees as the tendons and ligaments around the bones and joints become inflamed, resulting in pain and stiffness. Ankylosing spondylitis tends to affect people in late adolescence or early adulthood. IL-21/IL-21R antagonists can be useful in treating, preventing, or alleviating ankylosing spondylitis, or one or more symptoms thereof.

[0193] Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation in the intestines. Two examples of inflammatory bowel disease are Crohn's disease and ulcerative colitis. IL-21/IL-21R antagonists can be useful in treating, preventing, or alleviating inflammatory bowel disease or one or more symptoms of inflammatory bowel disease.

[0194] Crohn's disease causes inflammation in the small intestine. Crohn's disease usually occurs in the lower part of the small intestine (the ileum), but it can affect any part of the digestive tract, from the mouth to the anus. The inflammation can extend deep into the lining of the affected organ, causing pain and making the intestines empty frequently, resulting in diarrhea. The most common symptoms of Crohn's disease are abdominal pain, often in the lower right area, and diarrhea. Rectal bleeding, weight loss, and fever may also occur. Bleeding may be serious and persistent, leading to anemia. Direct visualization of the bowel may be useful to determine the extent of inflammation.

[0195] Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the large intestine. The inflammation usually occurs in the rectum and lower part of the colon, but it may affect the entire colon. Ulcerative colitis rarely affects the small intestine except for the end section, called the terminal ileum. The inflammation makes the colon empty frequently, causing diarrhea. Ulcers form in places where the inflammation has killed the cells lining

the colon; the ulcers bleed and produce pus. The most common symptoms of ulcerative colitis are abdominal pain and bloody diarrhea. Patients also may experience fatigue, weight loss, loss of appetite, rectal bleeding, and loss of body fluids and nutrients. About half of patients have mild symptoms. Others suffer frequent fever, bloody diarrhea, nausea, and severe abdominal cramps. Ulcerative colitis may also cause problems such as arthritis, inflammation of the eye, liver disease (hepatitis, cirrhosis, and primary sclerosing cholangitis), osteoporosis, skin rashes, and anemia. Diagnosis of ulcerative colitis typically depends on identifying bloody stool and direct visualization of the colon.

[0196] Psoriasis is a chronic skin disease of scaling and inflammation. Psoriasis occurs when skin cells quickly rise from their origin below the surface of the skin and pile up on the surface before they have a chance to mature. Usually this movement (also called turnover) takes about a month, but in psoriasis it may occur in only a few days. In its typical form, psoriasis results in patches of thick, inflamed skin covered with silvery scales. These patches, which are sometimes referred to as plaques, usually itch or feel sore. They most often occur on the elbows, knees, other parts of the legs, scalp, lower back, face, palms, and soles of the feet, but they can occur on skin anywhere on the body. Diagnosis of psoriasis is based primarily on these characteristic symptoms. A skin biopsy can be useful in diagnosis. IL-21/ IL-21R antagonists can be useful in treating, preventing, or alleviating psoriasis or one or more symptoms of psoriasis. Psoriatic arthritis occurs in some patients with psoriasis, a scaling skin disorder. Psoriatic arthritis often affects the joints at the ends of the fingers and toes and is accompanied by changes in the fingernails and toenails. Back pain may occur if the spine is involved. IL-21/IL-21R antagonists can be useful in treating, preventing, or alleviating psoriasis or one or more symptoms of psoriasis or psoriatic arthritis.

[0197] Glomerular diseases include both proliferative and nonproliferative disorders. Glomerulonephritis is a disorder presenting with intraglomerular inflammation and cell proliferation (see, e.g., Hricik et al. (1998) *New Eng. J. Med.* 339:888-99. Nonproliferative and sclerosing glomerulopathies include membranous glomerulopathy, diabetic nephropathy, focal segmental

glomerulosclerosis, thin basement membrane disease, amyloidosis, light-chain nephropathy, HIV nephropathy, Alport's syndrome, drug-induced glomerulopathies, and minimal-change disease. The inflammation accompanying glomerular disease arises largely due to antibody-mediated glomerular injury that results from autoimmunity. Activation of humoral immunity can lead to the production of antibodies against glomerular cell surfaces (e.g., basement membranes), and circulating antigen-antibody complexes are deposited in the glomerulus, reported to contribute to glomerulonephritis pathology. Glomerular injury and glomerulonephritis thus often result from larger systemic autoimmune disorders, such as, e.g., SLE, hepatitis, and fibrotic disorders. Glomerulonephritis also may be associated with IgA nephropathy, Henoch-Schonlein purpura, infection (caused by, e.g., bacteria, virus, protozoa), vasculitides, cryoglobulinemia, inherited nephritis, granulomatosis (e.g., Wegener's granulomatosis, microscopic polyangitis, and Churg-Strauss syndrome), glomerular basement membrane disease, Goodpasture's syndrome, nephritic syndrome (as occurs with, e.g., diabetes mellitus, lupus (e.g., SLE), amyloidosis, drug use, cancer, and infection), lipodystrophy, sickle cell disease, complement deficiencies, membrane proliferative glomerulonephritis, lupus nephritis, and lupus membranous nephropathy. IL-21/IL-21R antagonists can be useful in treating, ameliorating, or preventing glomerulonephritis or one or more symptoms of glomerulonephritis, and other glomerular diseases.

[0198] IL-21/IL-21R antagonists can be used to prevent or treat tissue/graft rejection or symptoms associated with rejection, e.g., before, during, or after transplantation of an organ, tissue, or cells, e.g., heart, lung, liver, kidney, pancreas, or bone marrow. Transplant/graft rejection occurs when the immune system of the host organism raises an immune response against nonself antigens in the transplanted tissue, e.g., syngeneic, allogeneic, or xenogeneic tissue. Rejection can be mediated, for example, by antibodies, lymphocytes or both and can manifest itself in a variety of different ways, including, e.g., hyperacute rejection (e.g., during the early post-transplant period), acute rejection, and chronic rejection (generally, a slowly developing process causing a progressive

decline in graft function). Rejection is often accompanied by inflammation and can result in the damage and/or failure of the transplanted tissue or organ, e.g., vasculopathy, fibrosis, or a loss of organ function. During rejection, the host may experience general discomfort, pain or swelling in the area of the transplant, and/or fever. Organ and tissue transplants can be monitored for rejection, e.g., by examination of biopsies for signs of rejection, or by assessing organ function. Histopathological signs of rejection include, e.g., increased expression of HLA class II antigens, e.g., in renal tubular cells following kidney transplantation. Liver function, e.g., can be assessed by measuring serum levels of bilirubin and hepatic enzymes, e.g., alkaline phosphatase; kidney function can be assessed, e.g., by measuring serum creatine levels.

[0199] Osteoarthritis (OA) is characterized by the breakdown of cartilage at the joints. This allows bones under the cartilage to rub together, causing pain, swelling, and loss of motion of the joint. Over time, the joint may lose its normal shape, and bone spurs or osteophytes may grow on the edges of the joint. Additionally, bits of bone or cartilage can break off and float inside the joint space causing more pain and damage. People with OA typically have joint pain and limited movement. Unlike some other forms of arthritis, OA affects only joints and not internal organs. Positive factors for diagnosis of OA include loss of cartilage as seen by X-ray. IL-21/IL-21R antagonists can be useful in treating, preventing, or alleviating OA or one or more symptoms of OA.

Respiratory Disorders

[0200] IL-21/IL-21R antagonists can be used to treat respiratory disorders including, but not limited to, asthma (e.g., allergic and nonallergic asthma); bronchitis (e.g., chronic bronchitis); chronic obstructive pulmonary disease (COPD) (e.g., emphysema, e.g., cigarette-induced emphysema); conditions involving airway inflammation, eosinophilia, fibrosis and excess mucus production, e.g., cystic fibrosis, pulmonary fibrosis, and allergic rhinitis.

[0201] The methods for treating or preventing asthma include those for extrinsic asthma (also known as allergic asthma or atopic asthma), intrinsic asthma (also

known as nonallergic asthma or nonatopic asthma) or combinations of both, which has been referred to as mixed asthma. Extrinsic or allergic asthma includes incidents caused by, or associated with, e.g., allergens, such as pollens, spores, grasses or weeds, pet danders, dust, mites, etc. As allergens and other irritants present themselves at varying points over the year, these types of incidents are also referred to as seasonal asthma. Also included in the group of extrinsic asthma is bronchial asthma and allergic bronchopulmonary aspergillosis.

[0202] Asthma that can be treated or alleviated by the present methods include those caused by infectious agents, such as viruses (e.g., cold and flu viruses, respiratory syncytial virus (RSV), paramyxovirus, rhinovirus and influenza viruses). RSV, rhinovirus and influenza virus infections are common in children, and viral infection is a leading cause of respiratory tract illnesses in infants and young children. Children with viral bronchiolitis can develop chronic wheezing and asthma, which can be treated using the methods of the invention. Also included are the asthma conditions that may be brought about in some asthmatics by exercise and/or cold air. The methods are useful for asthmas associated with smoke exposure (e.g., cigarette-induced and industrial smoke), as well as industrial and occupational exposures, such as smoke; ozone; noxious gases; sulfur dioxide; nitrous oxide; fumes, including isocyanates, from paint, plastics, polyurethanes, varnishes, etc.; wood, plant, or other organic dusts; etc. The methods are also useful for asthmatic incidents associated with food additives, preservatives, or pharmacological agents. Also included are methods for treating, inhibiting, or alleviating the types of asthma referred to as silent asthma or cough variant asthma.

[0203] The methods disclosed herein are also useful for treatment and alleviation of asthma associated with gastroesophageal reflux (GERD), which can stimulate bronchoconstriction. GERD, along with retained bodily secretions, suppressed cough, and exposure to allergens and irritants in the bedroom can contribute to asthmatic conditions and have been collectively referred to as nighttime asthma or nocturnal asthma. In methods of treatment, inhibition or alleviation of asthma associated with GERD, a pharmaceutically effective amount of the IL-21/IL-21R

- 69 -

antagonist can be used as described herein in combination with a pharmaceutically effective amount of an agent for treating GERD. These agents include, but are not limited to, proton pump inhibiting agents like PROTONIX[®] brand of delayed-release pantoprazole sodium tablets, PRILOSEC[®] brand omeprazole delayed release capsules, ACIPHEX[®] brand rebeprazole sodium delayed release tablets, or PREVACID[®] brand delayed release lansoprazole capsules.

Atopic Disorders and Symptoms Thereof

[0204] “Atopic” refers to a group of diseases where there is often an inherited tendency to develop an allergic reaction. Examples of atopic disorders include allergy, allergic rhinitis, atopic dermatitis, and hay fever. An IL-21/IL-21R pathway antagonist can be administered to ameliorate an atopic disorder or one or more of the symptoms thereof.

[0205] Symptoms of allergic rhinitis (hay fever) include itchy, runny, sneezing, or stuffy noses, and itchy eyes. An IL-21/IL-21R pathway antagonist can be administered to ameliorate one or more of these symptoms.

[0206] Atopic dermatitis is a chronic disease that affects the skin. Information about atopic dermatitis is available, e.g., from NIH Publication No. 03-4272. In atopic dermatitis, the skin can become extremely itchy, leading to redness, swelling, cracking, weeping clear fluid, and finally, crusting and scaling. In many cases, there are periods of time when the disease is worse (called exacerbations or flares) followed by periods when the skin improves or clears up entirely (called remissions). Atopic dermatitis is often referred to as “eczema,” which is a general term for the several types of inflammation of the skin. Atopic dermatitis is the most common of the many types of eczema. Examples of atopic dermatitis include: allergic contact eczema or dermatitis (e.g., sometimes manifested as a red, itchy, weepy reaction where the skin has come into contact with a foreign substance, such as poison ivy or certain preservatives in creams and lotions); contact eczema (e.g., a localized reaction that includes redness, itching, and burning where the skin has come into contact with an allergen or with an irritant

such as an acid, a cleaning agent, or other chemical); dyshidrotic eczema (e.g., an irritation of the skin on the palms of hands and soles of the feet characterized by clear, deep blisters that itch and burn); neurodermatitis (e.g., scaly patches of the skin on the head, lower legs, wrists, or forearms caused by a localized itch (such as an insect bite) that become intensely irritated when scratched); nummular eczema (e.g., manifested as coin-shaped patches of irritated skin-most common on the arms, back, buttocks, and lower legs-that may be crusted, scaling, and extremely itchy); seborrheic eczema (e.g., manifested as yellowish, oily, scaly patches of skin on the scalp, face, and occasionally other parts of the body). Additional particular symptoms include stasis dermatitis, atopic pleat (e.g., Dennie-Morgan fold), cheilitis, hyperlinear palms, hyperpigmented eyelids: eyelids that have become darker in color from inflammation or hay fever, ichthyosis, keratosis pilaris, lichenification, papules, and urticaria. An IL-21/IL-21R pathway antagonist can be administered to ameliorate one or more of these symptoms.

Fibrotic Disorders

[0207] Although production of collagen is a highly regulated process, its disturbance may lead to the development of tissue fibrosis. Abnormal accumulation of fibrous materials may ultimately lead to organ failure (Border et al. (1994) *New Engl. J. Med.* 331:1286-92). Injury to any organ leads to a stereotypical physiological response: platelet-induced hemostasis, followed by an influx of inflammatory cells and activated fibroblasts. Cytokines derived from these cell types drive the formation of new extracellular matrix and blood vessels (granulation tissue). The generation of granulation tissue is a carefully orchestrated program in which the expression of protease inhibitors and extracellular matrix proteins is upregulated, and the expression of proteases is reduced, leading to the accumulation of extracellular matrix.

[0208] The development of fibrotic conditions, whether induced or spontaneous, is caused at least in part by stimulation of fibroblast activity. The influx of inflammatory cells and activated fibroblasts into the injured organ depends on the ability of these cell types to interact with the interstitial matrix, which contains

primarily collagens. Many of the diseases associated with the proliferation of fibrous tissue are both chronic and often debilitating, including for example, skin diseases such as scleroderma. Some, including pulmonary fibrosis, can be fatal due in part to the fact that the currently available treatments for this disease have significant side effects and are generally not efficacious in slowing or halting the progression of fibrosis (Nagler et al. (1996) *Am. J. Respir. Crit. Care Med.* 154:1082-86).

[0209] Fibrotic disorders include disorders characterized by fibrosis, e.g., fibrosis of an internal organ, a dermal fibrosing disorder, and fibrotic conditions of the eye. Fibrosis of internal organs (e.g., liver, lung, kidney, heart blood vessels, gastrointestinal tract), occurs in disorders such as pulmonary fibrosis, myelofibrosis, liver cirrhosis, mesangial proliferative glomerulonephritis, crescentic glomerulonephritis, diabetic nephropathy, renal interstitial fibrosis, renal fibrosis in patients receiving cyclosporin, and HIV associated nephropathy.

[0210] Dermal fibrosing disorders include, e.g., scleroderma, morphea, keloids, hypertrophic scars, familial cutaneous collagenoma, and connective tissue nevi of the collagen type. Fibrotic conditions of the eye include conditions such as diabetic retinopathy, postsurgical scarring (for example, after glaucoma filtering surgery and after cross-eye surgery), and proliferative vitreoretinopathy.

[0211] Additional fibrotic conditions that may be treated by the methods of the present invention include: rheumatoid arthritis, diseases associated with prolonged joint pain and deteriorated joints, systemic sclerosis (including progressive systemic sclerosis), polymyositis, dermatomyositis, eosinophilic fasciitis, morphea (localized scleroderma), Raynaud's syndrome, and nasal polyposis.

[0212] An IL-21/IL-21R pathway antagonist can be administered to treat or prevent fibrotic disorders or to ameliorate one or more of the symptoms of these disorders.

Assays for Measuring the Activity of IL-21/IL-21R Antagonists as Modulators of Cytokine Production and Cell Proliferation/Differentiation

[0213] The activity of IL-21/IL-21R antagonists as modulator of cytokine production and cell proliferation/differentiation can be tested using any one of a number of routine factor-dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

[0214] Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al. (1986) *J. Immunol.* 137:3494-500; Bertagnolli et al. (1990) *J. Immunol.* 145:1706-12; Bertagnolli et al. (1991) *Cellular Immunology* 133:327-41; Bertagnolli et al. (1992) *J. Immunol.* 149:3778-83; Bowman et al. (1994) *J. Immunol.* 152:1756-61. Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In *Current Protocols in Immunology*. J. E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon gamma, Schreiber, R. D. In *Current Protocols in Immunology*. J. E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

[0215] Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In *Current Protocols in Immunology*. J. E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al. (1991) *J. Exp. Med.* 173:1205-11; Moreau et al. (1988) *Nature* 336:690-92; Greenberger et al. (1983) *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-38; Measurement of mouse and human interleukin 6, Nordan, R. In *Current Protocols in Immunology*. J. E.e.a.

Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al. (1986) *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-61; Measurement of human Interleukin 11, Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In *Current Protocols in Immunology*. J. E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9, Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In *Current Protocols in Immunology*. J. E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

[0216] Assays for T cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In vitro* assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al. (1980) *Proc. Natl. Acad. Sci. U.S.A.* 77:6091-95; Weinberger et al. (1981) *Eur. J. Immun.* 11:405-11; Takai et al. (1986) *J. Immunol.* 137:3494-500; Takai et al. (1988) *J. Immunol.* 140:508-12.

EXAMPLES

[0217] The invention will be further illustrated in the following nonlimiting examples.

Example 1: Isolation and Characterization of Murine MU-1 cDNAs

[0218] A partial fragment of the murine homolog of the MU-1 receptor was isolated by PCR using oligonucleotides derived from the human sequences. cDNA was prepared from RNA isolated from 17-day old murine thymus and from the murine 2D6 T cell line. A DNA fragment of approximately 300 nucleotides was amplified from the cDNA by PCR with the following oligonucleotides, corresponding to regions 584-603 and 876-896, respectively, of the human cDNA sequence in FIG. 1 (corresponding to SEQ ID NO:1):

- 74 -

AGCATCAAGCCGGCTCCCC (5p)(SEQ ID NO:11)

CTCCATTCACTCCAGGTCCC (3p) (SEQ ID NO:12)

Amplification was carried out using Taq polymerase in 1X Taq buffer containing 1.5 mM of magnesium chloride for 30 cycles at 94°C for one minute, 50°C for 1 minute, and 72°C for one minute. The DNA sequence of this fragment was determined, and two oligonucleotides were derived from an internal portion of this fragment with the following sequences:

TTGAACGTGACTGRGGCCTT (5P) (SEQ ID NO:13)

TGAATGAAGTGCCTGGCTGA (3P) (SEQ ID NO:14)

[0219] The oligonucleotides were used to amplify an internal 262-nucleotide fragment of the original PCR product (corresponding to nucleotides 781-1043 in of the murine cDNA sequence of FIG. 1, and SEQ ID NO:9) to use as a hybridization probe to screen a cDNA library isolated from the 2D6 T cell line. Filters were hybridized at 65°C using standard 5X SSC hybridization conditions and washed into SSC at 65°C. Twenty clones were isolated that hybridized to the probe in a screen of 426,000 clones. DNA sequence was determined from two independent clones. Full-length sequence of clone #6 confirmed that it was the full-length murine homolog of human MU-1 (SEQ ID NO:9).

[0220] The full-length nucleotide sequence of murine MU-1 is shown in FIG. 1 (corresponding to SEQ ID NO:9). The nucleotide sequence has a predicted leader sequence at nucleotides 407-464, coding sequence at nucleotides 407-1993, termination codon at nucleotides 1994-1996. Nucleotides 1-406 correspond to the 5' untranslated region, and nucleotides 1997-2628 correspond to the 3' untranslated region (SEQ ID NO:9).

[0221] The predicted protein sequence of murine MU-1 is shown in FIG. 2 (corresponding to SEQ ID NO: 10). This murine MU-1 protein contains a predicted leader sequence determined by SPScan (score= 10.1) (corresponding to amino acids 1-19 of SEQ ID NO: 10), and a predicted transmembrane domain (corresponding to amino acids 237-253 of SEQ ID NO:10). Predicted signaling motifs include the following regions in FIG. 2B: Box 1: amino acids 265-274 of SEQ ID NO: 10; Box 2: amino acids 310-324 of SEQ ID NO: 10, six tyrosine

- 75 -

residues at positions 281, 319, 361, 368, 397, and 510 of SEQ ID NO:10.

Potential STAT docking sites include: STAT5: EDDGYPA (SEQ ID NO:20); STAT3: YLQR.

Example 2: Comparison of Human and Murine MU-1:

[0222] The GAP algorithm was used to compare the human and murine MU-1 amino acids. Human MU-1 was cloned using a 70-amino acid region of the human IL-5 receptor (SEQ ID NO:3) for searching a GenBank database, as well as primers for PCR (SEQ ID NOs:4 and 5), and hybridization oligonucleotides (SEQ ID NOs:6 and 7). A comparison of the murine and human predicted protein sequences is shown in FIG. 4. The amino acids were 65.267% identical using the GAP algorithm. The alignment was generated by BLOSUM62 amino acid substitution matrix (Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89: 10915-19). Gap parameters = Gap Weight: 8, Average Match = 2.9 12, Length Weight = 2, Average Mismatch = -2.003; Percent Similarity = 69.466.

[0223] A comparison of the human and murine cDNA nucleotide sequences is shown in FIG. 3. The DNA sequences are 66.116% identical when aligned using the GAP algorithm. Gap Parameters: Gap Weight = 50, Average Match 10.000, Length Weight = 3, Average Mismatch = 0.000, Percent Similarity = 66.198.

[0224] Both human and mouse MU-1 proteins are members of the Type 1 cytokine receptor superfamily. Evaluation of the sequence of both murine and human MU-1 reveals the presence of potential Box-1 and Box-2 signaling motifs. Six tyrosine residues are present in the cytoplasmic domain and could also be important in signaling functions of MU-1. Comparison of the sequences of MU-1 with other members of the family suggested the presence of potential docking sites for STAT 5 and STAT 3.

Example 3: Determination of STAT signaling pathways used by Human MU-1

[0225] BAF-3 cells were engineered to express a chimeric cytokine receptor consisting of the extracellular domain of the human EPO receptor and the intracellular domain of the MU-1 receptor. BAF-3 cells that expressed huEPORJMU-1(cyto) chimeric receptors proliferated in response to human

- 76 -

soluble EPO. These cells were analyzed to determine which STAT molecules were phosphorylated in response to EPO signaling. Briefly, control unmodified parental BAF-3 cells and EPOR/MU chimeric BAF-3 cells were rested from IL-3 containing growth medium, and restimulated with either IL-3 or EPO for 0, 15, 30 and 60 minutes. The cells were pelleted and resuspended in ice-cold lysis buffer containing orthovanadate to preserve phosphorylated tyrosines. Equal amounts of cell lysate were electrophoresed by SDS-PAGE and blotted onto nitrocellulose membranes for western analysis. Duplicate blots were stained for phosphorylated and nonphosphorylated forms of STAT 1, 3, 5, and 6 by using antibodies specific for each form of the STAT molecule. HELA cells, nonactivated and activated with alpha-interferon, were used as positive controls. [0226] These results indicated that under these specific conditions, signaling through MU-1 results in the phosphorylation of STAT 5 at all time points tested (T=0, T=15', T=30', T=60'). Treatment of controls or the chimeric BAF-3 cells with IL-3 resulted in phosphorylation of STAT 3, but not STAT 1 or 5.

Example 4: Tissue Expression of Murine and Human MU-1

Example 4.1: Northern Analysis

[0227] Northern blots of polyA⁺ RNA from various tissues (Clontech, Palo Alto, CA) were performed as recommended by the manufacturer. For the murine blots, a 262-nucleotide fragment corresponding to nucleotides 781-1043 of FIG. 1 and SEQ ID NO:9 was used for hybridization.

[0228] A single transcript of murine MU-1 was detected in adult murine spleen, lung, and heart tissues. The larger transcript observed in human tissues was not observed in mouse tissues.

[0229] Two transcripts of human MU-1 were detected in adult human lymphoid tissues, PBLs, thymus, spleen and lymph node, and in fetal lung.

Example 4.2: In Situ Hybridization

[0230] In situ hybridization studies were performed by Phylogency Inc. of Columbus, OH (according to the method of Lyons et al. (1990) *J. Cell. Biol.* 111:2427-36). Briefly, serial 5-7 micron paraffin sections were deparaffinized,

- 77 -

fixed, digested with proteinase K, treated with tri-ethanolamine and dehydrated. cRNAs were prepared from linearized cDNA templates to generate antisense and sense probes. The cRNA transcripts were synthesized according to manufacturer's conditions (Ambion) and labeled with ³⁵S-UTP. Sections were hybridized overnight, washed under stringent conditions, and treated with RNase A and dipped in nuclear track emulsion and exposed for 2-3 weeks. Control sections were hybridized with sense probes to indicate the background level of the procedure. The murine probe consisted of a 186-bp fragment corresponding to nucleotides 860-1064 (SEQ ID NO:9). The human probe was a 23-bp PCR product generated from human MU-1 DNA.

[0231] Murine MU-1 expression was observed in the lymph nodes of the adult small intestine at germinal centers. Specialized lymph nodes and Peyer's patches also exhibited murine MU-1 expression.

[0232] Human MU-1 expression was detected at germinal centers of the lymph nodules in the cortex. The medulla, which contains macrophages, was negative for human MU-1. In human spleen, human MU-1 expression was detected in the regions of white pulp but not red pulp.

Example 5: Expression of Human MU-1 in cells and cell lines:

[0233] RNase protection analysis was performed on resting and activated human T cells and the B cell lines, Raji and RPMI 8866, and the T cell line Jurkat. Human T cells were activated with anti-CD3 and anti-CD28. The cell lines were activated by phorbol ester and ionomycin. MU-1 riboprobe-producing plasmid was constructed by inserting a 23-bp PCR product (PCR was performed by using 5' primer CACAAAGCTTCAGTATGAGCTGCAGTACAGGAACCGGGA (SEQ ID NO:15) and 3' primer CACAGGATCCCTTTAACTCCTCTGACTGGGTCTGAAAGAT (SEQ ID NO:16) into the BamHI and HindIII sites of pGEM3zf(-) (Promega, Madison, WI) vector). To make the riboprobe, the riboprobe-producing plasmid was linearized with HindIII. The resulting DNA was phenol/chloroform extracted and precipitated with ethanol. T7 RNA polymerase was used to make the riboprobe

according to the protocol suggested by the vendor (PharMingen, San Diego, CA).

The RNase protection assay was performed by using PharMingen's RIBOQUANT™ Multi-Probe Ribonuclease Protection Assay system. 2.0 µg of total RNA were included in each RPA reaction, after RNase digestion, the protected riboprobes were run on a QUICKPOINT™ rapid nucleic acid separation system (Novex, San Diego, CA). Gels were dried and exposed according to the suggestion of the vendor.

[0234] Human MU-1 RNA is upregulated in anti-CD3+ anti-CD28-stimulated human purified CD3+ cells when compared with unstimulated populations. MU-1 is also upregulated upon restimulation in Th1 and Th2-skewed T cell populations. The B cell lines, RPMI 8866 and Raji, constitutively express MU-1 while the Jurkat T cell line does not.

Example 6: Binding of Human MU-1 to Known Cytokines

[0235] Both human and murine Ig fusion proteins were constructed and immobilized on Biacore chips in an effort to identify the ligand for MU-1. A variety of cell culture conditioned media as well as a panel of known cytokines were evaluated for binding to MU-1. Some cytokines were also tested in combination with other receptor chains in the family to consider the possibility that MU-1 may require a second receptor chain for ligand binding. The following cytokines were tested and found to be negative for MU-1 binding: mIL-2, hIL-2, hIL-15, mIL-7, TSLP, TSLP + IL-7, TSLP + IL-7R, TSLP + IL-7g, TSLP + IL-2, TSLP + IL-2 + IL-2Rbeta, IL2-Rbeta, IL-2Rgamma, IL-7R, IL-2 + IL-2Rbeta, IL-2 + IL-2Rgamma, IL-15 + IL-2Rbeta, IL-15 + IL-2Rgamma, IL-7 + IL-2Rgamma, IL-2 + IL-7R, IL-15 + IL-7R, IL-7 + IL-7R. Known receptors have been immobilized as well and tested for MUFc binding with negative results. IL-15 will bind to IL-2Rb but not IL-2Rg or MUFc.

Example 7: Inhibition of IL-21/IL-21R Activity Ameliorates the Severity of Symptoms in Collagen-Induced Arthritis (CIA) Mice

[0236] This example shows that IL-21R antagonists, e.g., IL-21R-Ig fusion proteins (murine IL-21RFc protein or “muIL-21RFc”) or anti-IL-21R antibodies, ameliorate symptoms in a CIA murine model.

[0237] Male DBA/1 (Jackson Laboratories, Bar Harbor, ME) mice were used for all experiments. Arthritis was induced with the use of bovine collagen type II (Chondrex, Redmond, WA). Bovine collagen type II (Chondrex) was dissolved in 0.1 M acetic acid and emulsified in an equal volume of complete Freund's adjuvant (Sigma) containing 1 mg/ml *Mycobacterium tuberculosis* (strain H37RA). 100 µg of bovine collagen was injected subcutaneously in the base of the tail on day 0. On day 21, mice were injected subcutaneously, in the base of the tail, with a solution containing 100 µg of bovine collagen in 0.1 M acetic acid that had been mixed with an equal volume of incomplete Freund's adjuvant (Sigma). Naïve animals received the same sets of injections, minus collagen. The dosing protocol is shown schematically in FIG. 16. MuIL-21RFc was administered prophylactically or therapeutically to DBA mice. In the therapeutic regimen, treatment was initiated if disease was observed for two consecutive days in a mouse.

[0238] Mice were monitored at least three times a week for disease progression. Individual limbs were assigned a clinical score based on the index: 0 = normal, no swelling; 1 = visible erythema accompanied by 1-2 swollen digit, or mild swelling in ankle; 2 = pronounced erythema, characterized by mild to moderate paw swelling and/or two swollen digits; 3 = extensive swelling of the entire paw, i.e., extending into ankle or wrist joint; 4 = resolution of swelling, ankylosis of the paw; difficulty in use of limb or joint rigidity. Thus, the sum of all limb scores for any given mouse yielded a maximum total body score of 16.

[0239] At various stages of disease, animals were euthanized, tissues were harvested and paws were fixed in 10% formalin for histology or 4% paraformaldehyde, pH 7.47, decalcified in 20% EDTA (pH 8.0) and embedded in paraffin for *in situ* hybridization. Using light microscopy the paws were scored

- 80 -

on a 5-grade scoring method (0-4) to characterize the intensity and extent of arthritis. Inflammatory infiltrates were used for scoring in addition to other changes related to the inflammation, such as pannus formation, fibrosis of the synovial membrane, articular cartilage erosion and/or subchondral bone destruction. Histology grades were determined using readings of individual paws: NAD = 0 or nothing abnormal discovered; 1 = slight to moderate; 2 = mild to moderate; 3 = marked; and 4 = massive.

[0240] A reduction in the severity of the symptoms was observed after prophylactic treatment of CIA mice using muIL-21RFc (100 µg or 200 µg) administered intraperitoneally (IP) every other day starting one day before the collagen boost (data not shown).

[0241] The effects of muIL-21RFc (200 µg/mouse 3x/week) on a semi-therapeutic CIA mouse as a function of day post-treatment are shown in FIG. 17. Mouse Ig (200 µg/mouse 3x/week) was used as a control. A reduction in the severity score is shown starting from day 7 post-treatment.

[0242] These experiments demonstrate that administration of an IL-21R antagonist, e.g., IL-21R-Fc fusion proteins, to CIA mice either prophylactically or semi-therapeutically significantly ameliorated arthritic symptoms.

Example 8: *In situ* hybridization of IL-21R transcripts

[0243] The expression of IL-21R mRNA in arthritic paws of mice with CIA was determined. Anti-sense murine IL-21R riboprobes were used (FIG. 18A); sense probes were used as negative controls (FIG. 18B). Digoxigenin-labeled probes were prepared with the use of a DIG RNA labeling mix (Roche Diagnostics, Mannheim, Germany), as described by the manufacturer. Expression of IL-21 receptor mRNA was detected in macrophages, neutrophils, fibroblasts, a subpopulation of lymphocytes, synoviocytes and epidermis (FIG. 18A). Decreased staining was seen in the control paws or with sense probes (FIG. 18B). mIL-21R mRNA positive cells were: neutrophils (N), and macrophages (M). *In situ* hybridization shows enhanced expression of IL-21R in the paws of arthritic mice.

Example 9: Inhibition of IL-21/IL-21R Activity Ameliorates the Severity of IBD-like Symptoms in the HLA-B27 Rat Model

[0244] This example shows that IL-21R antagonists, e.g., IL-21R-Ig fusion proteins (murine IL-21RFc protein or “muIL-21RFc”) or anti-IL-21R antibodies, ameliorate IBD-like symptoms in HLA-B27 rat model.

[0245] A murine IL-21 Receptor-Fc fusion polypeptide (MuIL-21RFc) was generated as described herein and was evaluated for its ability to alleviate inflammation of the bowel in the HLA-B27 rat model. The HLA-B27 rat model has been extensively used to evaluate IBD therapies because the bowel inflammation observed in the model shares several clinical, histological, and immunological features with IBD in humans (reviewed in, e.g., Elson et al. (1995) *Gastroenterology*, 109:1344-67; Blanchard et al. (2001) *European Cytokine Network* 12:111-18; Kim et al. (1999) *Arch. Pharm. Res.* 22:354-60). For example, the HLA-B27 rat overexpresses human major histocompatibility complex I allele B27 and B2-microglobulin gene products. Such gene products are associated with the development of chronic inflammatory diseases, such as IBD.

[0246] Rats utilized in the study had developed chronic inflammation of the gastrointestinal tract (GI) as evidenced by clinical signs of persistent diarrhea. Stools were assigned a clinical score (0-3) based on the index: 0 = normal with formed stool pellets; 1 = soft, with formed stool pellets; 2 = loose, no formation of stool pellets; and 3 = watery diarrhea (see FIG. 19). The rats were monitored for 18 days during which stools were evaluated for disease progression. A clinical score of 3 is indicative of persistent diarrhea (shown as IgG control). MuIL-21RFc was administered (6 mg/kg IP, 3X week) to five HLA-B27 transgenic rats/group for a period of 18 days. Another group was given 6 mg/ml mEnbrel (soluble TNF-receptor Fc fusion), a positive control. A third group, consisting of an equal number of mice, was administered IgG as a control in the same manner and dosage.

[0247] A marked reduction in the clinical score was detected in the groups treated with MuIL-21RFc and mEnbrel, compared to the IgG control (see FIGS. 19 and 20). Administration of MuIL-21RFc showed an efficacy similar to

mEnbrel in ameliorating IBD-like symptoms. Results from this study demonstrate that the administration of MuIL-21RFc decreases bowel inflammation with similar efficacy as mEnbrel in a HLA-B27 rat model relative to rats administered control IgG (see FIGS. 19 and 20).

[0248] The alleviation of symptoms expressed in terms of improved stool score was confirmed by histological analysis. Rats treated with MuIL-21RFc scored significantly lower disease severity than those treated with control, IgG, in regards to ulceration, inflammation, lesions depth, and fibrosis (see FIG. 21). The histological analysis was assigned a clinical score from 0-2 or 0-3, as indicated, where a higher score is indicative of increased severity in the rat IBD model. A significant decrease of inflammation in the bowel was detected in all categories examined in groups treated with MuIL-21RFc and mEnbrel relative to control. MuIL-21RFc showed a similar efficacy as mEnbrel in ameliorating the histological signs of disease severity. To support an extension of the results shown above to humans, FIG. 19 (right side panel) shows *in situ* hybridization of MU-1 mRNA in the lymphocytes and lymph nodes of the normal human intestine, indicating expression of MU-1 mRNA in the organ relevant to the disease.

Example 10: Inhibition of IL-21/IL-21R Activity Delays Allogeneic Skin Graft Rejection in Mice

[0249] This example shows that IL-21R antagonists, e.g., IL-21R-Ig fusion proteins (murine IL-21RFc protein or “muIL-21RFc”) or anti-IL-21R antibodies, delays allogeneic skin graft rejection in mice, and thus prolongs graft survival.

[0250] Administration of MuIL-21RFc was shown to delay allogeneic skin graft rejection in mice injected with retrovirally transduced T cells. FIG. 22 depicts a graph showing the percentage of graft survival relative to days post-adoptive transfer. In this model, nude mice show healed allogeneic skin grafts because the mice have no detectable T cells. When activated B6 T cells that had been retrovirally engineered to secrete control GFP or IL-21 were injected into the nude mice, grafts were rejected (see FIG. 22). If the T cells were engineered to secrete MuIL-21RFc (which is expected to neutralize IL-21-made by these cells),

the grafts survived for longer time intervals as shown in FIG. 22 (indicated by the IL-21R-Fc compared to the GFP and IL-21 controls). Ten mice were used for the GFP and MuIL-21R-Fc, respectively; fifteen mice were used for the IL-21 controls. These results demonstrate a role for IL-21R antagonists in prolonging graft survival.

Example 11: Inhibition of IL-21/IL-21R Activity Reduces Disease Symptoms in a CD45RB^{hi} Adoptive Transfer Model

[0251] This example shows that IL-21R antagonists, e.g., IL-21R-Ig fusion proteins (murine IL-21R-Fc protein or “muIL-21R-Fc”) or anti-IL-21R antibodies, ameliorate symptoms in a mouse model of psoriasis and inflammatory bowel disease (IBD).

[0252] Transfer of CD45RB^{hi} CD4⁺ naïve T cells into severe combined immunodeficient (SCID) mice results in colitis and/or skin lesions resembling psoriasis, depending upon cage housing conditions. BALBc CD45RB^{hi} CD4⁺ T cells (naïve population) were sorted from spleen cells first by negative selection on columns for CD4⁺ T cells and then further sorted by flow cytometry, selecting for high CD45 expression. 4×10^5 cells of this population were transferred into female C.B-17 SCID mice, and the mice were scored for several weeks for clinical signs of psoriasis and IBD. Mice housed under static cage conditions develop inflammatory bowel disease; mice housed under regular conditions with air flow changes also develop psoriasis. Mice were scored for psoriasis on a scale from 1-6: 1 = mild, moderate erythema (usually eyelids and ears) <2% of body; 2 = mild scaling and moderate to severe erythema (usually ear and face) 2-10 % of body; 3 = severe erythema and scaling (ear face and trunk) 10-20% of body; 4 = very severe erythema throughout body 20-40% of body; 5 = very severe erythema throughout body, 40-60% of body; 6 = very severe erythema throughout body 60-100% of body. Mice were scored for IBD by weight loss and stool score: 0 = normal; 1 = soft; 2 = diarrhea; 3 = diarrhea containing blood and mucus.

[0253] Treatment using muIL-21R-Fc was effective in ameliorating psoriasis-like symptoms. In mice that developed skin inflammation, treatment by

intraperitoneal injection with 200 µg muIL-21RFc 3x per week beginning eight weeks after CD45RB^{hi} cell transfer resulted in reduced erythema, scaling and hair loss when compared to control mice treated with anti-*E. tenella* Ig (FIG. 23). Treatment of CD45RB^{hi} recipient mice with 200 µg muIL-21RFc 3x per week at the time of cell transfer resulted in delayed onset of psoriasis and less severe clinical disease compared to controls over the course of the experiment (FIG. 35).

The results of the experiment are summarized in FIG. 36.

[0254] Treatment using muIL-21RFc was also effective in ameliorating inflammatory bowel symptoms. Treatment of CD45RB^{hi} recipient mice with 200 µg or 400 µg muIL-21RFc three times per week at the time of cell transfer resulted in a significant reduction of clinical signs of colitis as measured by body weight loss (FIG. 37) and stool score (FIG. 38) when compared with Ig control-treated mice. The results are summarized in FIG. 39. Macroscopic evaluation of colons from control-treated CD45RB^{hi} recipients showed severe thickening and swelling which was almost completely suppressed in mice treated with muIL-21RFc. Microscopically, control-treated mice also exhibited a greater degree of epithelial hyperplasia and leukocyte infiltration in the lamina propria/submucosa when compared with muIL-21RFc-treated mice.

Additionally, serum cytokines were measured from control-treated mice and muIL-21RFc-treated mice. Of several cytokines measured, only gamma interferon (IFN-γ) was detectable in the serum. Treatment with muIL-21RFc at 200 µg or 400 µg doses resulted in significantly reduced serum levels of IFN-γ when compared with Ig control-treated mice (FIG. 40). IFN-γ can be used as a biomarker for IL-21R antagonist efficacy in IBD.

[0255] CD45RB^{hi} (naïve) and CD45RB^{lo} (memory) subsets were tested by a proliferation assay for their response to IL-21. In the IBD transfer model, only the naïve cells cause disease, and disease can be suppressed by the addition of the memory population. In this assay, purified populations were stimulated with plate-bound anti-CD3 and tested for ³H-thymidine incorporation in response to IL-21. The naïve population showed a significantly increased response to IL-21

- 85 -

compared to the memory population (FIG. 41). This suggests that IL-21 is an important cytokine for the expansion of this population in vivo.

[0256] Addition of IL-21 to activated CD4⁺ CD45RB^{hi} cells in culture induced the secretion of multiple cytokines. Anti-CD3-stimulated CD45RB^{hi} CD4⁺ T cells were treated with 100 units/ml IL-2 or 1 ng/ml, 10 ng/ml or 100 ng/ml IL-21. In response to IL-21, CD45RB^{hi} cells secreted increased levels of IL-2, IL-4, IL-10, IL-17, IL-18, IL-22, IFN- γ and TNF α (FIG. 42). Blockade of endogenous IL-21 by addition of 50 μ g/ml or 100 μ g/ml muIL-21RFc resulted in decreased levels of cytokines in these cultures compared to cultures treated with an Ig control (FIG. 43).

[0257] Taken together, these results indicate that IL-21 is a potent potential player in the inflammatory responses in this model and that IL-21R antagonists can be of therapeutic benefit in Th1-mediated diseases such as Crohn's and psoriasis.

Example 12: Mice Lacking IL-21R Show a Reduction in Antigen-induced Airway Inflammation

[0258] This example shows that transgenic knockout mice lacking the IL-21 receptor (IL-21R $-/-$) have a significantly reduced response to antigen-induced airway inflammation and airway hyperresponsiveness.

[0259] IL-21R $-/-$ and wild type (WT $+/+$) C57BL/6 mice (8-12 weeks old) were immunized by intraperitoneal injection of 20 μ g OVA emulsified in 2.25 mg alum (Alum Inject; Pierce) on days 0 and 14. On days 26, 27 and 28 the airways were challenged with an aerosol of 5% OVA in PBS for 30 min. Forty-eight hours after the last OVA challenge, animals were assessed for changes in lung resistance and dynamic compliance to aerosolized methacholine. OVA sensitization and challenge resulted in a significant increase in airway hyperresponsiveness after aerosolization of methacholine in WT $+/+$ mice when compared with OVA-sensitized PBS-challenged WT $+/+$ mice (FIG. 24). However, there was no difference of airway hyperresponsiveness in OVA-sensitized/OVA-challenged IL-21R $-/-$ mice to aerosolized methacholine over the

entire dose range compared to OVA-sensitized /OVA-challenged WT +/+ mice (FIG. 24).

[0260] Animals were then sacrificed and blood and bronchoalveolar lavage fluid (BALF) collected for analysis of pulmonary inflammation, cytokine levels and total and anti-OVA IgE titers. BALF was collected by bronchoalveolar lavage with 3x 0.7 ml of PBS. Total BALF cell numbers were increased approximately 36 fold after OVA challenge in WT +/+ mice, compared with PBS-challenged controls in contrast to a 3-fold increase over PBS-challenged controls in IL-21R –/– animals (FIG. 25A). Furthermore, total cell numbers within the BALF of OVA-sensitized/OVA-challenged IL-21R –/– mice were significantly lower than those observed in OVA-sensitized/OVA-challenged WT +/+ animals. There was no difference in BALF total cell numbers in OVA-sensitized/PBS-challenged IL-21R –/– and WT +/+ mice (FIG. 25A). OVA challenge resulted in a significant increase in BALF eosinophils in both WT +/+ and IL-21R –/– mice, compared to identically sensitized but PBS-challenged controls. Absolute numbers of BALF eosinophils were significantly attenuated in IL-21 –/– animals compared to those observed in OVA-sensitized/OVA-challenged WT +/+ animals (FIG. 25B). Deletion of IL-21R also significantly attenuated the increases in numbers of BALF lymphocytes (FIG. 25C) and neutrophils (FIG. 25D) after OVA challenge.

[0261] Levels of IL-5, IL-13 and TNF α within the BALF increased significantly in OVA-sensitized/challenged WT +/+ mice compared with PBS-challenged controls (FIGS. 26 and 27). In contrast, OVA-sensitization and challenge induced a very modest increase in the levels of these cytokines in the BALF of IL-21R –/– mice as compared with PBS-challenged controls and levels were significantly lower than those observed in OVA-sensitized/OVA-challenged WT animals (FIGS. 26 and 27). TNF α and IL-5 levels in BALF were quantified using a cytometric bead array kit (Mouse Th1/Th2 Cytokine CBA, BD Biosciences, San Diego, CA). IL-13 levels in BALF were quantified by ELISA.

[0262] As shown in FIGS. 28A-B, serum total IgE and anti-OVA IgE levels after OVA sensitization/OVA challenge in IL-21R –/– were much lower compared

with identically treated WT+/+ mice. However, there was no significant difference in the IL-21R -/- and WT +/+ mice when either total or OVA-specific IgE levels were compared after PBS challenge.

[0263] These results suggest that inhibition of IL-21-mediated responses can provide therapeutic value in the treatment of allergy and asthma.

Example 13: Inhibition of IL-21/IL-21R Activity Ameliorates the Severity of Symptoms in a MRL-*Fas*^{lpr} Lupus Model

[0264] This example shows that IL-21R antagonists, e.g., IL-21R-Ig fusion proteins (murine IL-21RFc protein or “muIL-21RFc”) or anti-IL-21R antibodies, ameliorate systemic lupus erythematosus (SLE)-like symptoms in an MRL-*Fas*^{lpr} mouse model.

[0265] Male MRL-*Fas*^{lpr} mice were used for all experiments. These mice present multiple symptoms similar to human SLE, including DNA autoantibodies, destruction of multiple tissues, and immune complex glomerulonephritis. 400 µg MuIL-21RFc or an isotype control was injected intraperitoneally three times per week beginning at 10 weeks of age, and the mice were analyzed weekly for disease progression. At 15 weeks, mice were sacrificed for further analysis. Each treatment group contained 10 mice.

[0266] MuIL-21RFc treatment significantly reduced the levels of circulating anti-dsDNA autoantibodies (FIG. 29) and serum total IgG (FIG. 30) in MRL-*Fas*^{lpr} mice, as measured by ELISA. Briefly, for measurement of anti-dsDNA autoantibodies, dsDNA was coated on a titer plate, serum antibodies were added, and antibodies were detected using an anti-mouse secondary antibody. For measurement of total IgG, serum was adhered to a titer plate, followed by detection using an anti-mouse secondary antibody.

[0267] Treatment with MuIL-21RFc also reduced the accumulation of IgG deposits in MRL-*Fas*^{lpr} mouse kidney. At 15 weeks, mice were sacrificed and frozen kidney sections (5 µm) were stained with goat anti-mouse IgG-FITC. Fluorescence intensity was scored on a scale of 0 to 3. FIG. 31 shows the total fluorescence intensity measured in kidney sections from treated and control mice.

- 88 -

[0268] These results show that therapeutic treatment with an IL-21R antagonist can alleviate lupus-like symptoms.

Example 14: Animal Model of Lupus and GVHD: Lack of Autoantibody Formation and IgG Deposition in the Kidneys of IL-21R Deficient Mice Engrafted with B6 bm12 Spleen Cells

[0269] Experiments were conducted to investigate the response of IL-21R knockout (KO) mice in the chronic graft-versus-host-disease (GVHD) model of systemic lupus erythematosus (SLE) (Chen et al. (1998) *J. Immunol.* 161:5880-85). This model comprises representative aspects of both SLE and GVHD.

[0270] The animals used were: B6.C-H2^{bm12}/KhEG (bm12), Jackson Labs (spleen cells); IL-21R-2 KO mice, Charles River Labs (CRL); C57/B6 wild type (WT) mice, Charles River Labs; and C57/B6 wild type mice, Taconic (TAC) (Germantown, NY).

[0271] Appropriate donor mice were sacrificed on the day of disease induction via CO₂ exposure. Spleens were harvested and mulched. Red blood cells were lysed using 0.16M NH₄Cl : 0.17M TrisCl (9:1) at 1ml lysis solution per spleen, for a total of 5 minutes with occasional mixing. Cell suspensions were counted using trypan blue and adjusted to a final concentration of 2x10⁸ cells/ml using sterile phosphate buffered saline. 0.5 ml of the appropriate cell suspension was then injected intraperitoneally into the appropriate recipient mouse (as indicated in Table 2, below). The recipient mice were then monitored weekly for urine protein and weight gain/loss. Every two weeks, each mouse was bled via retro-orbital sinus, and the sera were stored for further analysis. ELISA assays were performed on all sera collected at each of the time points (as described in Zouali and Stollar (1986) *J. Immunol. Methods* 90:105-10) for the detection of autoantibodies against double-stranded DNA.

[0272] At 12 weeks post-disease induction, half of the animals from each group were euthanized, and the spleen and both kidneys were collected. The left kidney was preserved (intact) in 10% nonbuffered formalin and stained with H&E. Scoring for staining was performed according to the method of Chen et al., *supra*. Score parameters included: perivascular lymphocytic infiltration, interstitial

lymphocytic infiltration, hypercellularity and basement membrane thickening. The right kidney was cut longitudinally and each half was embedded cut side down in a tissue block cassette. The right kidney was then analyzed using immunohistochemical techniques for the presence of immune deposits, specifically IgG, IgM and C3.

Table 2

	Group	Donor	Recipient	n
1	IL-21R KO	bm12	CRL IL-21R KO	8
2	CRL-GVHD (C-GVHD)	bm12	CRL B6	10
3	TAC-GVHD (T-GVHD)	bm12	TAC B6	10
4	CRL-Control (C-Control)	CRL B6	CRL B6	5
5	TAC-Control (T-Control)	TAC B6	TAC B6	5

[0273] The results from these experiments are shown in FIG. 44. No anti-dsDNA autoantibodies were detected in any of the IL-21R knockout mice at any time point (FIG. 44A). In addition, FIG. 44B shows that at twenty weeks post disease induction, IgG deposition is not observed in the kidneys of IL-21R-deficient mice when compared with GVHD mice. Thus, mice deficient for IL-21R do not generate autoantibodies in the GVHD-SLE model, nor do they form IgG deposits in kidneys. Accordingly, treatment of individuals with IL-21/IL-21R antagonists may provide an effective therapy for both SLE and GVHD.

[0274] The contents of all references, pending patent applications (inclusive of 60/599,086, filed August 5, 2004 and 60/639,176, filed December 23, 2004), published patent applications (inclusive of 2003/0108549, filed October 4, 2002), and published patents cited throughout this application are hereby incorporated by reference.

Equivalents

[0275] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

WHAT IS CLAIMED IS:

1. A method of treating, ameliorating, or preventing an autoimmune or inflammatory disorder in a mammalian subject, comprising administering to the subject an IL-21/IL-21R antagonist selected from the group consisting of an anti-IL-21R antibody, an anti-IL-21 antibody, an antigen-binding fragment of an anti-IL-21R antibody, an antigen-binding fragment of an anti-IL-21 antibody, and an IL-21R soluble fragment, in an amount sufficient to treat, ameliorate, or prevent the disorder.
2. A method of treating, ameliorating, or preventing a disorder selected from the group consisting of an arthritic disorder, an atopic disorder, a respiratory disorder, a skin inflammatory disorder, an intestinal inflammatory disorder, a fibrotic disorder, systemic lupus erythematosus, transplant/graft rejection, and a disorder associated with transplant/graft rejection, in a mammalian subject, comprising administering to the subject an IL-21/IL-21R antagonist selected from the group consisting of an anti-IL-21R antibody, an anti-IL-21 antibody, an antigen-binding fragment of an anti-IL-21R antibody, an antigen-binding fragment of an anti-IL-21 antibody, and an IL-21R soluble fragment, in an amount sufficient to treat, ameliorate, or prevent the disorder.
3. The method of claim 2, wherein the anti-IL-21R antibody is capable of binding to an IL-21R comprised of an amino acid sequence at least 90% identical to the sequence set forth in SEQ ID NO:2, and wherein the IL-21R is capable of binding IL-21.
4. The method of claim 3, wherein the arthritic disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis.

- 91 -

5. The method of claim 4, wherein the arthritic disorder is rheumatoid arthritis.
6. The method of claim 3, wherein the respiratory disorder is asthma or chronic obstructive pulmonary disease.
7. The method of claim 3, wherein the fibrotic disorder is selected from the group consisting of fibrosis of an internal organ, a dermal fibrosing disorder, a fibrotic condition of the eye, systemic sclerosis, polymyositis, dermatomyositis, eosinophilic fasciitis, Raynaud's syndrome, glomerulonephritis and nasal polyposis.
8. The method of claim 3, wherein the intestinal inflammatory disorder is selected from the group consisting of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.
9. The method of claim 3, wherein the skin inflammatory disorder is psoriasis.
10. The method of claim 3, wherein the atopic disorder is selected from the group consisting of allergic asthma, atopic dermatitis, urticaria, eczema, allergic rhinitis, and allergic enterogastritis.
11. The method of claim 10, wherein the atopic disorder is allergic asthma.
12. The method of claim 3, wherein the disorder associated with transplant/graft rejection is graft versus host disease.
13. The method of claim 3, wherein the disorder is transplant/graft rejection.
14. The method of claim 3, wherein the disorder is systemic lupus erythematosus.

- 92 -

15. The method of claim 2, wherein the mammalian subject is a human.
16. The method of claim 2, wherein the IL-21R soluble fragment is comprised of an IL-21R extracellular domain and an Fc immunoglobulin fragment.
17. The method of claim 16, wherein the IL-21R extracellular domain comprises about amino acids 1-235 of SEQ ID NO:2.
18. The method of claim 2, wherein the IL-21R soluble fragment is comprised of an amino acid sequence at least 90% identical to the sequence set forth in SEQ ID NO:29.
19. The method of claim 2, wherein the IL-21/IL-21R antagonist is an anti-IL-21R antibody, or an antigen-binding fragment thereof.
20. The method of claim 2, wherein the IL-21/IL-21R antagonist is an anti-IL-21 antibody, or an antigen-binding fragment thereof.
21. A fusion protein comprised of an extracellular domain of an IL-21R and an Fc immunoglobulin fragment, wherein the IL-21R has an amino acid sequence at least 90% identical to the sequence set forth in SEQ ID NO:2, and wherein the fusion protein is capable of binding IL-21.
22. The fusion protein of claim 21, comprised of an amino acid sequence at least 90% identical to the sequence set forth in SEQ ID NO:29.
23. A vector having a nucleotide sequence encoding the fusion protein of claim 21.
24. A recombinant host cell comprising the vector of claim 23.

- 93 -

25. A method of producing a fusion protein comprising:
- (a) culturing the recombinant host cell of claim 24 under conditions such that the fusion protein is expressed; and
 - (b) recovering the fusion protein.
26. A pharmaceutical composition comprising an IL-21/IL-21R antagonist and a pharmaceutically acceptable carrier.
27. The pharmaceutical composition of claim 26, wherein the IL-21/IL-21R antagonist is selected from the group consisting of an anti-IL-21R antibody, an anti-IL-21 antibody, an antigen-binding fragment of an anti-IL-21R antibody, an antigen-binding fragment of an anti-IL-21 antibody, and an IL-21R soluble fragment.
28. The pharmaceutical composition of claim 27, wherein the IL-21R soluble fragment is comprised of an extracellular domain of an IL-21R and an Fc immunoglobulin fragment.
29. A method of transplanting/grafting an organ, tissue, cell or group of cells to a mammalian subject comprising the steps of:
- (a) administering to the subject an antagonist of IL-21/IL-21R selected from the group consisting of an anti-IL-21R antibody, an anti-IL-21 antibody, an antigen-binding fragment of an anti-IL-21R antibody, an antigen-binding fragment of an anti-IL-21 antibody, and an IL-21R soluble fragment, in an amount sufficient to reduce the risk of transplant/graft rejection; and
 - (b) transplanting/grafting an organ, tissue, cell or group of cells to the subject,
- wherein the transplanting/grafting step (b) occurs either before, during, or after the administering step (a).

- 94 -

30. The method of claim 29, wherein the organ, tissue, cell or group of cells transplanted/grafted is selected from the group consisting of heart, kidney, liver, lung, pancreas, bone marrow, cartilage, cornea, neuronal tissue, and cells thereof.

31. A method of treating, preventing or ameliorating transplant/graft rejection in a mammalian transplant/graft recipient comprising:

- (a) detecting a symptom of transplant/graft rejection in a transplant/graft recipient; and
- (b) administering to the transplant/graft recipient an IL-21/IL-21R antagonist selected from the group consisting of an anti-IL-21R antibody, an anti-IL-21 antibody, an antigen-binding fragment of an anti-IL-21R antibody, an antigen-binding fragment of an anti-IL-21 antibody, and an IL-21R soluble fragment.

32. The method of claim 31, wherein the symptom of transplant/graft rejection is selected from the group consisting of inflammation, decreased organ function, signs of rejection in biopsy, and fibrosis.

FIG. 1

1 GTCGACGCGG CGGTACCAGC TGTCTGCCCC CTTCCTCTGT GGTGTGCTTC
51 ACGGTCACTT GCTTGTCTGA CCGCAAGTCT GCCCATCCCT GGGGCAGCCA
101 ACTGGCCTCA GCGCGTGCCC CAGGCGTGCC CTGTCTCTGT CTGGCTGCCC
151 CAGCCCTACT GTCTTCCTCT GTGTAGGCTC TGCCCAGATG CCGGCTGGT
201 CCTCAGCTC AGGACTATCT CAGCAGTGAC TCCCCTGATT CTGGAATTGC
251 ACCTGACTGA ACTCCTGCCC ACCTCAAACC TTCACCTCCC ACCACCACCA
301 CTCCGAGTCC CGCTGTGACT CCCACGCCCC GGAGACCACC CAAGTGCCCC
351 AGCCTAAGA ATGGCTTTCT GAGAAAGACC CTGAAGGAGT AGGTCTGGGA
401 CACAGCATGC CCGGGGGCCC AGTGGCTGCC TTAATCCTGC TGATTCTCCA
451 TGGAGCTTGG AGCTGCCTGG ACCTCACTTG CTACACTGAC TACCTCTGGA
501 CCATCACCTG TGTCTGGAG ACACGGAGCC CCAACCCAG CATACTCAGT
551 CTCACCTGGC AAGATGAATA TGAGGAACTT CAGGACCAAG AGACCTTCTG
601 CAGCCTACAC AGGTCTGGCC ACAACACCAC ACATATATGG TACACGTGCC
651 ATATGCGCTT GTCTCAATTC CTGTCCGATG AAGTTTTCAT TGTCAATGTG
701 ACGGACCAGT CTGGCAACAA CTCCAAGAG TGTGGCAGCT TTGTCTGGC
751 TGAGAGCATC AAACCAGCTC CCCCCTTGAA CGTGAATGTG GCCTTCTCAG
801 GACGCTATGA TATCTCTGG GACTCAGCTT ATGACGAACC CTCCAATAC
851 GTGCTGAGGG GCAAGCTACA ATATGAGCTG CAGTATCGGA ACCTCAGAGA
901 CCCCTATGCT GTGAGGCCGG TGACCAAGCT GATCTCAGTG GACTCAAGAA
951 ACGTCTCTCT TCTCCCTGAA GAGTTCCACA AAGATTCTAG CTACCAGCTG
1001 CAGGTGCGGG CAGCGCCTCA GCCAGGCACT TCATTCAGGG GGACCTGGAG
1051 TGAGTGGAGT GACCCCGTCA TCTTTCAGAC CCAGGCTGGG GAGCCCGAGG
1101 CAGGCTGGGA CCTCAGATG CTGCTGCTCC TGGCTGTCTT GATCATTGTC
1151 CTGGTTTTCA TGGGTCTGAA GATCCACCTG CCTTGGAGGC TATGGAAAAA
1201 GATATGGGCA CCAGTGCCCA CCCCAGAGAG TTTCTTCCAG CCCCTGTACA
1251 GGGAGCACAG CGGGAACCTC AAGAAATGGG TTAATACCCC TTTCACGGCC
1301 TCCAGCATAG AGTTGGTGCC ACAGAGTTCC ACAACAACAT CAGCCTTACA
1351 TCTGTCAATG TATCCAGCCA AGGAGAGAA GTTCCCGGGG CTGCGGGGTC
1401 TGGAGAGCA ACTGGAGTGT GATGGAATGT CTGAGCCTGG TCACTGGTGC

FIG.1 (continued)

1451 ATAATCCCCCT TGGCAGCTGG CCAAGCGGTC TCAGCCTACA GTGAGGAGAG
1501 AGACCGGCCA TATGGTCTGG TGTCCATTGA CACAGTGA CT GTGGGAGATG
1551 CAGAGGGCCT GTGTGTCTGG CCTGTAGCT GTGAGGATGA TGGCTATCCA
1601 GCCATGAACC TGGATGCTGG CCGAGAGTCT GGCCCTAATT CAGAGGATCT
1651 GCTCTTGGTC ACAGACCCTG CTTTTCTGTC TTGCGGCTGT GTCTCAGGTA
1701 GTGGTCTCAG GCTTGGAGGC TCCCCAGGCA GCCTACTGGA CAGGTTGAGG
1751 CTGTCAATTG CAAAGGAAGG GGA CTGGACA GCAGACCCAA CCTGGAGAAC
1801 TGGGTCCCCA GGAGGGGGCT CTGAGAGTGA AGCAGGTTCC CCCCCTGGTC
1851 TGGACATGGA CACATTGAC AGTGGCTTTG CAGGTTGAGA CTGTGGCAGC
1901 CCCGTGGAGA CTGATGAAGG ACCCCCTGGA AGCTATCTCC GCCAGTGGGT
1951 GGTCAGGACC CCTCCACCTG TGGACAGTGG AGCCAGAGC AGCTAGCATA
2001 TAATAACCAG CTATAGTGAG AAGAGGCCTC TGAGCCTGGC ATTTACAGTG
2051 TGAACATGTA GGGGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG
2101 TGTGTGTGTG TGTGTGTGTG TGTCTGGGT TGTGTGTTAG CACATCCATG
2151 TTGGGATTTG GTCTGTTGCT ATGTATTGTA ATGCTAAATT CTCTACCCAA
2201 AGTTCTAGGC CTACGAGTGA ATTCTCATGT TTACAAACTT GCTGTGTAAA
2251 CCTTGTTCCT TAATTTAATA CCATTGGTTA AATAAAATTG GCTGCAACCA
2301 ATTACTGGAG GGATTAGAGG TAGGGGGCTT TTGAGTTACC TGT TTGGAGA
2351 TGGAGAAGGA GAGAGGAGAG ACCAAGAGGA GAAGGAGGAA GGAGAGGAGA
2401 GGAGAGGAGA GGAGAGGAGA GGAGAGGAGA GGAGAGGAGA GGAGAGGAGA
2451 GGCTGCCGTG AGGGGAGAGG GACCATGAGC CTGTGGCCAG GAGAAACAGC
2501 AAGTATCTGG GGTACACTGG TGAGGAGGTG GCCAGGCCAG CAGTTAGAAG
2551 AGTAGATTAG GGGTGACCTC CAGTATTTGT CAAAGCCAAT TAAAATAACA
2601 AAAAAAAAAA AAAAGCGGCC GCTCTAGA

FIG.2A

1 MPRGPVAALL LLILHCAWSC LDITCYTDYL WTITCVLETR SPNPSILSLT
51 WQDEYEELQD QETFCSLHRS GHNTTHIWYT CHMRLSQFLS DEVFIVNVTQ
101 QSGNNSQECG SFVLAESIKP APPLNVTVAF SGRYDISWDS AYDEPSNYVL
151 RGKLOVELQY RNLRDPIAVR PVTKLISVDS RNVSLLPEEF HKDSSYQLQV
201 RAAPOPGTSE RGTWSEWSDP VIFQTQAGEP EAGWDPHMLL LLAVLIIVLV
251 FMGLKIHLPW RLWKKIWAPV PTPESFFQPL YREHSGNFKK WVNTPFTASS
301 IELVQSSTT TSALHLSLYP AKKKFPGLP GLEEQLCECG MSEPGHWCII
351 PLAAQAVSA YSEERDRPYG LVSIDTVTVG DAEGLCVWPC SCEDDGYPAM
401 NLDAGRESGP NSEDLLIVTD PAFLSCGCVS GSGLRLGGSP GSLEDRRLRS
451 FAKEGDWTAD PTWRTGSPGG GSESEAGSPP GLDMDTFDSG FAGSDCGSPV
501 ETDEGPFRSY LRQWVVRTPP PVDGAQSS




Figure 2B

FIG.3

```

huMU-1 .....NNGTCGACTGGAGGCCAGCTGCCCGTCATCA 32
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CAGCCCTACTGTCTTCTCTGTGTAGGCTCTGCCAGATGCCCGGC... 196

huMU-1 GAGTGACAGGTCTTATGACAGCCTGATTGGTGACTCGGGCTGGGTGTGGA 82
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 TGGTCCCTCAGCCTCAGGACTATCTCAGCAGTGACTC.CCCTGATTCTGGA 245

huMU-1 TTCTCAGCCAGGCCTCTGCCTGCTTTCTCAGACCCCTCATCT...GTCAC 129
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CTTGCACCTGACTGAACCTCTGCCACCTCAAACCTTCACCTCCACCCAC 295

huMU-1 CCCCACGCTGAACCCAGCTG.....CCACCCCAAGAAGCCCATCAGACT 173
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CACCACTCCGAGTCCCGCTGTGACTCCACGCCAGGAGACCACCAAGT 345

huMU-1 GCCCCAGCACACGGAATGGATTCTGAGAAAGACCGAAACAGAAGGC 223
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 G.CCCCAGCCTAAAGAATGGCTTTCTGAGAAAGACCTGAAGGAGTAGGT 394

huMU-1 CCGTGGGAGTCAGCATGCCGCGTGCTGGGCCGCCCTTGCTCCTGCTG 273
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 C...TGGGACACAGCATGCCCGGGGCCAGTGCTGCCCTTACTCCTGCTG 442

huMU-1 CTGCTCCAGGGAGGCTGGGGCTGCCCGACCTCGTCTGCTACACCGATTA 323
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 ATTCTCCATGGAGCTTGGAGCTGCCTGGACCTCACTTGCTACACTGACTA 492

huMU-1 CCTCCAGACGGTCATCTGCATCCTGGAAATGTGGAACCTCCACCCAGCA 373
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CCTCTGGACCATCACCTGTCTCCTGGAGACACGGAGCCCAACCCAGCA 542

huMU-1 CGCTCACCCCTTACCTGGCAAGACCAAGTATGAAGAGCTGAAGGACGAGGCC 423
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 TACTCAGTCTCACCTGGCAAGATGAATATGAGGAACCTCAGGACCAAGAG 592

huMU-1 ACCTCTGCAGCCTCCACAGGTGGGCCACAAATGCCACGCATGCCACCTA 473
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 ACCTTCTGCAGCTACACAGGTCTGGCCACAACACCACACATATATGGTA 642

huMU-1 CACCTGCCACATGGATGTATTCCACTTCATGGCCGACGACATTTTCAGTG 523
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CACGTGCCATATGCGCTTGTCTCAATTCTGTCCGATGAAGTTTTCATTG 692

huMU-1 TCAACATCACAGACCAGTCTGGCAACTACTCCAGGAGTGTGGCAGCTTT 573
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 TCAATGTGACGGACAGTCTGGCAACAACCTCCAAGAGTGTGGCAGCTTT 742

huMU-1 CTCCTGGCTGAGAGCATCAAGCCGGCTCCCCCTTTCAACGTGACTGTGAC 623
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 GTCTTGGCTGAGAGCATCAAACAGCTCCCCCTTGAACGTGACTGTGGC 792

huMU-1 CTTCTCAGGACAGTATAATATCTCCTGGCGCTCAGATTACGAAGACCCTG 673
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CTTCTCAGGACGCTATGATATCTCCTGGGACTCAGCTTATGACGAACCT 842

huMU-1 CCTTCTACATGCTGAAGGGCAAGCTTCAGTATGAGCTGCAGTACAGGAAC 723
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CCAACTACGTGCTGAGGGGCAAGCTACAATATGAGCTGCAGTATCGGAAC 892

huMU-1 CGGGGAGACCCCTGGGCTGTGAGTCCGAGGAGAAAGCTGATCTCAGTGGA 773
      : : : : : : : : : : : : : : : : : : : : : :
murMU-1 CTCAGAGACCCCTATGCTGTGAGCCCGGTGACCAAGCTGATCTCAGTGGA 942

huMU-1 CTCAAGAAGTGTCTCCCTCTCCCCCTGGAGTTCCGCAAGACTCGAGCT 823

```

FIG.3 (continue)

murMU-1	CTCAGAAACGCTCTCTCTTCTCCCTGAAGAGTTCACAAAGATTCTAGCT	992
huMU-1	ATGAGCTGCAGGTGCGGGCAGGGCCCATGCCTGGCTCCTCTACACAGGGG	873
murMU-1	ACCAGCTGCAGGTGCGGGCAGCGCCTCAGCCAGGCACTTCATTACAGGGG	1042
huMU-1	ACCTGGAGTGAATGGAGTGACCCGGTCATCTTCAGACCCAGTCAGAGGA	923
murMU-1	ACCTGGAGTGAGTGGAGTGACCCGGTCATCTTCAGACCCAGGCTGGGGA	1092
huMU-1	GTTAAAGGAAGGCTGGAACCCCTCACCTGCTGCTTCTCTCTCTGCTTGTC	973
murMU-1	GCCCAGGGCAGGCTGGGACCCCTCACATGCTG...CTGCTCTGGCTGTCT	1139
huMU-1	TAGTCTTCATTCTGCTTCTGGAGCCTGAAGACCCATCCATTGTGGAGG	1023
murMU-1	TGATCATTGTCTCTGGTTTTCATGGGTCTGAAGATCCACCTGCCTTGGAGG	1189
huMU-1	CTATGGAAGAGATATGGG...CCGTCCCCAGCCCTGAGCGGTTCTTCAT	1070
murMU-1	CTATGAAAAAGATATGGGCACAGTGCCCAACCCCTGAGAGTTTCTTCCA	1239
huMU-1	GCCCCGTGACAGGGGTGCAGCGGAGACTTCAAGAAATGGGTGGGTGCAC	1120
murMU-1	GCCCCGTGACAGGGAGCACAGCGGGAACCTCAAGAAATGGGTGAATACCC	1289
huMU-1	CCTTCACTGGCTCCAGCCTGGAGCTGGGACCTGGAGCCAGAGGTGCCC	1170
murMU-1	CTTTCACGGCTCCAGCATAGAGTTGGTGCCACAGAGTTCACACAACA	1339
huMU-1	TCCACCCCTGGAGGTGTACAGCTGCCACCCACCCAGGAGCCCGGCCAAGAG	1220
murMU-1	TCAGCCTTACATCTGT...CATTGTATCCAGCCAAGGA	1374
huMU-1	GCTGCAGCTCACGGAGCTACAAGAACCAGCAGAGCTGGTGGAGTCTGACG	1270
murMU-1	GAAGAAGTTCCTCGGGGCTGCCGGGTCTGGAAGAGCAACTGGAGTGTGATG	1424
huMU-1	GTGTGCCCAAGCCACGCTTCTGG...CCGACAGCCAGAACTCG	1311
murMU-1	GAATGTCTGAGCCTGGTCACTGGTGCATAATCCCTTGGCAGCTGGCCAA	1474
huMU-1	GGGGGCTCAGCTTACAGTGAGGAGAGGGATCGGCCATACGGCCTGGTGTC	1363
murMU-1	GCGGTCTCAGCCTACAGTGAGGAGAGAGACCGGCCATATGGTCTGGTGTC	1524
huMU-1	CATTGACACAGTGACTGTGCTAGATGCAGAGGGGCCATGCACCTGGCCCT	1411
murMU-1	CATTGACACAGTGACTGTGGGAGATGCAGAGGGCCTGTGTGTCTGGCCCT	1574
huMU-1	GCAGCTGTGAGGATGACGGCTACCCAGCCCTGGACCTGGATGCTGGCCCTG	1461
murMU-1	GTAGCTGTGAGGATGATGGCTATCCAGCCATGAACCTGGATGCTGGCCGA	1624
huMU-1	GAGCCCAAGCCAGGCTAGAGGACCCACTCTTGGATGAGGGACACAGT	1511
murMU-1	GAGTCTGGCCCTAATTACAGGGATCTGCTCTTGGTCAAGACCTGCTTT	1674
huMU-1	CCTGTCTCTGTGGCTGTGTCTCAGCTGGCAGCCCTGGGCTAGGAGGGCCCC	1561
murMU-1	TCTGTCTTGGGGCTGTGTCTCAGGTAGTGGTCTCAGGCTTGGAGGCTCCC	1724
huMU-1	TGGGAAGCTTCTGGACAGACTAAAGCCACCCTTGAGATGGGAGGAG	1611
murMU-1	CAGGCAGCTACTGGACAGGTTGAGGCTGTCAATTGCAAAGGAAGGGGAC	1774
huMU-1	TGGGCTGGGGGACTGCCCTGGGGTGGCCGGTCACTTGGAGCGGCTTCA	1661

FIG.3 (continued)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	
--	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	--

FIG.3 (continue, ,

murMU-1 AGATTAGGGGTGACCTCCAGTATTGTCAAAGCCAATTAAAATAACAAA 2603
humMU-1 AAAAATCTAGA..... 2567
murMU-1 AAAAATAAAGCGGCCGCTCTAGA 2628

FIG.4


Human MU-1 MPRGWAAPLLLLLLOGGWGCPDLVCYTDYLOTVICILEMNNLHPSTLTLT 50
 ||||| | ||||| | | | | | ||||| | | | | | . || | | |
 MurineMU-1 MPRGPVAAALLLJLNGAWSCDLTCYTDYLWTITCVLETRSPNPSILSLT 50
 Human MU-1 WODQYEELKDEATSCSLHRSAHNATHATYTCMDVFFHMADDIFSVNITD 100
 ||||| ||||| | | ||||| | | | ||||| | | | | | |||||
 MurineMU-1 WODEYEELQDOETFCSLHRSGHNTTHIWTCHMRLSOFLSDEVFIVNVTD 100
 Human MU-1 OSGNYSOECGSFLLAESIKPAPPFNVTVTFSGQYNISWRSOYEDPAFYML 150
 ||||| ||||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
 MurineMU-1 OSGNNSOECGSFVLAESIKPAPPLNVTVAFSGRYDISWDSAYDEPSNYVL 150
 Human MU-1 KGKLOYELOQRNRGDPWAVSPRRKLISVDSRSVSLPLEFRKDSSEYEQV 200
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 MurineMU-1 RGNLOYELOQRNLRDPYAVRPVTKLISVDSRNVSLLPECFHKDSSEYQLOV 200
 Human MU-1 RAGPMGSSSYOGTWSEWSOPVI FOTQSEELKEGWNPHLLLLLLVIVFIP 250
 || | || | | | | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 RAAPOPGTSFRGTWSEWSOPVI FOTQAGEPEAGWDPHMLLLAVLIIVL 249
 Human MU-1 AFWSLKTHPLWRLWKKIWA VPSPERFFHPLYKGCSDGFKKWVGAPFTGS 299
 | | | | | | | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 VFMGLKIHLPWRLWKKIWA PVPTPEFFQPLYREHSGNFKKWVNTPTFTAS 299
 Human MU-1 SLELGPWSPEVPSTLEVYSCHPPRSPAKRLQTELOEPAELVESDGVPKP 349
 ||||| | | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 SIELVPOSSTTTTSAI NLSLYPAKEKKFPGLPGLEEQLCDGMSEP 344
 Human MU-1 SFW . . . PTAQNSGGSAYSEERDRPYGLVSI DTVTVLDAEGPCTWPCSCD 396
 | | | | | | | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 GHWCIIPLAAGQAVSAYSEERDRPYGLVSI DTVTVGDAEGLCVWPCSCD 394
 Human MU-1 DGYPALDLDAGLEPSGLEDPLLDAGTTVLSCGCVSAGSPGLGGPLGSLL 446
 ||||| ||||| | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 DGYPAMNLDAGRESGPNSDLLLLVTDP AFLSCGCVSGSGLRLGGSPGSLL 444
 Human MU-1 DRKPPPLADGEDWAGGLPWGGRSPGGVSESEAGSPLAGLDMOTFDSGFVG 496
 ||| | | | | | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 DRLRLSFAKEGDWTADPTWRTGSPGGGSESEAGSP . PGLDMOTFDSGFAG 493
 Human MU-1 SDCSSPVECDFTSPGDEGPPRSYLQWVV . JPPPLSSPGFOAS 539
 ||| |||| | | | | | | | | | | | | | | | | | | | | |
 MurineMU-1 SDCGSPVET DEGPPRSYLQWVVRTPPPVD . GAQSS 529

FIG. 5

	1		50
humu	---MPRGWAA PLLLLL..LO GGWG.....	CPDLVCYTDY	LQTVICILEM
mousemu	---MPRGPA ALLLLI..LH GAWG.....	CLDLTCYTDY	LWTITCVLET
humil2:bc	MAAPALSWRL PLLJLELPLA TSWASAAVNG	TSOFTCFYNS	RANISCVWSQ
	51		100
humu	WN..LHPSTL TLTHODQYEE LKDEATSCSL	HRSAAHATHA	TYTCHM....
mousemu	RS..PNPSIL SLTWODEYEE LQDQETFCSL	HRSQHNTTHI	WYTCHM....
humil2:bc	DGALQDTSCQ VHAWPDR...RRWNOTCELLPVSQA	SWACNLIIGA
	101		150
humu	.DVFHFMADD IFSVNITDQS GN..YSOECG	SFLLAESIKP	APPFNVTVTF
mousemu	.RLSOFLSDE VFIIVNVTDQS GN..NSOECG	SFVLAESIKP	APPLNVTVAF
humil2:bc	PDSQKLTTVD IVTLRVLCRE GVRWRVMAIQ	DFKPFENLRL	MAPISLQVVH
	151		200
humu	..SGOYNISW ASDYEDPAFY MLKGLQYEL	OYRNRGDPWA	VSPRRKLISV
mousemu	..SGRYDISW DSAYDEPSNY VLRGLQYEL	OYRNLRDPYA	VRPVTKLISV
humil2:bc	VETHRCNISW E..ISOASHY FER.HLEFEA	RTLSPPGHTE	EAP...LLTL
	201		250
humu	DSRSVSLPL EFRKDSSYEL QVRAGPMPS	SYOGTHSEHS	DPVIFOTQS.
mousemu	DSRNVSLPE EFHKDSSYOL QVRAAPQPGT	SFRGTWSEHS	DPVIFOTQA.
humil2:bc	KQKQEWICLE TLTPDQYEF QVRVKPLOGE	F..TTWSPHS	QPLAFRTKPA
	251		300
humu	..EELKEGWN PHLLLLL...LLVIVFIPAF	WSLKTHPLWR	LWKKTHA.VP
mousemu	..GEPEAGWD PHMLLLL...AVLIIVL.VF	MGLKIHLPWR	LWKKTHA.VP
humil2:bc	ALGKDTIPWL GHLLVGLSGA FGFIIIVYLL	INCRNTGPW.	LKKVLKCNTP
	301		350
humu	SPERFFMPLY KGCSDGFKKW VGAPFTGSSL	ELGPWSPEVP	STLEVISCHP
mousemu	TPESFFOPLY REHSGNFKKW VNTPTASSI	ELVPOSSTIT	SAL.....BL
humil2:bc	DPSKFFSOLS SEHGGOVQKW LSSPFPSSSF	SPGGLAPEJS	PLEVLERDKV
	351		400
humu	PRSPAKRIOL TELQEP...E LVESDGVPKP	SFW...PTAQ	NSGGSAYSEE
mousemu	SLYPAKKEKF PGLPGL...E QLECDGMSEP	GHWCIIPLAA	GOAVSAYSEE
humil2:bc	TQLLQODKV PEPASLSSNH SLTSCFTNOG	YFFFHLPDAL	EIEACQVYFT
	401		450
humu	RDRPIGLVSI DTVTVLDAEG PC...TWPCS	CEDDGIPALD	LDAGLEPSPG
mousemu	RDRPTGLVSI DTVTVGDAEG LC...VWPCS	CEDDGIPAMN	LDAGRESGPH
humil2:bc	YD.PYSEEDP DEGVAGAPTG SSPQPLQPLS	GEDDAYCTF.PS
	451		500
humu	LEDPLLDAGT TVLSCGCVSA GSPGLGGPLG	SLLDRKPPPL	AD..GEDWAG
mousemu	SEDLLLVTDP AFLSCGCVSG SGLRLGGSPG	SLLDRLRISF	AK..EGDWT
humil2:bc	ADDLLIFS.P SLL..GGPSP PSTAPGGS.G	AGEERNPPSL	QERVPRDWD
	501		550
humu	GLPHGGRSPG GVSESEAGSP LAGLDMDTFD	SGFVGSDCSS	PVECDFTSPG
mousemu	DPTWRTGSPG GGSESEAGSP .PGLDMDTFD	SGFAGSDCGS	PVET.....
humil2:bc	Q..PLGPPTPG VPDLVDFOPP P...ELVLR	AGEEVPDAG.	PRE.GVSFPW
	551		588
humu	DEGPPTSILR QWVVI PPPLS SPGPQAS---	-----	
mousemu	DEGPPTSILR QWVVRTPPPV DSGAQSS---	-----	
humil2:bc	SRPPGQGEFR ALNARLPLNT DAYLSLQELO	GODPTHLV	

FIG.6

Signaling through MU-1



atg Met 1	aaa Lys	ttc Phe	tta Leu	gtc Val 5	aac Asn	gtt Val	gcc Ala	ctt Leu	gtt Val 10	ttt Phe	atg Met	gtc Val	gtg Val 15	tac Tyr 15	att Ile	48
tct Ser	tac Tyr	atc Ile	tat Tyr 20	gcc Ala	ggc Gly	agc Ser	gga Gly	cac His 25	cac His	cat His	cat His	cac His	cac His 30	ggt Gly	agc Ser	96
ggc Gly	gac Asp	tat Tyr 35	aaa Lys	gac Asp	gat Asp	gac Asp	gat Asp 40	aag Lys	ggt Gly	tcc Ser	gga Gly	tgc Cys 45	ccc Pro	gac Asp	ctc Leu	144
gtc Val	tgc Cys 50	tac Tyr	acc Thr	gat Asp	tac Tyr	ctc Leu 55	cag Gln	acg Thr	gtc Val	atc Ile	tgc Cys 60	atc Ile	ctg Leu	gaa Glu	atg Met	192
tgg Trp 65	aac Asn	ctc Leu	cac His	ccc Pro	agc Ser 70	acg Thr	ctc Leu	acc Thr	ctt Leu	acc Thr 75	tgg Trp	caa Gln	gac Asp	cag Gln	tat Tyr 80	240
gaa Glu	gag Glu	ctg Leu	aag Lys	gac Asp 85	gag Glu	gcc Ala	acc Thr	tcc Ser	tgc Cys 90	agc Ser	ctc Leu	cac His	agg Arg	tgc Ser 95	gcc Ala	288
cac His	aat Asn	gcc Ala	acg Thr 100	cat His	gcc Ala	acc Thr	tac Tyr	acc Thr 105	tgc Cys	cac His	atg Met	gat Asp	gta Val 110	ttc Phe	cac His	336
ttc Phe	atg Met	gcc Ala 115	gac Asp	gac Asp	att Ile	ttc Phe	agt Ser 120	gtc Val	aac Asn	atc Ile	aca Thr	gac Asp 125	cag Gln	tct Ser	ggc Gly	384
aac Asn	tac Tyr 130	tcc Ser	cag Gln	gag Glu	tgt Cys	ggc Gly 135	agc Ser	ttt Phe	ctc Leu	ctg Leu	gct Ala 140	gag Glu	agc Ser	atc Ile	aag Lys	432
ccg Pro 145	gct Ala	ccc Pro	cct Pro	ttc Phe	aac Asn 150	gtg Val	act Thr	gtg Val	acc Thr	ttc Phe 155	tca Ser	gga Gly	cag Gln	tat Tyr	aat Asn 160	480
atc Ile	tcc Ser	tgg Trp	cgc Arg	tca Ser 165	gat Asp	tac Tyr	gaa Glu	gac Asp	cct Pro 170	gcc Ala	ttc Phe	tac Tyr	atg Met	ctg Leu 175	aag Lys	528
ggc Gly	aag Lys	ctt Leu	cag Gln 180	tat Tyr	gag Glu	ctg Leu	cag Gln	tac Tyr 185	agg Arg	aac Asn	cgg Arg	gga Gly	gac Asp 190	ccc Pro	tgg Trp	576
gct Ala	gtg Val	agt Ser 195	ccg Pro	agg Arg	aga Arg	aag Lys	ctg Leu 200	atc Ile	tca Ser	gtg Val	gac Asp 205	tca Ser	aga Arg	agt Ser	gtc Val	624
tcc Ser 210	ctc Leu	ctc Leu	ccc Pro	ctg Leu	gag Glu	ttc Phe 215	cgc Arg	aaa Lys	gac Asp	tgc Ser	agc Ser 220	tat Tyr	gag Glu	ctg Leu	cag Gln	672

Fig. 7A

gtg	cgg	gca	ggg	ccc	atg	cct	ggc	tcc	tcc	tac	cag	ggg	acc	tgg	agt	720
Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser	Ser	Tyr	Gln	Gly	Thr	Trp	Ser	
225					230					235					240	
gaa	tgg	agt	gac	ccg	gtc	atc	ttt	cag	acc	cag	tca	gag	gag	tta	aag	768
Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	Thr	Gln	Ser	Glu	Glu	Leu	Lys	
				245					250					255		
gaa	ggc	tgg	aac	taa	tga	SEQ ID NO: 22										786
Glu	Gly	Trp	Asn	SEQ	ID	NO: 23										
	260															

Fig. 7B

gcggccgcac cacc atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg	50
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu	
1 5 10	
ctg ctc cag gga ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat	98
Leu Leu Gln Gly Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp	
15 20 25	
tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc	146
Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro	
30 35 40	
agc acg ctc acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac	194
Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp	
45 50 55 60	
gag gcc acc tcc tgc agc ctc cac agg tgc gcc cac aat gcc acg cat	242
Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His	
65 70 75	
gcc acc tac acc tgc cac atg gat gta ttc cac ttc atg gcc gac gac	290
Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp	
80 85 90	
att ttc agt gtc aac atc aca gac cag tct ggc aac tac tcc cag gag	338
Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu	
95 100 105	
tgt ggc agc ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc	386
Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe	
110 115 120	
aac gtg act gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca	434
Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser	
125 130 135 140	
gat tac gaa gac cct gcc ttc tac atg ctg aag ggc aag ctt cag tat	482
Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr	
145 150 155	
gag ctg cag tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg	530
Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg	
160 165 170	
aga aag ctg atc tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg	578
Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu	
175 180 185	
gag ttc cgc aaa gac tgc agc tat gag ctg cag gtg cgg gca ggg ccc	626
Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro	
190 195 200	
atg cct ggc tcc tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg	674
Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro	
205 210 215 220	

Fig. 8A

gtc atc ttt cag acc cag tca gag gag tta aag gaa ggc tgg aac ggc	722
Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly	
225 230 235	
tcc ggc tct aga gac aaa act cac aca tgc cca ccg tgc cca gca cct	770
Ser Gly Ser Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	
240 245 250	
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag	818
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	
255 260 265	
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg	866
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	
270 275 280	
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac	914
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	
285 290 295 300	
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac	962
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	
305 310 315	
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac	1010
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	
320 325 330	
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc	1058
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu	
335 340 345	
cca gtc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga	1106
Pro Val Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg	
350 355 360	
gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag	1154
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys	
365 370 375 380	
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac	1202
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp	
385 390 395	
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag	1250
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys	
400 405 410	
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc	1298
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser	
415 420 425	
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca	1346
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser	
430 435 440	

Fig. 8B

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1394
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
445 450 455 460

ctc tcc ctg tcc ccg ggt aaa tgagtgaatt c SEQ ID NO: 24 1426
Leu Ser Leu Ser Pro Gly Lys SEQ ID NO: 25
465

Fig. 8C

Q ID NO:26	gcggccgcac	cacc	atg	ccg	cgt	ggc	tgg	gcc	gcc	ccc	ttg	ctc	ctg	ctg		50
Q ID NO:27			Met	Pro	Arg	Gly	Trp	Ala	Ala	Pro	Leu	Leu	Leu	Leu		
			1				5				10					
	ctg	ctc	cag	gga	ggc	tgg	ggc	tgc	ccc	gac	ctc	gtc	tgc	tac	acc	gat
	Leu	Leu	Gln	Gly	Gly	Trp	Gly	Cys	Pro	Asp	Leu	Val	Cys	Tyr	Thr	Asp
			15				20				25					98
	tac	ctc	cag	acg	gtc	atc	tgc	atc	ctg	gaa	atg	tgg	aac	ctc	cac	ccc
	Tyr	Leu	Gln	Thr	Val	Ile	Cys	Ile	Leu	Glu	Met	Trp	Asn	Leu	His	Pro
			30				35				40					146
	agc	acg	ctc	acc	ctt	acc	tgg	caa	gac	cag	tat	gaa	gag	ctg	aag	gac
	Ser	Thr	Leu	Thr	Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp
			45				50				55					194
	gag	gcc	acc	tcc	tgc	agc	ctc	cac	agg	tcg	gcc	cac	aat	gcc	atg	cat
	Glu	Ala	Thr	Ser	Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His
					65					70					75	242
	gcc	acc	tac	acc	tgc	cac	atg	gat	gta	ttc	cac	ttc	atg	gcc	gac	gac
	Ala	Thr	Tyr	Thr	Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp
					80					85					90	290
	att	ttc	agt	gtc	aac	atc	aca	gac	cag	tct	ggc	aac	tac	tcc	cag	gag
	Ile	Phe	Ser	Val	Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu
					95				100							338
	tgt	ggc	agc	ttt	ctc	ctg	gct	gag	agc	atc	aag	ccg	gct	ccc	cct	ttc
	Cys	Gly	Ser	Phe	Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe
					110							120				386
	aac	gtg	act	gtg	acc	ttc	tca	gga	cag	tat	aat	atc	tcc	tgg	cgc	tca
	Asn	Val	Thr	Val	Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser
					125						135					140
	gat	tac	gaa	gac	cct	gcc	ttc	tac	atg	ctg	aag	ggc	aag	ctt	cag	tat
	Asp	Tyr	Glu	Asp	Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr
					145					150					155	482
	gag	ctg	cag	tac	agg	aac	cgg	gga	gac	ccc	tgg	gct	gtg	agt	ccg	agg
	Glu	Leu	Gln	Tyr	Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg
					160				165						170	530
	aga	aag	ctg	atc	tca	gtg	gac	tca	aga	agt	gtc	tcc	ctc	ctc	ccc	ctg
	Arg	Lys	Leu	Ile	Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu
					175				180							578
	gag	ttc	cgc	aaa	gac	tcg	agc	tat	gag	ctg	cag	gtg	cgg	gca	ggg	ccc
	Glu	Phe	Arg	Lys	Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro
					190							200				626
	atg	cct	ggc	tcc	tcc	tac	cag	ggg	acc	tgg	agt	gaa	tgg	agt	gac	ccg
	Met	Pro	Gly	Ser	Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro
						210										674
											215					220

Fig. 9A

gtc atc ttt cag acc cag tca gag gag tta aag gaa ggc tgg aac ggc Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly 225 230 235	722
tcc ggc tct aga gac aaa act cac aca tgc cca ccg tgc cca gca cct Ser Gly Ser Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 240 245 250	770
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 255 260 265	818
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 270 275 280	866
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 285 290 300	914
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315	962
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val His Gln Asp 320 325 330	1010
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 335 340 345	1058
cca gtc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga Pro Val Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 350 355 360	1106
gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 365 370 375 380	1154
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395	1202
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 400 405 410	1250
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 415 420 425	1298
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 430 435 440	1346

Fig. 9B

tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	1394
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	
445					450					455					460	
ctc	tcc	ctg	tcc	ccg	ggt	aaa	tca	gga	atg	gca	tca	atg	aca	gga	ggt	1442
Leu	Ser	Leu	Ser	Pro	Gly	Lys	Ser	Gly	Met	Ala	Ser	Met	Thr	Gly	Gly	
				465					470					475		
caa	caa	atg	ggt	tct	gga	tct	cat	cat	cat	cat	cat	cat	tct	gga	ggt	1490
Gln	Gln	Met	Gly	Ser	Gly	Ser	His	His	His	His	His	His	Ser	Gly	Gly	
			480					485					490			
tgagaattc																1499

Fig. 9C

gcggccgcac cacc	atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg	50
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu	1 5 10	
ctg ctc cag gga ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat	98	
Leu Leu Gln Gly Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp	15 20 25	
tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc	146	
Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro	30 35 40	
agc acg ctc acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac	194	
Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp	45 50 55 60	
gag gcc acc tcc tgc agc ctc cac agg tgc gcc cac aat gcc acg cat	242	
Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His	65 70 75	
gcc acc tac acc tgc cac atg gat gta ttc cac ttc atg gcc gac gac	290	
Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp	80 85 90	
att ttc agt gtc aac atc aca gac cag tct ggc aac tac tcc cag gag	338	
Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu	95 100 105	
tgt ggc agc ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc	386	
Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe	110 115 120	
aac gtg act gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca	434	
Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser	125 130 135 140	
gat tac gaa gac cct gcc ttc tac atg ctg aag ggc aag ctt cag tat	482	
Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr	145 150 155	
gag ctg cag tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg	530	
Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg	160 165 170	
aga aag ctg atc tca gtg gac tca aga agt gtc tcc ctc etc ccc ctg	578	
Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu	175 180 185	
gag ttc cgc aaa gac tgc agc tat gag ctg cag gtg cgg gca ggg ccc	626	
Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro	190 195 200	
atg cct ggc tcc tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg	674	
Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro	205 210 215 220	

Fig. 10A

gtc atc ttt cag acc cag tca gag gag tta aag gaa ggc tgg aac ggc Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly	722
tcc ggc tct aga gac aaa act cac aca tgc cca ccg tgc cca gca cct Ser Gly Ser Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	770
gaa gcc ctg ggg gca ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag Glu Ala Leu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	818
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	866
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	914
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	962
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	1010
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu	1058
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg	1106
gaa cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys	1154
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp	1202
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys	1250
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser	1298
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser	134

Figure 10B

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1394
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 460
445 450 455

ctc tcc ctg tcc ccg ggt aaa tgagtgaatt C SEQ ID NO: 28 1426
Leu Ser Leu Ser Pro Gly Lys SEQ ID NO: 29
465

Figure 10C

atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly 1 5 10 15	48
ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr 20 25 30	96
gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr 35 40 45	144
ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser 50 55 60	192
tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr 65 70 75 80	240
tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val 85 90 95	288
aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt Asn Ile Thr Asp Gln Ser Gly Asn Tyr 105 Ser Gln Glu Cys Gly Ser Phe 100 110	336
ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val 115 120 125	384
acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp 130 135 140	432
cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr 145 150 155 160	480
agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile 165 170 175	528
tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys 180 185 190	576
gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser 195 200 205	624
tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln 210 215 220	672

Figure 11A

acc cag tca gag gag tta aag gaa ggc tgg aac aaa acc gaa acc tcc 720
Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Lys Thr Glu Thr Ser
225 230 235 240

cag gtt gct ccg gca taa tga SEQ ID NO: 30 741
Gln Val Ala Pro Ala SEQ ID NO: 31
245

atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly 1 5 10 15	48
ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr 20 25 30	96
gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr 35 40 45	144
ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser 50 55 60	192
tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr 65 70 75 80	240
tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val 85 90 95	288
aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe 100 105 110	336
ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val 115 120 125	384
acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp 130 135 140	432
cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr 145 150 155 160	480
agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile 165 170 175	528
tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys 180 185 190	576
gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser 195 200 205	624
tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln 210 215 220	672

Fig. 12A

acc cag tca gag gag tta aag gaa ggc tgg aac gat gac gat gac aag Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Asp Asp Asp Asp Lys 225 230 235 240	720
ggc tcc ggc gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa Gly Ser Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255	768
gcc ctg ggg gca ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Ala Leu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270	816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285	864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300	912
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320	960
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335	1008
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350	1056
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365	1104
cca cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380	1152
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400	1200
gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415	1248
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc aag Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430	1296
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445	1344

Fig. 12B

```
tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc etc 1392
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

tcc ctg tcc ccg ggt aaa tga SEQ ID NO: 32 1413
Ser Leu Ser Pro Gly Lys SEQ ID NO: 33
465 470
```

Fig. 12C

Q ID NO:34	atg	ccc	cgg	ggc	cca	gtg	gct	gcc	tta	ctc	ctg	ctg	att	ctc	cat	gga	48
Q ID NO:35	Met	Pro	Arg	Gly	Pro	Val	Ala	Ala	Leu	Leu	Leu	Leu	Ile	Leu	His	Gly	
1					5				10					15			
	gct	tgg	agc	tgc	ctg	gac	ctc	act	tgc	tac	act	gac	tac	ctc	tgg	acc	96
	Ala	Trp	Ser	Cys	Leu	Asp	Leu	Thr	Cys	Tyr	Thr	Asp	Tyr	Leu	Trp	Thr	
				20					25					30			
	atc	acc	tgt	gtc	ctg	gag	aca	cgg	agc	ccc	aac	ccc	agc	ata	ctc	agt	144
	Ile	Thr	Cys	Val	Leu	Glu	Thr	Arg	Ser	Pro	Asn	Pro	Ser	Ile	Leu	Ser	
			35					40					45				
	ctc	acc	tgg	caa	gat	gaa	tat	gag	gaa	ctt	cag	gac	caa	gag	acc	ttc	192
	Leu	Thr	Trp	Gln	Asp	Glu	Tyr	Glu	Glu	Leu	Gln	Asp	Gln	Glu	Thr	Phe	
			50				55					60					
	tgc	agc	cta	cac	agg	tct	ggc	cac	aac	acc	aca	cat	ata	tgg	tac	acg	240
	Cys	Ser	Leu	His	Arg	Ser	Gly	His	Asn	Thr	Thr	His	Ile	Trp	Tyr	Thr	
	65					70					75					80	
	tgc	cat	atg	cgc	ttg	tct	caa	ttc	ctg	tcc	gat	gaa	gtt	ttc	att	gtc	288
	Cys	His	Met	Arg	Leu	Ser	Gln	Phe	Leu	Ser	Asp	Glu	Val	Phe	Ile	Val	
					85						90				95		
	aat	gtg	acg	gac	cag	tct	ggc	aac	aac	tcc	caa	gag	tgt	ggc	agc	ttt	336
	Asn	Val	Thr	Asp	Gln	Ser	Gly	Asn	Asn	Ser	Gln	Glu	Cys	Gly	Ser	Phe	
				100					105					110			
	gtc	ctg	gct	gag	agc	atc	aaa	cca	gct	ccc	ccc	ttg	aac	gtg	act	gtg	384
	Val	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Leu	Asn	Val	Thr	Val	
			115					120					125				
	gcc	ttc	tca	gga	cgc	tat	gat	atc	tcc	tgg	gac	tca	gct	tat	gac	gaa	432
	Ala	Phe	Ser	Gly	Arg	Tyr	Asp	Ile	Ser	Trp	Asp	Ser	Ala	Tyr	Asp	Glu	
		130					135					140					
	ccc	tcc	aac	tac	gtg	ctg	agg	ggc	aag	cta	caa	tat	gag	ctg	cag	tat	480
	Pro	Ser	Asn	Tyr	Val	Leu	Arg	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	
	145					150					155					160	
	cgg	aac	ctc	aga	gac	ccc	tat	gct	gtg	agg	ccg	gtg	acc	aag	ctg	atc	528
	Arg	Asn	Leu	Arg	Asp	Pro	Tyr	Ala	Val	Arg	Pro	Val	Thr	Lys	Leu	Ile	
					165					170					175		
	tca	gtg	gac	tca	aga	aac	gtc	tct	ctt	ctc	cct	gaa	gag	ttc	cac	aaa	576
	Ser	Val	Asp	Ser	Arg	Asn	Val	Ser	Leu	Leu	Pro	Glu	Glu	Phe	His	Lys	
				180					185					190			
	gat	tct	agc	tac	cag	ctg	cag	gtg	cgg	gca	gcg	cct	cag	cca	ggc	act	624
	Asp	Ser	Ser	Tyr	Gln	Leu	Gln	Val	Arg	Ala	Ala	Pro	Gln	Pro	Gly	Thr	
			195					200					205				
	tca	ttc	agg	ggg	acc	tgg	agt	gag	tgg	agt	gac	ccc	gtc	atc	ttt	cag	672
	Ser	Phe	Arg	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	
		210					215					220					

Fig. 13A

acc cag gct ggg gag ccc gag gca ggc tgg gac ggc tcc ggc tct aga	720
Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Gly Ser Gly Ser Arg	
225 230 235 240	
 gagccccgcg gaccgacaat caagccctgt cctccatgca aatgcccagg taagtcaacta	780
gaccagagct ccactcccgg gagaatggta agtgctataa acatccctgc actagaggat	840
aagccatgta cagatccatt tccatctctc ctcatcagca cctaacctcg aggggtggacc	900
atccgtcttc atcttcctc caaagatcaa ggatgtactc atgatctccc tgagcccat	960
agtcacatgt gtgggtgggtg atgtgagcga ggatgaccca gatgtccaga tcagctggtt	1020
tgtgaacaac gtggaagtac acacagctca gacacaaacc catagagagg attacaacag	1080
tactctccgg gtgggtcagtg cctccccat ccagcaccag gactggatga gtggcaaggc	1140
tttcgcatgc gccgtcaaca acaaagacct ccagcgccc atcgagagaa ccatctcaa	1200
acccaaaggt gagagctgca gcctgactgc atggggggtg ggatgggcat aaggataaag	1260
gtctgtgtgg acagccttct gcttcagcca tgaccttgt gtatgtttct accctcacag	1320
ggtcagtaag agctccacag gtatatgtct tgcctccacc agaagaagag atgactaaga	1380
aacaggtcac tctgacctgc atgggtcacag acttcatgcc tgaagacatt tacgtggagt	1440
ggaccaacaa cgggaaaaca gagctaaact acaagaacac tgaaccagtc ctggactctg	1500
atggttctta ctcatgtac agcaagctga gagtggaaaa gaagaactgg gtggaaagaa	1560
atagctactc ctgttcagtg gtccacgagg gtctgcacaa tcaccacacg actaagagct	1620
tctcccgac tccgggtaaa tgagctcagc acccacaaaa ctctcaggtc caaagagaca	1680
cccacactca tctccatgct tcccttgat aaataaagca ccagcaatg cctgggacca	1740
tgtaatagga attc	1754

Fig. 13B

ctgcaggctg acaccacc atg ccc cgg ggc cca gtg gct gcc tta ctc ctg	51
Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu	1 5 10
ctg att ctc cat gga gct tgg agc tgc ctg gac ctc act tgc tac act	99
Leu Ile Leu His Gly Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr	15 20 25
gac tac ctc tgg acc atc acc tgt gtc ctg gag aca cgg agc ccc aac	147
Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn	30 35 40
ccc agc ata ctc agt ctc acc tgg caa gat gaa tat gag gaa ctt cag	195
Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln	45 50 55
gac caa gag acc ttc tgc agc cta cac agg tct ggc cac aac acc aca	243
Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly His Asn Thr Thr	60 65 70 75
cat ata tgg tac acg tgc cat atg cgc ttg tct caa ttc ctg tcc gat	291
His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp	80 85 90
gaa gtt ttc att gtc aat gtg acg gac cag tct ggc aac aac tcc caa	339
Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln	95 100 105
gag tgt ggc agc ttt gtc ctg gct gag agc atc aaa cca gct ccc ccc	387
Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro	110 115 120
ttg aac gtg act gtg gcc ttc tca gga cgc tat gat atc tcc tgg gac	435
Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp	125 130 135
tca gct tat gac gaa ccc tcc aac tac gtg ctg agg ggc aag cta caa	483
Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln	140 145 150 155
tat gag ctg cag tat cgg aac ctc aga gac ccc tat gct gtg agg ccg	531
Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro	160 165 170
gtg acc aag ctg atc tca gtg gac tca aga aac gtc tct ctt ctc cct	579
Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro	175 180 185
gaa gag ttc cac aaa gat tct agc tac cag ctg cag gtg cgg gca gcg	627
Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala	190 195 200
cct cag cca ggc act tca ttc agg ggg acc tgg agt gag tgg agt gac	675
Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp	205 210 215

Fig. 14A

```
ccc gtc atc ttt cag acc cag gct ggg gag ccc gag gca ggc tgg gac 723
Pro Val Ile Phe Gln Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp
220 225 230 235

ggc agc gga cac cac cat cat cac cac ggt agc ggc gac tat aaa gac 771
Gly Ser Gly His His His His His His Gly Ser Gly Asp Tyr Lys Asp
240 245 250

gat gac gat aag tagtgagaat tc SEQ ID NO: 36 795
Asp Asp Asp Lys SEQ ID NO: 37
255
```

Fig. 14B

atg aaa ttc tta gtc aac gtt gcc ctt gtt ttt atg gtc gtg tac att Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile 1 5 10 15	48
tct tac atc tat gcc ggc agc gga cac cac cat cat cac cac ggt agc Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His Gly Ser 20 25 30	96
ggc gac tat aaa gac gat gac gat aag ggt tcc gga tgc ctg gac ctc Gly Asp Tyr Lys Asp Asp Asp Lys Gly Ser Gly Cys Leu Asp Leu 35 40 45	144
act tgc tac act gac tac ctc tgg acc atc acc tgt gtc ctg gag aca Thr Cys Tyr Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr 50 55 60	192
cgg agc ccc aac ccc agc ata ctc agt ctc acc tgg caa gat gaa tat Arg Ser Pro Asn Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr 65 70 75 80	240
gag gaa ctt cag gac caa gag acc ttc tgc agc cta cac agg tct ggc Glu Glu Leu Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly 85 90 95	288
cac aac acc aca cat ata tgg tac acg tgc cat atg cgc ttg tct caa His Asn Thr Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln 100 105 110	336
ttc ctg tcc gat gaa gtt ttc att gtc aat gtg acg gac cag tct ggc Phe Leu Ser Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly 115 120 125	384
aac aac tcc caa gag tgt ggc agc ttt gtc ctg gct gag agc atc aaa Asn Asn Ser Gln Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys 130 135 140	432
cca gct ccc ccc ttg aac gtg act gtg gcc ttc tca gga cgc tat gat Pro Ala Pro Pro Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp 145 150 155 160	480
atc tcc tgg gac tca gct tat gac gaa ccc tcc aac tac gtg ctg agg Ile Ser Trp Asp Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg 165 170 175	528
ggc aag cta caa tat gag ctg cag tat cgg aac ctc aga gac ccc tat Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr 180 185 190	576
gct gtg agg ccg gtg acc aag ctg atc tca gtg gac tca aga aac gtc Ala Val Arg Pro Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val 195 200 205	624
tct ctt ctc cct gaa gag ttc cac aaa gat tct agc tac cag ctg cag Ser Leu Leu Pro Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln 210 215 220	672

Fig. 15A

gtg	egg	gca	gcg	cct	cag	cca	ggc	act	tca	ttc	agg	ggg	acc	tgg	agt	720
Val	Arg	Ala	Ala	Pro	Gln	Pro	Gly	Thr	Ser	Phe	Arg	Gly	Thr	Trp	Ser	
225					230					235					240	
gag	tgg	agt	gac	ccc	gtc	atc	ttt	cag	acc	cag	gct	ggg	gag	ccc	gag	768
Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	Thr	Gln	Ala	Gly	Glu	Pro	Glu	
				245					250					255		
gca	ggc	tgg	gac	tagtgagaat	tc	SEQ ID NO: 38										792
Ala	Gly	Trp	Asp			SEQ ID NO: 39										
			260													

Fig. 15B

Timetable for the CIA Model




FIG.16




FIG.17




FIG. 18

mIL21RFc reduces disease in spontaneous model of Inflammatory
bowel disease when administered therapeutically





FIG. 19

Murine IL21R-Fc reduces clinical signs of IBD in HLAB27 rat model of autoimmunity



Dosing MWF

FIG. 20


Soluble IL21R reduces clinical signs of IBD in HLAB27 rat model of autoimmunity

Histological scoring of disease severity in rat IBD model

Group	Ulceration (0-2)	Inflammation (0-3)	Lesion Depth (0-3)	Fibrosis 0-2	Total score 0-10
IgG 6 mg/kg	1.8 + 0.45	2.6 + 0.37	1.93 + 0.60	1.33 + 0.34	7.67 + 1.62
TNFR-Fc 6 mg/kg	0.53 + 0.30	1.00 + 0.53*	0.40 + 0.37	0.33 + 0.24	2.27 + 1.23
IL21R-Fc 6 mg/kg	0.53 + 0.56	0.80 + 0.45*	0.47 + 0.45	0.20 + 0.30	2.00 + 1.70
*sig < vehicle (p < 0.05) ANOVA & Duncan's New Multiple Range Test					

FIG. 21

Retroviral Transduction of Graft Rejecting T cells IL-21R α



B6 T cells were infected with
GFP, IL-21 or IL-21R retrovirus.
3 X 10⁵ sorted, infected cells
were injected into B6 nu/nu mice
with existing BALB/c skin grafts.

FIG. 22


Therapeutic treatment with IL21RFc reverses clinical signs of psoriasis in CD45RBhi adoptive transfer model



Before treatment with IL21Rfc:
loss of hair on face and back



9 doses of IL21Rfc: hair is
restored



Mice were dosed ip with murine IL21RFc 200ug MWF

FIG. 23

Figure 24




Figure 25




Figure 26




Figure 27






Figure 28








Figure 31




Figure 32





Figure 33



IL21 amplifies inflammatory response

IL21R-Fc inhibits binding of IL21 to IL21 receptor

Anti-IL21R antibody blocks binding of IL21 to IL21 receptor

Anti-IL21 antibody sequesters IL21 from IL21 receptor

Figure 34




Figure 35





Figure 36

<u>Treatment</u>	<u>Incidence of Psoriasis</u>	<u>Avg Day Onset</u>	<u>Ttest</u>	<u>Psoriasis</u>	
				<u>Avg Highest Score</u>	<u>Ttest</u>
200ug Anti Etenella	9/10	13.3+3.28		2.72+1.09	
200ug mL-21r	9/10	30.67+ 21.58	0.043	1.78+1.09	0.086

Figure 37






Figure 38




Figure 39

IBD#14 IBD(Stool)						
<u>Treatment</u>	<u>Incidence of IBD</u>	<u>Avg Day Onset</u>	<u>Ttest</u>	<u>Avg Highest Score</u>	<u>Ttest</u>	<u>Ttest</u>
400ug Anti Etenella	9/10	36.22± 14.86		1.778±0.441		
200ug mL-21r	6/10	36.67±13.74	0.954	1.167±0.408	0.018	
400ug mL-21r	8/10	45.5±17.485	0.261	1±0		7E-04

Figure 40




Figure 41




Figure 42A




Figure 42B





Figure 43






Figure 44A




Figure 44B

SEQUENCE LISTING

<110> Wyeth

<120> Antagonizing Interleukin-21 Receptor Activity

<130> 01997.043400

<150> US 60/599,086

<151> 2004-08-05

<150> US 60/639,176

<151> 2004-12-23

<160> 39

<170> PatentIn version 3.1

<210> 1

<211> 2665

<212> DNA

<213> Human

<400> 1

gtcgactgga ggcccagctg cccgtcatca gagtgacagg tcttatgaca gcctgattgg	60
tgactcgggc tgggtgtgga ttctcacccc aggcctctgc ctgctttctc agaccctcat	120
ctgtcacccc cacgctgaac ccagctgcca cccccagaag cccatcagac tgccccagc	180
acacggaatg gatttctgag aaagaagccg aaacagaagg cccgtgggag tcagcatgcc	240
gcgtggctgg gccgccccct tgctcctgct gctgctccag ggaggctggg gctgccccga	300
cctcgtctgc tacaccgatt acctccagac ggtcatctgc atcctggaaa tgtggaacct	360
ccaccccagc acgctcacc ttacctggca agaccagtat gaagagctga aggacgaggc	420
cacctcctgc agcctccaca ggtcggccca caatgccacg catgccacct acacctgcca	480
catggatgta ttccacttca tggccgacga cattttcagt gtcaacatca cagaccagtc	540
tggcaactac tcccaggagt gtggcagctt tctcctggct gagagcatca agccggctcc	600
ccctttcaac gtgactgtga ccttctcagg acagtataat atctcctggc gctcagatta	660
cgaagaccct gccttctaca tgctgaaggg caagcttcag tatgagctgc agtacaggaa	720
ccggggagac ccctgggctg tgagtccgag gagaaagctg atctcagtgg actcaagaag	780
tgtctccctc ctccccctgg agttccgcaa agactcgagc tatgagctgc aggtgcgggc	840
agggcccatg cctggctcct cctaccaggg gacctggagt gaatggagtg acccggtcat	900
ctttcagacc cagtcagagg agttaaagga aggctggaac cctcacctgc tgcttctcct	960
cctgcttgtc atagtcttca ttctgcctt ctggagcctg aagaccatc cattgtggag	1020
gctatggaag aagatatggg ccgtccccag ccctgagcgg ttcttcatgc ccctgtacaa	1080
gggctgcagc ggagacttca agaaatgggt gggcgcaccc ttcactggct ccagcctgga	1140

```

gctgggaccc tggagcccag aggtgccctc caccctggag gtgtacagct gccacccacc 1200
acggagcccg gccaaaggc tgcagctcac ggagctacaa gaaccagcag agctgggtgga 1260
gtctgacggg gtgcccgaagc ccagcttctg gccgacagcc cagaactcgg ggggctcagc 1320
ttacagtgag gagagggatc ggccatacgg cctgggtgtcc attgacacag tgactgtgct 1380
agatgcagag gggccatgca cctggccctg cagctgtgag gatgacggct acccagccct 1440
ggacctggat gctggcctgg agcccagccc aggcctagag gacccactct tggatgcagg 1500
gaccacagtc ctgtcctgtg gctgtgtctc agctggcagc cctgggctag gaggggccct 1560
gggaagcctc ctggacagac taaagccacc ccttgacagat ggggaggact gggctggggg 1620
actgccctgg ggtggccggt cacctggagg ggtctcagag agtgaggcgg gctcaccct 1680
ggccggcctg gatatggaca cgtttgacag tggctttgtg ggctctgact gcagcagccc 1740
tgtggagtgt gacttcacca gccccgggga cgaaggaccc ccccgagct acctcccca 1800
gtgggtggtc attcctccgc cactttcgag ccctggaccc caggccagct aatgaggctg 1860
actggatgtc cagagctggc caggccactg ggccctgagc cagagacaag gtcacctggg 1920
ctgtgatgtg aagacacctg cagcctttgg tctcctggat gggcctttga gcctgatgtt 1980
tacagtgtct gtgtgtgtgt gtgcatatgt gtgtgtgtgc atatgcatgt gtgtgtgtgt 2040
gtgtgtctta ggtgcgagcagg ggcattgtcca cgtgtgtgtg tgattgcacg tgctgtggg 2100
cctgggataa tgcccatggt actccatgca ttcacctgcc ctgtgcatgt ctggactcac 2160
ggagctcacc catgtgcaca agtgtgcaca gtaaacgtgt ttgtgggtcaa cagatgacaa 2220
cagccgtcct ccctcctagg gtcttgtgtt gcaagttggg ccacagcatc tccggggcctt 2280
tgtgggatca gggcattgcc tgtgactgag gcggagccca gccctccagc gtctgcctcc 2340
aggagctgca agaagtccat attgttccct atcacctgcc aacaggaagc gaaaggggat 2400
ggagtgaacc catggtgacc tcgggaatgg caattttttg ggcggcccct ggacgaagg 2460
ctgaatcccg actctgatac cttctggctg tgctacctga gccaagtcgc ctcccctctc 2520
tgggctagag tttccttata cagacagtgg ggaaggcatg acacacctgg gggaaattgg 2580
cgatgtcacc cgtgtacggg acgcagccca gagcagaccc tcaataaacg tcagcttcct 2640
tcaaaaaaaaa aaaaaaaaaat ctaga 2665

```

```

<210> 2
<211> 538
<212> PRT
<213> Human

<400> 2

```

3/31

Met	Pro	Arg	Gly	Trp	Ala	Ala	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Gln	Gly	1	5	10	15
Gly	Trp	Gly	Cys	Pro	Asp	Leu	Val	Cys	Tyr	Thr	Asp	Tyr	Leu	Gln	Thr	20	25	30	
Val	Ile	Cys	Ile	Leu	Glu	Met	Trp	Asn	Leu	His	Pro	Ser	Thr	Leu	Thr	35	40	45	
Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp	Glu	Ala	Thr	Ser	50	55	60	
Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr	Thr	65	70	75	80
Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser	Val	85	90	95	
Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe	100	105	110	
Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr	Val	115	120	125	
Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp	130	135	140	
Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	145	150	155	160
Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile	165	170	175	
Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys	180	185	190	
Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser	195	200	205	
Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	210	215	220	
Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His	Leu	Leu	Leu	225	230	235	240
Leu	Leu	Leu	Leu	Val	Ile	Val	Phe	Ile	Pro	Ala	Phe	Trp	Ser	Leu	Lys	245	250	255	
Thr	His	Pro	Leu	Trp	Arg	Leu	Trp	Lys	Lys	Ile	Trp	Ala	Val	Pro	Ser	260	265	270	
Pro	Glu	Arg	Phe	Phe	Met	Pro	Leu	Tyr	Lys	Gly	Cys	Ser	Gly	Asp	Phe	275	280	285	
Lys	Lys	Trp	Val	Gly	Ala	Pro	Phe	Thr	Gly	Ser	Ser	Leu	Glu	Leu	Gly	290	295	300	
Pro	Trp	Ser	Pro	Glu	Val	Pro	Ser	Thr	Leu	Glu	Val	Tyr	Ser	Cys	His	305	310	315	320
Pro	Pro	Arg	Ser	Pro	Ala	Lys	Arg	Leu	Gln	Leu	Thr	Glu	Leu	Gln	Glu				

4/31

	325		330		335
Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp					
	340		345		350
Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp					
	355		360		365
Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala					
	370		375		380
Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro					
	385		390		400
Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp					
	405		410		415
Pro Leu Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser					
	420		425		430
Ala Gly Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg					
	435		440		445
Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro					
	450		455		460
Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser					
	465		470		480
Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly					
	485		490		495
Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp					
	500		505		510
Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro					
	515		520		525
Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser					
	530		535		

<210> 3
 <211> 70
 <212> PRT
 <213> Human

<400> 3

Leu Met Thr Asn Ala Phe Ile Ser Ile Ile Asp Asp Leu Ser Lys Tyr					
1		5		10	15
Asp Val Gln Val Arg Ala Ala Val Ser Ser Met Cys Arg Glu Ala Gly					
	20		25		30
Leu Trp Ser Glu Trp Ser Gln Pro Ile Tyr Val Gly Asn Asp Glu His					
	35		40		45
Lys Pro Leu Arg Glu Trp Phe Val Ile Val Ile Met Ala Thr Ile Cys					
	50		55		60

Phe Ile Leu Leu Ile Leu
65 70

<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 4
gagtccgagg agaaagctga tctca 25

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Primer

<400> 5
gaaagatgac cgggtcactc catt 24

<210> 6
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Labelled Hybridization
Oligonucleotide

<400> 6
actcgagcta tgagctgcag gtgcgggca 29

<210> 7
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: NN14-1b (MU-1) Labelled
Hybridization Oligonucleotide

<400> 7
actcgagcta tgagctgcag gtgcgggca 29

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Motif Characteristic of the

Hematopoietin Receptor Family

<220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> Wherein Xaa is any amino acid.

<400> 8

Trp Ser Xaa Trp Ser
 1 5

<210> 9
 <211> 2628
 <212> DNA
 <213> Mouse

<400> 9
 gtgcagcgcgg cgggtaccagc tgtctgccc cttctcctgt ggtgtgcctc acggtcactt 60
 gcttgtctga ccgcaagtct gcccatccct ggggcagcca actggcctca gcccggtgcc 120
 caggcgtgcc ctgtctctgt ctggctgcc cagccctact gtcttcctct gtgtaggctc 180
 tgcccagatg cccggctggt cctcagcctc aggactatct cagcagtgac tcccctgatt 240
 ctggacttgc acctgactga actcctgccc acctcaaacc ttcacctccc accaccacca 300
 ctccgagtcc cgctgtgact cccacgccc ggagaccacc caagtgcccc agcctaaaga 360
 atggctttct gagaaagacc ctgaaggagt aggtctggga cacagcatgc cccggggccc 420
 actggctgcc ttactcctgc tgattctcca tggagcttgg agctgcctgg acctcacttg 480
 ctacactgac tacctctgga ccatcacctg tgtcctggag acacggagcc ccaaccccag 540
 catactcagt ctcacctggc aagatgaata tgaggaaact caggaccaag agaccttctg 600
 cagcctacac aggtctggcc acaacaccac acatatatgg tacacgtgcc atatgcgctt 660
 gtctcaattc ctgtccgatg aagttttcat tgtcaatgtg acggaccagt ctggcaacaa 720
 ctcccaagag tgtggcagct ttgtcctggc tgagagcatc aaaccagctc cccccttgaa 780
 cgtgactgtg gccttctcag gacgctatga tatctcctgg gactcagctt atgacgaacc 840
 ctccaactac gtgctgaggg gcaagctaca atatgagctg cagtatcgga acctcagaga 900
 cccctatgct gtgaggccgg tgaccaagct gatctcagtg gactcaagaa acgtctctct 960
 tctccctgaa gagttccaca aagattctag ctaccagctg cagggtgcggg cagcgcctca 1020
 gccaggcact tcattcaggg ggacctggag tgagtggagt gaccccgta tctttcagac 1080
 ccaggctggg gagcccgagg caggctggga cctcacaatg ctgctgctcc tggtgtctt 1140
 gatcattgtc ctgggtttca tgggtctgaa gatccacctg ctttgagggc tatggaaaaa 1200
 gatatgggca ccagtgccc cccctgagag tttcttccag cccctgtaca gggagcacag 1260

cggaacttc aagaaatggg ttaatacccc ttacacggcc tccagcatag agttggtgcc 1320
 acagagttcc acaacaacat cagccttaca tctgtcattg tatccagcca aggagaagaa 1380
 gttccccggg ctgccgggtc tggaagagca actggagtgt gatggaatgt ctgagcctgg 1440
 tcaactggtgc ataatcccct tggcagctgg ccaagcggtc tcagcctaca gtgaggagag 1500
 agaccggcca tatggtctgg tgtccattga cacagtgact gtgggagatg cagagggcct 1560
 gtgtgtctgg ccctgtagct gtgaggatga tggctatcca gccatgaacc tggatgctgg 1620
 ccgagagtct ggccctaatt cagaggatct gctcttggtc acagaccctg cttttctgtc 1680
 ttgcggctgt gtctcagga gtggtctcag gcttggaggc tccccaggca gcctactgga 1740
 caggttgagg ctgtcatttg caaaggaagg ggactggaca gcagacccaa cctggagaac 1800
 tgggtcccca ggagggggct ctgagagtga agcaggttcc cccctgggtc tggacatgga 1860
 cacatttgac agtggctttg caggttcaga ctgtggcagc cccgtggaga ctgatgaagg 1920
 accccctcga agctatctcc gccagtgggt ggtcaggacc cctccacctg tggacagtgg 1980
 agcccagagc agctagcata taataaccag ctatagttag aagaggcctc tgagcctggc 2040
 atttacagtg tgaacatgta ggggtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 2100
 tgtgtgtgtg tgtgtgtgtg tgtcttgggt tgtgtgttag cacatccatg ttgggatttg 2160
 gtctgttgct atgtattgta atgctaaatt ctctacccaa agttctaggc ctacgagtga 2220
 attctcatgt ttacaaactt gctgtgtaaa ccttgttcct taatttaata ccattgggta 2280
 aataaaaattg gctgcaacca attactggag ggattagagg tagggggcctt ttgagttacc 2340
 tgtttggaga tggagaagga gagaggagag accaagagga gaaggaggaa ggagaggaga 2400
 ggagaggaga ggagaggaga ggagaggaga ggagaggaga ggagaggaga ggctgccgtg 2460
 aggggagagg gaccatgagc ctgtggccag gagaaacagc aagtatctgg ggtacactgg 2520
 tgaggagggtg gccaggccag cagttagaag agtagattag gggtgacctc cagtatttgt 2580
 caaagccaat taaaataaca aaaaaaaaaa aaaagcggcc gctctaga 2628

<210> 10
 <211> 529
 <212> PRT
 <213> Mouse

<400> 10

Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
 1 5 10 15

Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
 20 25 30

8/31

```

Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
    35                                40                                45

Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
    50                                55                                60

Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
    65                                70                                75                                80

Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
    85                                90                                95

Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
    100                               105                               110

Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
    115                               120                               125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
    130                               135                               140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
    145                               150                               155                               160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
    165                               170                               175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
    180                               185                               190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
    195                               200                               205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210                               215                               220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu
    225                               230                               235                               240

Leu Leu Ala Val Leu Ile Ile Val Leu Val Phe Met Gly Leu Lys Ile
    245                               250                               255

His Leu Pro Trp Arg Leu Trp Lys Lys Ile Trp Ala Pro Val Pro Thr
    260                               265                               270

Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg Glu His Ser Gly Asn Phe
    275                               280                               285

Lys Lys Trp Val Asn Thr Pro Phe Thr Ala Ser Ser Ile Glu Leu Val
    290                               295                               300

Pro Gln Ser Ser Thr Thr Thr Ser Ala Leu His Leu Ser Leu Tyr Pro
    305                               310                               315                               320

Ala Lys Glu Lys Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu
    325                               330                               335

Glu Cys Asp Gly Met Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu
    340                               345                               350

Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro

```

9/31

355	360	365
Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala Glu Gly		
370	375	380
Leu Cys Val Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Met		
385	390	400
Asn Leu Asp Ala Gly Arg Glu Ser Gly Pro Asn Ser Glu Asp Leu Leu		
405	410	415
Leu Val Thr Asp Pro Ala Phe Leu Ser Cys Gly Cys Val Ser Gly Ser		
420	425	430
Gly Leu Arg Leu Gly Gly Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg		
435	440	445
Leu Ser Phe Ala Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg		
450	455	460
Thr Gly Ser Pro Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro		
465	470	475
Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp Cys		
485	490	495
Gly Ser Pro Val Glu Thr Asp Glu Gly Pro Pro Arg Ser Tyr Leu Arg		
500	505	510
Gln Trp Val Val Arg Thr Pro Pro Pro Val Asp Ser Gly Ala Gln Ser		
515	520	525

Ser

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 11
 agcatcaagc cggctccccc

20

<210> 12
 <211> 20
 <212> DNA
 <213> Artificial Primer

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 12
 ctccattcac tccaggtccc

20

<210> 13

<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 13
ttgaacgtga ctgrggcctt 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Murine MU-1 cDNA Internal Oligonucleotide

<400> 14
tgaatgaagt gcctggctga 20

<210> 15
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 5' PCR Primer

<400> 15
cacaaagctt cagtatgagc tgcagtacag gaaccgggga 40

<210> 16
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 3' PCR primer

<400> 16
cacaggatcc ctttaactcc tctgactggg tctgaaagat 40

<210> 17
<211> 224
<212> PRT
<213> Unknown Organism

<220>

<221> Unknown Organism

<222> (1)..(224)

<223> Description of Unknown Organism: Second polypeptide comprising an Fc region

<400> 17

11/31

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Leu Gly Ala Pro Ser
 1 5 10 15
 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 20 25 30
 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 35 40 45
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 50 55 60
 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 65 70 75 80
 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 85 90 95
 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile Glu Lys Thr
 100 105 110
 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 115 120 125
 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
 130 135 140
 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 145 150 155 160
 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 165 170 175
 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
 180 185 190
 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 195 200 205
 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 210 215 220

<210> 18
 <211> 617
 <212> DNA
 <213> Human

<400> 18
 gctgaagtga aaacgagacc aaggtctagc tctactgttg gtacttatga gatccagtcc 60
 tggcaacatg gagaggattg tcattctgtct gatgggtcatc ttcttgggga cactgggtcca 120
 caaatcaagc tccaagggtc aagatcgcca catgattaga atgcgtcaac ttatagatat 180
 tgttgatcag ctgaaaaatt atgtgaatga cttgggtccct gaatttctgc cagctccaga 240
 agatgtagag acaaactgtg agtgggtcagc tttttcctgc tttcagaagg cccaactaaa 300
 gtcagcaaatt acaggaaaca atgaaaggat aatcaatgta tcaattaaaa agctgaagag 360

gaaaccacct tccacaaatg cagggagaag acagaaacac agactaacat gcccttcatg 420
 tgattcttat gagaaaaaac cacccaaaga attcctagaa agattcaaatt cacttctcca 480
 aaagatgatt catcagcatc tgtcctctag aacacacgga agtgaagatt cctgaggatc 540
 taacttgcag ttggacacta tgttacatac tctaatatag tagtgaaagt catttctttg 600
 tattccaagt ggaggag 617

<210> 19
 <211> 162
 <212> PRT
 <213> Human

<400> 19

Met Arg Ser Ser Pro Gly Asn Met Glu Arg Ile Val Ile Cys Leu Met
 1 5 10 15
 Val Ile Phe Leu Gly Thr Leu Val His Lys Ser Ser Ser Gln Gly Gln
 20 25 30
 Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val Asp Gln
 35 40 45
 Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro Ala Pro
 50 55 60
 Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys Phe Gln
 65 70 75 80
 Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg Ile Ile
 85 90 95
 Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr Asn Ala
 100 105 110
 Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp Ser Tyr
 115 120 125
 Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu Leu
 130 135 140
 Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu
 145 150 155 160
 Asp Ser

<210> 20
 <211> 7
 <212> PRT
 <213> Human

<400> 20

Glu Asp Asp Gly Tyr Pro Ala

1

5

<210> 21
 <211> 16
 <212> PRT
 <213> Human

<400> 21

Met Pro Leu Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro
 1 5 10 15

<210> 22
 <211> 786
 <212> DNA
 <213> Human

<400> 22

atgaaattct tagtcaacgt tgcccttggt tttatggtcg tgtacatttc ttacatctat 60
 gccggcagcg gacaccacca tcataccacc ggtagcggcg actataaaga cgatgacgat 120
 aaggggtccg gatgccccga cctcgtctgc tacaccgatt acctccagac ggatcatctgc 180
 atcctggaaa tgtggaacct ccacccagc acgctcacc ttacctggca agaccagtat 240
 gaagagctga aggacgagc cacctcctgc agcctccaca ggtcggccca caatgccacg 300
 catgccacct acacctgcca catggatgta ttccacttca tggccgacga cattttcagt 360
 gtcaacatca cagaccagtc tggcaactac tcccaggagt gtggcagctt tctcctggct 420
 gagagcatca agccggctcc ccctttcaac gtgactgtga ccttctcagg acagtataat 480
 atctcctggc gctcagatta cgaagaccct gccttctaca tgctgaagg caagcttcag 540
 tatgagctgc agtacaggaa ccggggagac ccctgggctg tgagtccgag gagaaagctg 600
 atctcagtgg actcaagaag tgtctccctc ctccccctgg agttccgcaa agactcgagc 660
 tatgagctgc aggtgcgggc agggcccatg cctggctcct cctaccaggg gacctggagt 720
 gaatggagtg acccggtcac ctttcagacc cagtcagagg agttaaagga aggctggaac 780
 taatga 786

<210> 23
 <211> 260
 <212> PRT
 <213> Human

<400> 23

Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
 1 5 10 15

Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His Gly Ser
 20 25 30

Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser Gly Cys Pro Asp Leu
 35 40 45
 Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met
 50 55 60
 Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Gln Asp Gln Tyr
 65 70 75 80
 Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala
 85 90 95
 His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His
 100 105 110
 Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly
 115 120 125
 Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Ile Lys
 130 135 140
 Pro Ala Pro Pro Phe Asn Val Thr Val Thr Phe Ser Gly Gln Tyr Asn
 145 150 155 160
 Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys
 165 170 175
 Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp
 180 185 190
 Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val
 195 200 205
 Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln
 210 215 220
 Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser
 225 230 235 240
 Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys
 245 250 255
 Glu Gly Trp Asn
 260

<210> 24
 <211> 1426
 <212> DNA
 <213> Human

<400> 24
 gcggccgcac caccatgccg cgtggctggg ccgcccctt gctcctgctg ctgctccagg 60
 gaggctgggg ctgccccgac ctggtctgct acaccgatta cctccagacg gtcattctgca 120
 tcctggaaat gtggaacctc caccacagca cgctcaccct tacctggcaa gaccagtatg 180
 aagagctgaa ggacgaggcc acctcctgca gcctccacag gtcggccac aatgccacgc 240

15/31

```

atgccaccta cacctgccac atggatgtat tccacttcat ggccgacgac attttcagtg      300
tcaacatcac agaccagtct ggcaactact cccaggagtg tggcagcttt ctctgggctg      360
agagcatcaa gccggctccc cctttcaacg tgactgtgac cttctcagga cagtataata      420
tctctgggctg ctgagattac gaagaccctg ccttctacat gctgaagggc aagcttcagt      480
atgagctgca gtacaggaac cggggagacc cctgggctgt gagtccgagg agaaagctga      540
tctcagtgga ctcaagaagt gtctccctcc tccccctgga gttccgcaa gactcgagct      600
atgagctgca ggtgcgggca gggcccatgc ctggctcctc ctaccagggg acctggagtg      660
aatggagtgga cccggtcatc tttcagaccc agtcagagga gttaaaggaa ggctggaacg      720
gctccggctc tagagacaaa actcacacat gccaccctg cccagcacct gaactcctgg      780
ggggaccctc agtcttcctc ttcccccaa aaccaagga caccctcatg atctcccgga      840
cccctgaggt cacatgctg gtggtggacg tgagccacga agaccctgag gtcaagttca      900
actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt      960
acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggtgtaatg     1020
gcaaggagta caagtgaag gtctccaaca aagccctccc agtcccctc gagaaaacca     1080
tctccaaagc caaagggcag ccccgagaac cacagggtga caccctgccc ccatcccggg     1140
aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg     1200
acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc     1260
ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gtcaccgtg gacaagagca     1320
gggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact     1380
acacgcagaa gagcctctcc ctgtccccgg gtaaattgagt gaattc                       1426

```

<210> 25
<211> 467
<212> PRT
<213> Human

<400> 25

```

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
1           5           10           15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
          20           25           30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
          35           40           45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
          50           55           60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr

```

16/31

65	70								75						80		
Cys	His	Met	Asp	Val 85	Phe	His	Phe	Met	Ala 90	Asp	Asp	Ile	Phe	Ser 95	Val		
Asn	Ile	Thr	Asp 100	Gln	Ser	Gly	Asn	Tyr 105	Ser	Gln	Glu	Cys	Gly 110	Ser	Phe		
Leu	Leu	Ala 115	Glu	Ser	Ile	Lys	Pro 120	Ala	Pro	Pro	Phe	Asn 125	Val	Thr	Val		
Thr	Phe 130	Ser	Gly	Gln	Tyr	Asn 135	Ile	Ser	Trp	Arg	Ser 140	Asp	Tyr	Glu	Asp		
Pro 145	Ala	Phe	Tyr	Met	Leu 150	Lys	Gly	Lys	Leu	Gln 155	Tyr	Glu	Leu	Gln	Tyr 160		
Arg	Asn	Arg	Gly	Asp 165	Pro	Trp	Ala	Val	Ser 170	Pro	Arg	Arg	Lys	Leu 175	Ile		
Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu 185	Leu	Pro	Leu	Glu	Phe 190	Arg	Lys		
Asp	Ser	Ser 195	Tyr	Glu	Leu	Gln	Val 200	Arg	Ala	Gly	Pro	Met 205	Pro	Gly	Ser		
Ser	Tyr 210	Gln	Gly	Thr	Trp	Ser 215	Glu	Trp	Ser	Asp	Pro 220	Val	Ile	Phe	Gln		
Thr 225	Gln	Ser	Glu	Glu	Leu 230	Lys	Glu	Gly	Trp	Asn 235	Gly	Ser	Gly	Ser	Arg 240		
Asp	Lys	Thr	His	Thr 245	Cys	Pro	Pro	Cys	Pro 250	Ala	Pro	Glu	Leu	Leu 255	Gly		
Gly	Pro	Ser	Val 260	Phe	Leu	Phe	Pro	Pro 265	Lys	Pro	Lys	Asp	Thr 270	Leu	Met		
Ile	Ser	Arg 275	Thr	Pro	Glu	Val	Thr 280	Cys	Val	Val	Val	Asp 285	Val	Ser	His		
Glu	Asp 290	Pro	Glu	Val	Lys	Phe 295	Asn	Trp	Tyr	Val	Asp 300	Gly	Val	Glu	Val		
His 305	Asn	Ala	Lys	Thr	Lys 310	Pro	Arg	Glu	Glu	Gln 315	Tyr	Asn	Ser	Thr	Tyr 320		
Arg	Val	Val	Ser	Val 325	Leu	Thr	Val	Leu	His 330	Gln	Asp	Trp	Leu	Asn 335	Gly		
Lys	Glu	Tyr	Lys 340	Cys	Lys	Val	Ser	Asn 345	Lys	Ala	Leu	Pro	Val 350	Pro	Ile		
Glu	Lys	Thr 355	Ile	Ser	Lys	Ala	Lys 360	Gly	Gln	Pro	Arg	Glu	Pro 365	Gln	Val		
Tyr	Thr 370	Leu	Pro	Pro	Ser	Arg 375	Glu	Glu	Met	Thr	Lys 380	Asn	Gln	Val	Ser		
Leu 385	Thr	Cys	Leu	Val	Lys 390	Gly	Phe	Tyr	Pro	Ser 395	Asp	Ile	Ala	Val	Glu 400		

[illegible]

<210>	26
<211>	1499
<212>	DNA
<213>	Human

<400>	26						
gcggccgcac	caccatgccg	cgtggctggg	ccgccccctt	gctcctgctg	ctgctccagg		60
gaggctgggg	ctgccccgac	ctcgtctgct	acaccgatta	cctccagacg	gtcatctgca		120
tcctggaaat	gtggaacctc	caccccagca	cgtcaccct	tacctggcaa	gaccagtatg		180
aagagctgaa	ggacgaggcc	acctcctgca	gcctccacag	gtcggcccac	aatgccacgc		240
atgccaccta	cacctgccac	atggatgtat	tccacttcat	ggccgacgac	attttcagtg		300
tcaacatcac	agaccagtct	ggcaactact	cccaggagtg	tggcagcttt	ctcctggctg		360
agagcatcaa	gccggctccc	cctttcaacg	tgactgtgac	cttctcagga	cagtataata		420
tctcctggcg	ctcagattac	gaagaccctg	cctttctacat	gctgaagggc	aagcttcagt		480
atgagctgca	gtacaggaac	cggggagacc	cctgggctgt	gagtccgagg	agaaagctga		540
tctcagtgga	ctcaagaagt	gtctccctcc	tccccctgga	gttccgcaaa	gactcgagct		600
atgagctgca	ggtgcggggc	gggcccattg	ctggctcctc	ctaccagggg	acctggagtg		660
aatggagtg	cccgggtcatc	tttcagacct	agtcagagga	gttaaaggaa	ggctggaacg		720
gctccggctc	tagagacaaa	actcacacat	gcccaccgtg	cccagcacct	gaactcctgg		780
ggggaccgtc	agtcttcctc	ttccccccaa	aacccaagga	caccctcatg	atctcccgga		840
cccctgaggt	cacatgcgtg	gtgggtggacg	tgagccacga	agaccctgag	gtcaagttca		900
actggtacgt	ggacggcgtg	gaggtgcata	atgccaaagc	aaagccgcgg	gaggagcagt		960
acaacagcac	gtaccgtgtg	gtcagcgtcc	tcaccgtcct	gcaccaggac	tggtggaatg		1020
gcaaggagta	caagtgcaag	gtctccaaca	aagccctccc	agtccccatc	gagaaaacca		1080
tctccaaaagc	caaaagggcag	ccccgaqaac	cacaggtgta	caccctgccc	ccatcccggg		1140

```

aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg 1200
acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc 1260
ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gctcaccgtg gacaagagca 1320
ggatggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact 1380
acacgcagaa gagcctctcc ctgtccccgg gtaaatacagg aatggcatca atgacaggag 1440
gtcaacaaat gggttctgga tctcatcatc atcatcatca ttctggaggt tgagaattc 1499

```

<210> 27
 <211> 492
 <212> PRT
 <213> Human

<400> 27

```

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
1           5           10           15
Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
          20           25           30
Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
          35           40           45
Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
          50           55           60
Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
65           70           75           80
Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
          85           90           95
Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
          100          105          110
Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
          115          120          125
Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
          130          135          140
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
145          150          155          160
Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
          165          170          175
Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
          180          185          190
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
          195          200          205
Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
210          215          220

```

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Gly Ser Gly Ser Arg
 225 230 235 240
 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 245 250 255
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 260 265 270
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 275 280 285
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 290 295 300
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 305 310 315 320
 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 325 330 335
 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile
 340 345 350
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 355 360 365
 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
 370 375 380
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 385 390 395 400
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 405 410 415
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 420 425 430
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 435 440 445
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 450 455 460
 Pro Gly Lys Ser Gly Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly
 465 470 475 480
 Ser Gly Ser His His His His His His Ser Gly Gly
 485 490

<210> 28
 <211> 1426
 <212> DNA
 <213> Human

<400> 28
 gcggccgcac caccatgccg cgtggctggg ccgccccctt gctcctgctg ctgctccagg

60

```

gaggctgggg ctgccccgac ctcgtctgct acaccgatta cctccagacg gtcattctgca 120
tcctggaaat gtggaacctc caccocagca cgctcaccct tacctggcaa gaccagtatg 180
aagagctgaa ggacgaggcc acctcctgca gcctccacag gtcggcccac aatgccacgc 240
atgccaccta cacctgccac atggatgtat tccacttcat ggccgacgac attttcagtg 300
tcaacatcac agaccagtct ggcaactact cccaggagtg tggcagcttt ctcttggtg 360
agagcatcaa gccggctccc cctttcaacg tgactgtgac cttctcagga cagtataata 420
tctcctggcg ctcagattac gaagaccctg ctttctacat gctgaagggc aagcttcagt 480
atgagctgca gtacaggaac cggggagacc cctgggctgt gagtccgagg agaaagctga 540
tctcagtgga ctcaagaagt gtctccctcc tccccctgga gttccgcaa gactcgagct 600
atgagctgca ggtgcgggca gggcccatgc ctggctcctc ctaccagggg acctggagtg 660
aatggagtga cccggtcatc tttcagacct agtcagagga gttaaaggaa ggctggaacg 720
gctccggctc tagagacaaa actcacacat gccaccgtg cccagcacct gaagccctgg 780
gggcaccgtc agtcttctc tttcccccaa aaccaagga caccctcatg atctcccgga 840
cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag gtcaagttca 900
actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt 960
acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg 1020
gcaaggagta caagtgaag gtctccaaca aagccctccc agcccccatc gagaaaacca 1080
tctccaaagc caaagggcag ccccgagaac cacagggtga caccctgccc ccatcccggg 1140
aggagatgac caagaaccag gtcagcctga cctgcctggc caaaggcttc tatcccagcg 1200
acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc 1260
ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gctcaccgtg gacaagagca 1320
ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact 1380
acacgcagaa gagcctctcc ctgtcccccg gtaaatgagt gaattc 1426

```

<210> 29
 <211> 467
 <212> PRT
 <213> Human

<400> 29

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
 1 5 10 15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
 20 25 30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr

21/31

35					40					45					
Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp	Glu	Ala	Thr	Ser
50					55					60					
Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr	Thr
65					70					75					80
Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser	Val
				85					90					95	
Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe
			100					105					110		
Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr	Val
		115					120					125			
Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp
							135					140			
Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr
145					150					155					160
Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile
				165					170					175	
Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys
			180					185					190		
Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser
		195					200					205			
Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln
	210					215					220				
Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Gly	Ser	Gly	Ser	Arg
225					230					235					240
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Ala	Leu	Gly
				245					250					255	
Ala	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met
			260					265					270		
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His
		275					280					285			
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val
	290					295					300				
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr
305					310					315					320
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly
				325					330					335	
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile
			340					345					350		
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val
		355					360					365			

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
 370 375 380
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 385 390 395 400
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 405 410 415
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 420 425 430
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 435 440 445
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 450 455 460
 Pro Gly Lys
 465

<210> 30
 <211> 741
 <212> DNA
 <213> Human

<400> 30
 atgccgcgtg gctggggccgc ccccttgctc ctgctgctgc tccagggagg ctggggctgc 60
 cccgacctcg tctgctacac cgattacctc cagacggtca tctgcatcct ggaaatgtgg 120
 aacctccacc ccagcacgct cacccttacc tggcaagacc agtatgaaga gctgaaggac 180
 gaggccacct cctgcagcct ccacaggctg gccacacaatg ccacgcatgc cacctacacc 240
 tgccacatgg atgtattcca cttcatggcc gacgacattt tcagtgtcaa catcacagac 300
 cagtctggca actactccca ggagtgtggc agctttctcc tggctgagag catcaagccg 360
 gctccccctt tcaacgtgac tgtgaccttc tcaggacagt ataatatctc ctggcgctca 420
 gattacgaag accctgcctt ctacatgctg aagggcaagc ttcagtatga gctgcagtac 480
 aggaaccggg gagacccttg ggctgtgagt ccgaggagaa agctgatctc agtggactca 540
 agaagtgtct ccctcctccc cctggagttc cgcaaagact cgagctatga gctgcaggtg 600
 cgggcagggc ccatgcctgg ctccctctac caggggacct ggagtgaatg gagtgacctg 660
 gtcattcttc agaccagtc agaggagtta aaggaaggct ggaacaaaac cgaaacctcc 720
 caggttgctc cggcataatg a 741

<210> 31
 <211> 245
 <212> PRT
 <213> Human

<400> 31

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
 1 5 10 15

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
 20 25 30

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
 35 40 45

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
 50 55 60

Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
 65 70 75 80

Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
 85 90 95

Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
 100 105 110

Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
 115 120 125

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
 130 135 140

Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
 145 150 155 160

Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
 165 170 175

Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
 180 185 190

Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
 195 200 205

Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
 210 215 220

Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Lys Thr Glu Thr Ser
 225 230 235 240

Gln Val Ala Pro Ala
 245

<210> 32

<211> 1413

<212> DNA

<213> Human

<400> 32

atgccgcgtg gctgggccgc ccccttgctc ctgctgctgc tccagggagg ctggggctgc 60

cccgacctg tctgctacac cgattacctc cagacggtca tctgcatcct ggaaatgtgg 120

```

aacctccacc ccagcacgct cacccttacc tggcaagacc agtatgaaga gctgaaggac      180
gaggccacct cctgcagcct ccacaggtcg gcccacaatg ccacgcatgc cacctacacc      240
tgccacatgg atgtattcca cttcatggcc gacgacattt tcagtgtcaa catcacagac      300
cagtctggca actactccca ggagtgtggc agcttttctcc tggctgagag catcaagccg      360
gctccccctt tcaacgtgac tgtgaccttc tcaggacagt ataatatctc ctggcgctca      420
gattacgaag accctgcctt ctacatgctg aagggcaagc ttcagtatga gctgcagtac      480
aggaaccggg gagacccttg ggctgtgagt ccgaggagaa agctgatctc agtggactca      540
agaagtgtct ccctcctccc cctggaggtc cgcaaagact cgagctatga gctgcaggtg      600
cgggcagggc ccatgcctgg ctctcctac caggggacct ggagtgaatg gagtgacctg      660
gtcatctttc agaccagtc agaggagtta aaggaaggct ggaacgatga cgatgacaag      720
ggctccggcg aaaaaactca cacatgccc aagtgcccag cacctgaagc cctgggggca      780
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggaccctt      840
gaggtcacat gcgtgggtgg ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg      900
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac      960
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactgggt gaatggcaag     1020
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc     1080
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag     1140
atgaccaaga accaggtcag cctgacctgc ctgggtcaaag gcttctatcc cagcgacatc     1200
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg     1260
ctggactccg acggctcctt ctctctctat agcaagctca ccgtggacaa gagcaggtgg     1320
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg     1380
cagaagagcc tctccctgtc cccgggtaaa tga                                     1413

```

```

<210> 33
<211> 470
<212> PRT
<213> Human

```

```

<400> 33

```

```

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
1           5           10           15

```

```

Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
20           25           30

```

```

Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
35           40           45

```

25/31

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
 50 55 60
 Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
 65 70 75 80
 Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
 85 90 95
 Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
 100 105 110
 Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
 115 120 125
 Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
 130 135 140
 Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
 145 150 155 160
 Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
 165 170 175
 Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
 180 185 190
 Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
 195 200 205
 Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
 210 215 220
 Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Asp Asp Asp Asp Lys
 225 230 235 240
 Gly Ser Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
 245 250 255
 Ala Leu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 260 265 270
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 275 280 285
 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
 290 295 300
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
 305 310 315 320
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
 325 330 335
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
 340 345 350
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
 355 360 365
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn

26/31

370 375 380
 8
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 34
 <211> 1754
 <212> DNA
 <213> Mouse

<400> 34
 atgccccggg gccagtggtc tgccttactc ctgctgattc tccatggagc ttggagctgc 60
 ctggacctca cttgctacac tgactacctc tggaccatca cctgtgtcct ggagacacgg 120
 agcccccaacc ccagcatact cagtctcacc tggcaagatg aatatgagga acttcaggac 180
 caagagacct tctgcagcct acacaggtct ggccacaaca ccacacatat atggtacacg 240
 tgccatatgc gcttgtctca attcctgtcc gatgaagttt tcattgtcaa tgtgacggac 300
 cagtctggca acaactccca agagtgtggc agctttgtcc tggctgagag catcaaacca 360
 gctccccctc tgaacgtgac tgtggccttc tcaggacgct atgatattctc ctgggactca 420
 gcttatgacg aaccctccaa ctacgtgctg aggggcaagc tacaatatga gctgcagtat 480
 cggaacctca gagacccta tgctgtgagg ccggtgacca agctgatctc agtggactca 540
 agaaacgtct ctcttctccc tgaagagttc cacaagatt ctagctacca gctgcagggtg 600
 cgggcagcgc ctacagccagg cacttcattc agggggacct ggagtgagtg gactgacccc 660
 gtcattcttc agaccaggc tggggagccc gaggcaggct gggacggctc cggctctaga 720
 gagccccgcg gaccgacaat caagccctgt cctccatgca aatgcccagg taagtcacta 780
 gaccagagct cactcccgg gagaatggtg agtgctataa acatccctgc actagaggat 840
 aagccatgta cagatccatt tccattcttc ctcatcagca cctaacctcg aggggtggacc 900
 atccgtcttc atcttccctc caaagatcaa ggatgtactc atgatctccc tgagcccat 960
 agtcacatgt gtgggtggtg atgtgagcga ggatgaccca gatgtccaga tcagctgggtt 1020

27/31

```

tgtgaacaac gtggaagtac acacagctca gacacaaacc catagagagg attacaacag 1080
tactctccgg gtggtcagtg ccctcccat ccagcaccag gactggatga gtggcaaggc 1140
tttcgcatgc gccgtcaaca acaaagacct ccagcgccc atcgagagaa ccatctcaaa 1200
acccaaaggt gagagctgca gcctgactgc atgggggctg ggatgggcat aaggataaag 1260
gtctgtgtgg acagccttct gcttcagcca tgacctttgt gtatgtttct accctcacag 1320
ggtcagtaag agctccacag gtatatgtct tgccctccacc agaagaagag atgactaaga 1380
aacaggtcac tctgacctgc atggtcacag acttcatgcc tgaagacatt tacgtggagt 1440
ggaccaacaa cgggaaaaca gagctaaact acaagaacac tgaaccagtc ctggactctg 1500
atggttctta cttcatgtac agcaagctga gagtggaaaa gaagaactgg gtggaaagaa 1560
atagctactc ctgttcagtg gtccacgagg gtctgcacaa tcaccacacg actaagagct 1620
tctcccgga cccgggtaaa tgagctcagc acccacaaaa ctctcaggtc caaagagaca 1680
cccacactca tctccatgct tcccttgtat aaataaagca ccagcaatg cctgggacca 1740
tgtaatagga attc 1754

```

<210> 35
 <211> 240
 <212> PRT
 <213> Mouse

<400> 35

```

Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
1          5          10          15
Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
20          25          30
Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
35          40          45
Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
50          55          60
Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
65          70          75          80
Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
85          90          95
Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
100         105         110
Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
115         120         125
Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
130         135         140

```

28/31

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
 145 150 155 160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
 165 170 175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
 180 185 190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
 195 200 205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
 210 215 220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Gly Ser Gly Ser Arg
 225 230 235 240

<210> 36
 <211> 795
 <212> DNA
 <213> Mouse

<400> 36
 ctgcaggtcg acaccaccat gccccggggc ccagtggctg ccttactcct gctgattctc 60
 catggagctt ggagctgcct ggacctcact tgctacactg actacctctg gaccatcacc 120
 tgtgtccttg agacacggag ccccaacccc agcataactca gtctcacctg gcaagatgaa 180
 tatgaggaac ttcaggacca agagaccttc tgcagcctac acaggtcttg ccacaacacc 240
 acacatatat ggtacacgtg ccatatgcgc ttgtctcaat tcctgtccga tgaagttttc 300
 attgtcaatg tgacggacca gtctggcaac aactcccaag agtgtggcag ctttgtcctg 360
 gctgagagca tcaaaccagc tcccccttg aacgtgactg tggccttctc aggacgctat 420
 gatattctcct gggactcagc ttatgacgaa ccctccaact acgtgctgag gggcaagcta 480
 caatatgagc tgcagtatcg gaacctcaga gaccctatg ctgtgaggcc ggtgaccaag 540
 ctgatctcag tggactcaag aaacgtctct cttctccctg aagagttcca caaagattct 600
 agctaccagc tgcaggtgcg ggcagcgct cagccaggca cttcattcag ggggacctgg 660
 agtgagtgga gtgaccccgat catctttcag acccaggctg gggagcccga ggcaggctgg 720
 gacggcagcg gacaccacca tcatcaccac ggtagcggcg actataaaga cgatgacgat 780
 aagtagtgag aattc 795

<210> 37
 <211> 255
 <212> PRT
 <213> Mouse

<400> 37

29/31

Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
 1 5 10 15

Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
 20 25 30

Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
 35 40 45

Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
 50 55 60

Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
 65 70 75 80

Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
 85 90 95

Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
 100 105 110

Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
 115 120 125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
 130 135 140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
 145 150 155 160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
 165 170 175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
 180 185 190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
 195 200 205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
 210 215 220

Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Gly Ser Gly His His
 225 230 235 240

His His His His Gly Ser Gly Asp Tyr Lys Asp Asp Asp Asp Lys
 245 250 255

<210> 38
 <211> 792
 <212> DNA
 <213> Mouse

<400> 38
 atgaaattct tagtcaacgt tgcccttggt tttatgggtcg tgtacatttc ttacatctat 60
 gccggcagcg gacaccacca tcataccacc ggtagcggcg actataaaga cgatgacgat 120
 aagggttccg gatgcctgga cctcacttgc tacactgact acctctggac catcacctgt 180

30/31

```

gtcctggaga cacggagccc caaccccagc atactcagtc tcacctggca agatgaatat    240
gaggaacttc aggaccaaga gaccttctgc agcctacaca ggtctggcca caacaccaca    300
catatatggg acacgtgcca tatgcgcttg tctcaattcc tgtccgatga agttttcatt    360
gtcaatgtga cggaccagtc tggcaacaac tcccaagagt gtggcagctt tgtcctggct    420
gagagcatca aaccagctcc ccccttgaac gtgactgtgg ccttctcagg acgctatgat    480
atctcctggg actcagctta tgacgaaccc tccaactacg tgctgagggg caagctacaa    540
tatgagctgc agtatcgga cctcagagac ccctatgctg tgaggccggt gaccaagctg    600
atctcagtggt actcaagaaa cgtctctctt ctccctgaag agttccacaa agattctagc    660
taccagctgc aggtgcgggc agcgccctcag ccaggcactt cattcagggg gacctggagt    720
gagtggagtg accccgtcat ctttcagacc caggctgggg agcccgaggc aggctggggac    780
tagtgagaat tc                                                                792

```

<210> 39
 <211> 260
 <212> PRT
 <213> Mouse

<400> 39

```

Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
1              5              10              15

Ser Tyr Ile Tyr Ala Gly Ser Gly His His His His His His Gly Ser
20              25              30

Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser Gly Cys Leu Asp Leu
35              40              45

Thr Cys Tyr Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr
50              55              60

Arg Ser Pro Asn Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr
65              70              75              80

Glu Glu Leu Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly
85              90              95

His Asn Thr Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln
100             105             110

Phe Leu Ser Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly
115             120             125

Asn Asn Ser Gln Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys
130             135             140

Pro Ala Pro Pro Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp
145             150             155             160

Ile Ser Trp Asp Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg

```

NY Main 516391_1